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Abstract
The aryl hydrocarbon receptor is a ligand-dependent transcription factor that induces expression
of a number of genes encoding drug metabolizing enzymes, such as CYP1A1, CYP1A2 and
CYP1B1. Recently, it was suggested that the AhR signaling pathway may be involved in medi-
ating the anticancer activity of novel 2-(4-aminophenyl) benzothiazole drugs in MCF-7 breast
cancer cells. There is no direct proof of direct binding between these drugs and AhR, and it is
also unclear how AhR signaling per se plays a role in the activity of these drugs. This study in-
vestigates the role of AhR in the mechanism of action of the benzothiazole drugs by determining
the ability of these drugs to bind to the rat hepatic AhR, to induce CYP1A1 mRNA and to inhibit
cell growth in rat hepatoma H4-II-E cells. 
The apparent binding kinetics of [3H]-TCDD to AhR in rat liver cytosol were, KD= 0.37nM and
Bmax = 40 fmol/mg cytosolic protein. Using the standard assay conditions, 18 compounds com-
petitively displaced [3H]-TCDD from specific sites, and are ligands for AhR. Induction of
CYP1A1 mRNA by 5 compounds was determined in H4-II-E cells. The highest affinity ligand,
IH445, was the most potent with an EC50 ~ 80-fold lower than that of TCDD (60 pM) with no
detectable antagonistic activity in H4-II-E cells. The other high-affinity benzothiazoles tested
were (30-100) x 103-fold less potent for inducing CYP1A1 mRNA than TCDD. The binding
affinities of these compounds were 200-1000-fold higher than induction potency. For example,
5F 203 has a Ki value of 2.8 nM, induced CYP1A1 mRNA to similar maximal levels as seen
with TCDD, and has an EC50 of 3 PM. The 1000-fold difference for 5F 203 between binding
and CYP1A1 RNA induction was suggested to be a result of metabolism or that 5F 203 exhibits
partial AhR antagonist activity. The time course effect on the CYP1A1/E-actin mRNA ratios by
5F 203 revealed that the response was increasing linearly in response to 5F 203 at 4 h treatment,
indicating that the former possibilty is less likely to be a major factor. To address the second
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possibility, the antagonistic activity of 5F 203 on TCDD-induced CYP1A1 mRNA was investi-
gated. H4-II-E cells were treated with increasing concentrations of TCDD ± 1PM 5F 203. The
results demonstrated that 5F 203 shifted the EC50 of TCDD 100-fold to the right. Schild analysis
on the antagonism of TCDD-induced CYP1A1 mRNA by different concentrations of 5F 203
provided a quantitative explanation for the 1000-fold difference between binding and induction
for 5F 203. In contrast, the EC50 of 5F 203 in human MCF-7 cells was 2 nM, which is ~ 10-fold
less potent than TCDD. Moreover, 5F 203 had no detectable antagonistic activity on TCDD-
induced CYP1A1 mRNA. When 5F 203 was assessed for cell growth inhibition by MTT assay,
it was found active in MCF-7 cells with a GI50 of 18 nM, but failed to elicit the same effect in
H4-II-E cells. 
These results prove that 5F 203 is a potent agonist in MCF-7 cells, but a partial agonist in H4-
II-E cells. The partial agonism observed with 5F 203 is a compound-specific property given that
another analogue, IH 445, was found potent inducer of CYP1A1 mRNA with no antagonistic
activity. The results of this study reveal species-specific partial agonism of the AhR. The poten-
cy of the cytostatic effect of 5F 203 parallel potency for inducing CYP1A1 mRNA in both cells.
Moreover, both, the cytostatic effect of 5F 203 and partial agonism of AhR for inducing
CYP1A1 mRNA is species-specific. Whether agonism/antagonism for the induction of CYP1A1
mRNA is related to the anticancer activity of 5F 203 remains to be elucidated.
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Chapter 1 Introduction
Section 1.1 The aryl hydrocarbon receptor (AhR)
Section 1.1.1  Identification of the Ah receptor
In 1972, two different laboratories were working on the genetics of aryl hydrocarbon hydroxy-
lase (AHH) induction in mice in response to polycyclic hydrocarbons. They found that the dif-
ference in responsiveness to AHH induction between the sensitive strain (prototype C57BL/6
carrying the Ahb allele) and the relatively nonresponsive strain (prototype DBA/2 carrying the
Ahd allele) is controlled by a single autosomal locus, termed Ah (for aryl hydrocarbon respon-
siveness) [4]. Structure-activity relationships study performed by Poland and Glover (1973) on
the chlorinated dibenzo-p-dioxins and AHH induction showed good correlation between the
toxicity of these compounds and their inducing capacity, with halogenated aromatic compounds
such as dioxin being more potent agonists as AHH inducers than were the PAHs. This finding
led the researchers to hypothesize the existence of an Ah-encoded receptor, the aryl hydrocar-
bon receptor (AhR) [5]. In 1976, the hypothesis was confirmed and the receptor designated AhR
was identified using radiolabelled TCDD that exhibited specific, saturable and high-affinity to
the protein [6]. The protein is designated as the “ Ah receptor”, because it binds and mediates
the response to aromatic hydrocarbons.
Section 1.1.2  Expression of the Ah receptor 
The AhR was found in the tissues from several mammalian and non-mammalian species. In hu-
mans, it is expressed in placenta at the highest levels, also highly expressed in lung, heart, pan-
creas, and liver, and less expressed in brain, kidney, and skeletal muscles [7]. In rodents, it is
expressed in liver, lung, thymus, and kidney with much lower concentrations in testis, brain, and
skeletal muscles [251]. The expression of the AhR was confirmed in cultured cells, including
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rat hepatoma H4-II-E [7] [9] and human breast carcinoma MCF-7 cells [10] [11] [7] [253] [12]
[13] [14].
AhR is well conserved from invertebrates like Caenorhabditis elegans and Drosophila mela-
nogaster to vertebrates [15]. In mammalian species, only one AhR has been identified, AhR1.
Its molecular mass varies from 95 to 110 kDa [16] [17]. Recently, two AhR isoforms (AhR1
and AhR2) from two bird species have been isolated, the black-footed albatross (Phoebastria
nigripes) and common cormorant (Phalacrocorax carbo) [18]. The Ah locus, which encodes the
AhR, was found on mouse chromosome 12 [4] and human chromosome 7p21 [19].
Section 1.1.3  The Ah receptor structural domains
The AhR contains several structural domains revealed from the amino acid sequence deduced
from its cDNA [20]. AhR structural domains are represented in Figure 1.1. The molecular clon-
ing of the Ah receptor revealed that it was a member of a basic helix-loop-helix (bHLH) protein
family which includes PAS proteins: mammalian Per (a Drosophila protein involved in the
cicardian rhythm), Aryl hhydrocarbon receptor nuclear translocator (Arnt) protein, and Sim (a
Drosophila CNS developmental protein) [21] and the hypoxia-inducible factor 1 alpha (HIF-
1D) [22].
The AhR has a bHLH region located at the amino terminus required for DNA binding [23] and
contains sequences important for nuclear localization (NLS) [24] and nuclear export (NES)
[25]. The nuclear export sequence (NES), is responsible for the cytoplasmic shuttling of nuclear
AhR and leads to its ubiquitination and degradation [26]. The bHLH region also contains a do-
main of about 300 amino acids (non polar residues) situated next to the bHLH domain. This do-
main has homology with the PAS sequence motif. This PAS region contains two subdomains
of 110 amino acids, PAS A and PAS B domains, separated by a sequence of ~50 amino acids
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[27]. The PAS domain plays a role in AhR/Arnt dimerisation (PAS A) and ligand binding as
well as hsp90 binding (PAS B) [28], but it seems from deletion mutagenesis experiments on
both PAS A and PAS B that PAS B seems to be more important in ligand binding than PAS A
[29]. Moreover, PAS B is very important for stabilization of a functional AhR-Arnt conforma-
tion [30].
The transactivation domain (TA), situated at the carboxy terminal region is rich in glutamine
residues, and is responsible for the interactions with the general transcription machinery [31].  
Comparison of the rat, human and mouse AhR revealed that the amino terminal domain of the
AhR is highly conserved with 100% identity between the rat and mouse receptors and 98% be-
tween the rat and human receptors in the bHLH. The amino acid sequences in the PAS domain
was 96% identical between rat and mouse but only 86% between rat and human AhR. In con-
trast, the C-terminal domain sequence was less well conserved between the three species, with
Figure 1.1 Domain structure of AhR.   bHLH:basic-helix-loop-helix, NLS: nuclear localization sequence, NES: nu-
clear export  sequence, PAS: Per, Arnt and Sim, Arnt: aryl hydrocarbon receptor nuclear translocator protein, hsp90: heat-
shock protein 90, TAD: transactivation domain. (Adapted from [2]).
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79% identical amino acids between rat and mouse and only 61% between rat and human [32].
Another study showed that the alignment of the PAS domain sequences of all vertebrate AhRs
revealed 82 residues (41%) are conserved in the PAS domains of all these AhRs [261] (Figure
1.2). C-terminal variation explains why the molecular weight of Ah receptor is variable within
and across species (95 to 145 kDa) [33]. 
Figure 1.2 Alignement of PAS domain amino acid sequences of vertebrate AHRs and a possible
invertebrate AHR homolog.  (See text for discussion. Adapted from [261]).
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Section 1.1.3.1 The AhR ligand binding domain 
Although the AhR was identified 34 years ago, its tertiary structure is yet to be determined. The
crystallization of this receptor was hampered by low levels of expression (100-1000 fmol/mg
protein) and the instability of the receptor [34] which made work with it technically difficult.
As mentioned in Section 1.1.3, the ligand binding domain (LBD) amino acid sequence compar-
ison among species demonstrated a high degree of identity [35]. This observation motivated re-
searchers to investigate the importance of this domain. The murine LBD was mapped between
amino acids 230 and 421 [36]. It was shown that the affinity of this LBD for TCDD is similar
to that of the full-length AhR [36], hence it contains all the information necessary for ligand
binding. Based on that, successful transfection of this LBD into an expression system could be
a useful tool. Compared with the rat or mouse AhR, the human AhR appears to have lower af-
finity for TCDD; the KD in human was determined to be 1.6 nM, whereas its is about 0.27 nM
in mouse [35].
Site-directed mutagenesis was used to identify key ligand-binding residues. It was demonstrated
that the residue that influences the ligand binding affinity of the human AhR is a valine 381
(equivalent to the valine 375 of the mouse AhR), whereas this residue is alanine 375 in C57BL/
6 mice [35]. This difference in ligand-binding residues between the mouse and the human AhR
was shown to be the cause for the lower binding affinity of the human receptor [35] [37]. For
instance, replacing the valine 381 residue with an Alanine in the human LBD enhanced TCDD-
induced activity, whereas replacing valine 381 with an aspartate abolished completely TCDD
binding [35]. A recent study using mutated residues in the LBD of Gal4-AhR revealed that lig-
ands with low-or high- affinity do not interact with the same residues of the AhR ligand-binding
pocket [9]. 
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Some trials in our laboratory were done with the aim of cloning large amounts of functional
AhR LBD for crystallography study. Therefore, a Histidine-tag truncated AhR LBD was ex-
pressed in Spodoptera frugiperda insect cells (sf9) using a baculovirus expression system. The
system yield soluble AhR LBD protein at ~ 0.15% of cytosol protein with full ligand binding
activity. The study refined the minimal LBD to a region of 125 amino acids [38]. Microgram-
milligram quantities of the human AhR and the ARNT proteins were expressed using a baculo-
virus system [39]. To facilitate purification with Ni-NTA chromatography, a polyhistidine tag
was cloned at the C-termini. The results revealed that approximately 23% of the over-expressed
AhR was soluble whereas 77% formed insoluble aggregates. It was suggested that cellular fac-
tors were required for AhR/Arnt/DRE interactions and that these factors were removed during
purification. 
Waller and McKinney (1995) described a model for the ligand- binding site based on structure-
activity relationship studies with a significant number of AhR ligands. The model suggests that
the ligand-binding site is hydrophobic and AhR ligands are generally planar non-polar with
maximal dimensions of (14 x 12 x 5) Å [40] [41]. The structural diversity among AhR ligands
suggests that this receptor has a promiscuity of the ligand binding activity of the AhR [42].
Very recently, three different models for the mouse (mAhR)  PAS B LBD were developed by
Pandini et al (2007) [260] based on the sequence identity and similarity of the residues among
mAhR, HIF-2D and ARNT. These models identified a cavity within the core of the LBD of the
mAhR PAS B domain with an internal space sufficient for ligands as opposed to the well packed
cavity in HIF-2D and ARNT PAS structures (Figure 1.3).  
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As a summary, the three-dimensional structure of the LBD is yet to be defined. Once the LBD
structure is determined, further analysis could be carried out in order to elucidate how ligands
bind and activate AhR LBD. 
Section 1.1.4  AhR and associated proteins
Different laboratories have conducted proteomic studies on AhR. Some of the proteins bound
to AhR have been identified whereas others are still unknown. The receptor is found to be con-
stitutively present in the cytosol as an inactive complex with two molecules of 90-kDa heat
shock protein hsp90 [43], a 43-kDa protein known as Aryl hydrocarbon interacting protein
(AIP) [44], XAP2 [45] [46] or ARA9 [47] and a 23-kDa co-chaperone protein p23 [48]. 
hsp90 is one of the chaperone proteins that binds AhR. The role of this protein in the receptor
signaling is still unclear. It was postulated that the role of the protein is to repress receptor func-
tion given that the receptor bound to hsp90 did not dimerise with the Arnt protein [28]. It was
also suggested that hsp90 may be important for proper folding of AhR LBD, maintaining lig-
mod_HIF/ARNTmod_HIF2D mod_8templates
Figure 1.3 Cartoon representation of the three modeled structures of the mAhR LBD.  mod_HIF-2D:
model using only the HIF-2D template, mod_HIF/ARNT: model based on the HIF-2D and ARNT template structures.
mod_8templates: model using eight of the PAS structures. (The models were derived by MODELLER). (See text for dicus-
sion. Adapted from [260]).
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and-free AhR in a configuration that facilitates ligand binding and for the regulation of the nu-
clear localization of the AhR complex [49]. Moreover, hsp90 was found to be implicated in the
regulation of AhR function in vivo [49].
AIP appears to increase ligand-induced signaling through AhR; it binds to both AhR and hsp90
and it stabilizes the AIP-hsp90-AhR complex [50]. Recent work reported that AIP repressed the
transactivation potential of the AhR [51]. P23 appears to play a role in release of AhR from
hsp90 after ligand binding [48]. 
The Ah receptor nuclear translocator (Arnt) was cloned and identified as a component of the
nuclear form of the Ah receptor complex. The human Arnt-protein amino acid sequence is about
87 kDa. The protein is not a part of the ligand-binding subunit of the receptor. It was thought
that it is a factor required for the AhR complex to translocate from the cytosol to the nucleus to
bind the Dioxin Response Element (DRE) after binding ligand, a reason for the mis designation
of Arnt as a translocator [52]. It was found later on that Arnt is not involved in transport of the
Ah receptor into the nucleus, instead it dimerises with the ligand-bound AhR already translo-
cated in the nucleus [53]. It was shown also that this protein is required to direct the ligand-ac-
tivated AhR to enhancer elements upstream of the genomic target [21]. It has been demonstrated
that Arnt can bind to E-box motifs as a homodimer [54] and can form complexes with the HLH
proteins SIM and HIF-1 to mediate their biological responses [55]. A second form of Arnt from
rat termed Arnt2 has been described [56]. Furthermore, Arnt-nullizygous mice are lethal [57].
Arnt shares with AhR a structural organization in that it also has a bHLH domain, PAS domains
and a TA domain. However, the Arnt does not bind ligand nor hsp90. 
Section 1.1.5  Ah receptor ligands
AhR ligands can be either xenobiotics (xenos=foreign and bios=life) or endogenous. Typical
Rana Bazzi   Section 1.1.5
Page 26
exogenous ligands for the cytosolic Ah receptor include planar halogenated aromatic amines
(HAHs), polyaromatic hydrocarbons (PAHs) and their halogenated derivatives polychlorinated
biphenyls. These are synthetic chemicals and are either present in the environment or are pro-
duced during industrial processes. On the other hand, natural ligands that are formed in biolog-
ical systems are also identified. Structures of some AhR ligands are displayed in Figure 1.4.
Section 1.1.5.1Halogenated Aromatic Hydrocarbons (HAHs)
These include the polychlorinated dibenzo-p-dioxins (PCDDs), dibenzofurans and biphenyls
and related chemicals [58]. They represent a class of toxic environmental chemicals. These
chemicals are extremely dangerous and can have a significant impact on the health and well be-
ing of humans and animals because of their ubiquitous distribution, fat solubility, resistance to
biological and chemical degradation and potential for bioaccumulation [58]. The prototype,
2,3,7,8-Tetrachlorodibenzo-p-dioxin, (TCDD, dioxin), binds strongly to AhR and exhibits most
Figure 1.4 Structures for representative AhR ligands.  TCDD: 2,3,7,8-tetracholorodibenzo-p-dioxin, TCDF:
2,3,7,8-tetrachlorodibenzofuran, 3MC: 3-methylcholanthrene, ICZ: indolo[3,2-b]carbazole, FICZ:6-formylindolo[3,2-b]car-
bazole. (Adapted from [252]). 
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of its known functions via this receptor [254]. It was observed by competition binding studies
with congeners of TCDD that high-affinity ligands bind stereospecifically to AhR, i.e these lig-
ands are planar and contained halogen atoms in at least three of the four lateral positions [59]. 
Section 1.1.5.1.1 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)
The term "dioxin" refers to a group of chemicals, the polychlorinated dibenzo-p-dioxins
(PCDD). There are 75 possible congeners, one of them is 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD), a potent toxic compound in animals and humans [59]. It can be formed as a contami-
nant in the commercial herbicide 2,4,5-trichlorophenoxyacetic acid (2,4,5-T), a component of
Agent Orange and in other industrial chlorine processes such as waste incineration, chemical
and pesticide manufacturing and pulp and paper bleaching. Because of their solubility in lipids
and chemical stability, dioxins are concentrated along the food chain, and food has become the
major exposure pathway for humans. This lipophilic character enables them to cross cell mem-
branes and accumulate in the fatty tissue of the organism.
The toxicity of TCDD (measured as oral LD50) varies considerably among species. Classic ex-
amples are the guinea pig, where the LD50 is ~ 1µg/kg [154] and hamster ~ 5000 µg/kg [60]. 
The potency of TCDD is partially attributable to its resistance to metabolism [61] and high sol-
ubility in lipids [62]. The many toxic effects of TCDD and other HAHs include body weight
loss, thymic atrophy, hepatotoxicity and porphyria, carcinogenesis, teratogenesis, suppression
of the immune system, and reproductive toxicity [59] [63] [20]. These toxic effects depend on
the species, age and sex (reviewed in [58]). TCDD is classified as a “human carcinogen” [64].
Section 1.1.5.1.2 The 3,4,3',4'-Tetrachloroazoxybenzene (TCAOB)
TCAOB is a member of the halogenated aromatic hydrocarbons (HAH) family. It can be formed
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as an unwanted contaminant during the synthesis of 3,4-dichloroaniline and in the degradation
of herbicides in soil and was responsible for three outbreaks of acne (Chloracne) among chem-
ical workers [65].
It has typical dioxin-like effects, including thymic atrophy, increased liver weights, induction
of hepatic cytochrome P4501A, and decreased mean body weight gains [66]. 
TCAOB is a potent inducer of hepatic aryl hydrocarbon hydroxylase activity and competes for
stereospecific binding sites in mouse hepatic cytosol, (KD of TCAOB = 0.93 nM compared to
that of TCDD = 0.27 nM) [66], therefore, TCAOB was used as an unlabelled competitor for di-
oxin in binding assays [66]. 
Section 1.1.5.2 Polycyclic Aromatic hydrocarbons (PAHs)
Typical PAH ligands are benzo(a)pyrene, 3-methylcholanthrene (3MC), aromatic amines and
other related chemicals [59]. Polynuclear aromatic hydrocarbons (PAHs) also bind and activate
the AhR [67]. These chemicals are also toxic but less potent then HAHs. They are generated
from incomplete carbon combustion, high temperature cooking, diesel exhaust and cigarette
smoke [68]. Compared to the HAHs, the PAHs have lower binding affinity to the AhR (re-
viewed in [2]). 
Section 1.1.5.3 Natural ligands
In addition to synthetic and environmental chemicals, numerous naturally occurring dietary and
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endogenous ligands have been identified. 
AhR ligands were isolated from different vegetables, fruits, herbs and teas (reviewed in [2]).
These can be agonists such as quercetin [69], or antagonists as flavonoids [70]. Flavonoids rep-
resent the largest group of naturally occurring dietary AhR ligands. The indolo-[3,2-b]-carba-
zole (ICZ), an acidic condensation product formed from indole-3-carbinol (13C), has the most
highest-affinity natural AhR ligand identified to date [71] and is an agonist for AhR [72]. 
Many endogenous physiological chemicals have been isolated as candidate natural ligands for
AhR, such as endogenous tryptophan-derived natural chemicals, indirubin, indigo [73] and 6-
formylindolo[3,2-b]carbazole (FICZ), a tryptophan photoproduct [74]. Other ligands include
tryptamine [255], bilirubin [75] and lipoxin A4 [76]. 
Finally, AhR is still considered as an 'orphan receptor', for the lack of knowledge of its physio-
logical ligand. Extending the broad of knowledge of AhR ligands facilitates the prediction of
the properties of its endogenous ligand.
Section 1.1.6 The AhR signaling pathway
Section 1.1.6.1 Binding and translocation to nucleus
The AhR ligands, by the virtue of their lipophilicity, diffuse across the plasma membrane and
bind to AhR associated with hsp90 and other proteins. It is presumed that following ligand bind-
ing, the AhR undergoes conformational change that exposes a nuclear localization sequence (s)
[24] [30] that allows translocation to the nucleus [77]. This is a rapid process that occurs shortly
after ligand binding [78]. 
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Section 1.1.6.2 Dimerisation of AhR with Arnt 
In the nucleus, the AhR dissociates from the complex and dimerises with Arnt [68]. This het-
erodimirisation enables AhR to bind DNA (Xenobiotic Response Elements, XRE of target pro-
moters) [77]. Arnt was initially discovered as a necessary component of the AhR signal
transduction pathway, where it dimerises with the AhR to mediate many of the biological re-
sponses to halogenated aromatic hydrocarbons [79] [20] [80] [81]. The AhR/Arnt heterodimer
is depicted in Figure 1.6. 
AhR heterodimerises with Arnt at the bHLH and the PAS domains and this heterodimerisation
is essential for DNA recognition [79] [28]. Dimerisation of AhR with Arnt converts the AhR
into its high affinity DNA binding form [20] [30]. Selective deletion analysis identified a DNA
sequence, containing the core consensus sequence 5'-TNGCGTG-3', the core binding motif of
the dioxin or xenobiotic responsive element (DRE or XRE) to which AhR and Arnt bind directly
[82]. It was reported that AhR/Arnt heterodimerisation and/or XRE binding is regulated by
phosphorylation by a protein Kinase C (PKC) [83].
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Section 1.1.6.3 Transcriptional activation
The AhR/Arnt heterodimer is recruited with its associated factors to the enhancer and TATA
box regions of the XRE of the CYP1A1 promoter and other responsive genes [84] [85] [249].
Both, enhancer and promoter are required to mediate the induction of CYP1A1 by TCDD [86].
As a result, there is stimulation of transcription initiation of genes known as the (AhR) gene-
battery. It was found that, in Ah receptor- and Arnt- defective cells, TCDD fails to induce the
activation response [81]. This finding gives evidence that AhR together with Arnt are required
for CYP1A1 transcription activation. The general model for CYP1A1 induction is depicted in-
Figure 1.7.
Figure 1.6 The AhR/Arnt heterodimer.   Each protein contains a transactivation region (TA), a Per-AhR (Arnt)-
Sim (PAS) region, a helix-loop-helix (HLH) region and a basic region that binds XRE on DNA. In addition, AhR contains
a ligand binding region (PAS B) and a a region that binds hsp90 (HSP) when AhR is a monomer (unliganded). (see text for
discussion) (adapted from [3]).
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Another sequence, the BTE (basic transcription element) or the GC box sequence, localized in
the proximal promoter of CYP1A1, is also important for CYP1A1 induction. CYP1A1 gene ex-
pression is enhanced by Sp1 binding to the BTE which in turn, facilitates the binding of AhR/
Arnt to the XRE and vice versa. Binding of the AhR/Arnt heterodimer recruits P300, a histone
acetyl transferase (HAT) coactivator to the C-terminus of Arnt and several other coactivators,
such as, but not exclusively, SRC-1, NCoA-2 and p/CIP to the CYP1A1 enhancer region. Bind-
ing of PolII to the promoter enhances gene expression (reviewed in [252]). 
It was reported that chromatin structure has a important role in the regulation of gene transcrip-
tion [87] [88]. Whitlock JP et al., 1996 [3], proposed a model describing the role of chromatin
Figure 1.7 Description of AhR signaling pathway.  (See text for discussion. Adapted from [252]). .
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remodeling in the transcription of CYP1A1. In their model, the induction in response to drug is
associated with chromosome remodelling. So in the presence of inducers, AhR/Arnt heterodim-
er binds the enhancer and the enhancer/promoter region undergoes a change in structure. Sub-
sequently, the nucleosomes in the promoter region are disrupted then the transcription binding
protein (TBP) and other transcription factors occupy their cognate binding sites and initiate
transcription of CYP1A1 into mRNA. These mRNAs then get translated into CYP1A1 proteins
in the cytoplasm. In the absence of inducers, nucleosomes in the regulatory region are posi-
tioned to prevent any transcription occurring (reviewed in [3]).
TCDD binding to the AhR activates the receptor and as result, an array of genes are transcrip-
tionally activated or repressed [89]. The genes that are directly activated by AhR include some
phase I and phase II drug-metabolizing enzymes such as cytochrome P450 CYP1A1, CYP1A2,
CYP1B1, aldehyde dehydrogenase (ADH), NADPH-quinone-oxidoreductase (NQO1), glut-
hathione S-transferase (GST) Ya (GST1), uridine diphosphate glycosyltransferase 1 family
polypeptide A1 (UGT1A1) [90] [89], p27kip1[91] and N-myristoyl-transferase 2 [92]. Recently,
microarray analysis showed that AhR can regulate the expression of some genes indirectly by
binding to a factor (AHRE II) that binds DNA. In this case, AhR acts as a co-activator rather
than a transcription factor [93]. 
Overall, the activation of AhR signaling pathway is made of several steps starting from the lig-
and binding followed by translocation to the nucleus, binding with nuclear factors, transactiva-
tion of gene transcription and degradation [53]. These steps are differentially regulated in
different species.
However, the molecular mechanism by which the AhR signaling pathway is activated is still not
fully elucidated. As mentioned previously, this lack of information is attributed to the lack of
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structural information about AhR LBD.
The induction of CYP1A1 gene expression is considered one of the most sensitive indicators of
exposure of AhR agonists [94]. Moreover, the induction of expression of CYP1A1 is main-
tained in most species [33], therefore, induction of CYP1A1 has been used as a model system
to define the mechanism of action of AhR ligands. Based on CYP1A1 induction, several AhR
ligands were identified as agonists, partial agonists [95] [96] [97] and antagonists [98] [69] [41]
[99].
Section 1.1.6.4 Ligand binding-independent activation of the AhR
Generally, AhR activation is mediated by AhR ligands, however it was shown that activation of
AhR signal transduction could be mediated via a ligand-independent mechanism. In a study
conducted by Ma and Whitlock (1996), omeprazole (OME), a gastric anti-ulcer drug, induced
CYP1A1 but was not affected by 3’methoxy-4’-aminoflavone that was able to antagonize
TCDD-mediated CYP1A1 induction [100]. Later, Backlund and collaborators (1997), com-
pared OME with TCDD for binding (rat cytosol) and activating the Ah receptors in H4-II-E
cells [101]. Omeprazole and TCDD induced CYP1A1 gene (northern blot analysis) and protein
expression (western blot analysis) but OME, unlike TCDD, did not bind specifically rat AhR as
demonstrated by [3H]-TCDD competitive assay nor activated cytosolic AhR to an XRE-binding
form as shown by EMSA. However, both OME and TCDD recruited AhR and Arnt nuclear pro-
tein complex to XRE as shown by EMSA on nuclear extracts treated with both compounds. Ty-
rosine kinase inhibitors inhibited OME- but not TCDD-mediated CYP1A1 induction (mRNA
and protein) as well as AhR-induced binding to XRE indicating that OME activates AhR via
intracellular signal transduction which is tyrosine kinase-dependent, that is different from the
induction mediated by TCDD. 
Rana Bazzi   Section 1.2
Page 35
Section 1.2 Regulation of AhR and crosstalk
The AhR signal transduction pathway is controlled by regulatory mechanisms. It was shown
that degradation of AhR is necessary for proper activation. AhR degradation involves ubiquiti-
nation [102] and it occurs shortly (1-2 hours) after TCDD binding [103]. 
A nuclear protein that acts as a negative regulator of the AhR, the AhRR, has been identified
[104]. This protein is induced by AhR and binds to Arnt inhibiting the formation of the tran-
scriptionally active AhR/Arnt complex. 
The AhR interacts with other pathways involving the oestrogen receptor (ER) and androgen re-
ceptor. The cross talk between AhR and ER was supported with the observations that female
rats chronically treated with TCDD developed less mammary and uterine tumors [105]. The
cross-talk between AhR and ER is complex and it was shown that the AhR downregulates the
ER-mediated effects through multiple mechanisms, such as rapid metabolism of oestrogen by
CYP1A1 [106] [107], ER degradation by proteasomes through AhR [14], sharing common co-
factors, such as Arnt [108]. Recently, using Chromatin Immunoprecipitation (ChIP) assays,
TCDD was shown to recruit ERD to the CYP1A1 promoter which is enhanced by estradiol (E2)
[85].
In the case of the androgen receptor, exposure to TCDD inhibits androgen-mediated cell prolif-
eration through modulation of retinoblastoma protein (pRb) phosphorylation [256]. Finally, in-
hibition of AhR-mediated responses by hypoxic conditions have been demonstrated in mouse
Hepa-1 cells [109].
The regulation of AhR function appears to be tissue/cell-specific. One of the aspects of the spe-
cies-specific differences in AhR regulation is the interaction of AhR with nuclear proteins in-
cluding activators and co-repressors that are species/cell-specific [110].
Rana Bazzi   Section 1.3
Page 36
Section 1.3 AhR functions
Section 1.3.1  Regulation of xenobiotic metabolism
In general, several AhR ligands form highly reactive intermediates during metabolism by cyto-
chrome P450 which results ultimately in adduct formation. This is the case for PAHs that are
metabolized by several phase 1 enzymes, such as cytochrome P450s, CYP1A1 and CYP1B1 to
electrophilic derivatives that can mutate DNA [20] [59], whereas most of the HAHs are more
resistant to metabolic degradation and have higher binding affinity (in the pM range for HAHs,
compared to nM range for PAHs) which results in continuous activation of AhR and thus per-
sistent activation of gene expression [111]. This could explain the lesser potency of PAHs com-
pared to HAHs.
Section 1.3.2  Mediation of HAH toxicity
In addition to its role in modulating the induction of gene expression, numerous studies also
support a role of AhR in mediating toxicity. Previously, Poland and Glover have shown that the
potency of various halogenated dibenzo-p-dioxins at inducing the aryl hydrocarbon hydroxyla-
se AHH activity closely parallels their toxic potency (e.g. their potency to elicit acne) [5]. Struc-
ture-activity relationship (SAR) analysis on a variety of inbred strains of mice with different
functional AhR and HAH responsiveness confirmed the correlation of the structure-activity re-
lationship for receptor binding with toxic potency [58] [112]. For example, an addition of non-
lateral chlorines or removal of lateral chlorines from these planar structures decreases toxicity.
These findings were confirmed when Fernandez-Salguero and his collaborators administered
TCDD to AhR-knock-out mice and found that these mice were resistant to TCDD-induced bi-
ochemical or toxic effects [257]. Combined together, these data support the hypothesis that AhR
mediates HAHs toxic effects [59]. Another study was done on AhR expression in transgenic
mice revealed that the constitutively active AhR protein reduced the life span of the mice and
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induced tumours in the glandular part of the stomach. These results demonstrated the involve-
ment of the receptor in cancer and regulation of cell proliferation [113].
PAHs and HAHs are all toxic but they exhibit differences in toxic potency. The toxic and bio-
logical responses mediated by AhR are species -, tissue- and ligand-specific. Moreover, they are
dependent on the dose, length of exposure, strain, age and sex of animals [59]. 
Unlike the PAHs, TCDD is not genotoxic (does not bind covalently to DNA to form DNA ad-
ducts), but it is a very powerful tumour promoter [114]. It induces tumours in rodent models.
The pattern of these tumours varies among species. However, the mechanism(s) whereby HAHs
cause cancer are not known. Besides tumour promotion, exposure to TCDD results in several
toxicological effects, including chloracne, liver disorders, adverse effects on the immune sys-
tem, and reproductive and teratogenic defects [115].
What is known is that AhR-dependent transcription is required for dioxin toxicity [116] but it
is unknown how the activation of the AhR-dependent genes produces the multiplicity of toxic
responses characteristic of dioxin exposure. 
Section 1.3.3  Vascular development
In addition to its role in the adaptive metabolism of xenobiotics and in the toxic events that fol-
low exposure to TCDD [59], AhR seems to play a developmental role. Recent studies on the
phenotype of AhR null mice [68] [257] [117] [118], revealed that these mice display smaller
livers, reduced fecundity, and decreased body weights. This phenotype is presumed to result
from loss of AhR activation by endogenous ligand (s), although the identity of the responsible
chemical (s) remains elusive.
A recent study investigated the mechanism of DV closure which is the closure of a hepatic vas-
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cular shunt known as the ductus venous (DV). Previously, Walisser et al (2004) demonstrated
that AhR together with its heterodimeric partner, Arnt, plays a role in this vascular defect. Using
hypomorphic models of AhR and Arnt, it was demonstrated that these two proteins localize to
the nucleus and are required for normal DV closure, suggesting that AhR-Arnt heterodimerisa-
tion is essential for normal vascular development [119] [116]. 
Strikingly, the environmental pollutant TCDD has found to correct this physiological defect.
This suggests that chemicals of this class could have therapeutic applications in particular for
diagnosis developmental vascular defects [120]. This is consistent with the idea that an un-
known endogenous activator ligand participates in normal developmental signaling [119],
which can give insight for more research on a possible physiological role of AhR in this area.
Overall, AhR signaling can govern three distinct biological functions, up-regulation of xenobi-
otic metabolism, dioxin toxicity, and normal vascular development. 
Section 1.4 The AhR and anticancer therapy
The AhR is gaining increasing attention as a potential target for anticancer therapy. Since AhR
signaling is known to play a role in carcinogenesis by activating some procarcinogens into their
genotoxic forms by CYP1A1 and other phase I metabolizing enzymes [59] [20], research on
AhR antagonism as a chemopreventative strategy seems to be a promising area. For instance,
Safe and collaborators have focused on identifying selective AhR modulators (SAhRMs) that
are AhR agonists but with reduced ability to induce DRE responsive genes and exhibit antioes-
trogenic and antitumorigenic activity [121] [122]. Such SAhRMs, but not limited to, 6-methyl-
1,3,8-triCDF (6-MCDF) [94] and diindolylmethane (DIM) [123], which are AhR ligands and
partially inhibit TCDD-induced CYP1A1. These compounds were found to be highly effective
in inhibiting mammary tumour growth in Sprague-Dawley rats with induced cancers [94] [124].
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Also, several structurally-diverse natural products that exhibit chemoprotective anti-tumorigen-
ic properties have been characterized as AhR agonists/antagonists. These include flavonoids,
carotenoids, indole-3-carbinol (13C) and related compounds, and the antioxidant resveratrol.
All these compounds inhibit formation and/or growth of tumours in animal models, and their
mode of anti-carcinogenic action may, in part, be AhR-mediated [106]. 
Research on phenylbenzothiazoles has recently focused on AhR agonism in anticancer therapy.
Generally, these chemicals induce drug metabolizing enzymes (CYP1A1 for example) and get
biotransformed into activated forms leading to genotoxic effects. This is the case of some anti-
cancer phenylbenzothiazole derivatives [126] [128], with a selective and potent anticancer pro-
file in vivo against some human xenograft models and in vitro against some human cancer cells
[128] [130] [131]. This class of drugs will be covered later in this chapter. 
Section 1.5 AhR and drug metabolism
Humans are exposed daily to xenobiotics. Most of these chemicals are insoluble in water, but
soluble in fats and thus tend to accumulate in the body. In order to avoid their accumulation,
these chemicals must be rendered more polar and therefore more water soluble to facilitate their
excretion in the urine. This metabolism is due, by and large, to enzymes with broad substrate
specificity including the cytochrome P450 enzymes in the liver. In general, drugs undergo me-
tabolism reaction known as phase I and phase II metabolism.
Section 1.5.1  Phase I enzymes:
They involve oxidation (the P450 enzymes), reduction and hydrolysis. Most of these reactions
occur in the liver but some of them occur in the gut wall, plasma and the lung.
The hepatic microsomal cytochrome P450s are members of a superfamily of monooxygenases
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 that catalyse metabolism of xenobiotics, the initial step in the biotransformation and elimina-
tion of a wide variety of substrates, from endogenous steroids to environmental pollutants.
There are 57 known P450s in humans, among which 15 are involved in metabolizing xenobiot-
ics, including drugs. P450s are located primarily in the endoplasmic reticulum of liver tissue.
The cytochrome CYP 450 or P450 (P for pigment) owes its nomenclature to its characteristic
absorption maximum at 450 nm of carbon monoxide adduct. The enzyme exists as multiple
forms, each has different physiochemical properties [265]. Among multiple functions, P450s
are responsible for metabolic activation of procarcinogens, detoxification of xenobiotics and
drugs biotransformation and metabolism. Several cytochrome P450 enzymes are inducible by
xenobiotics [131]. 
Section 1.5.1.1 Nomenclature
The system is based on amino acid sequence homologies. The prefix CYP is followed by a
number indicating families, then a capital letter indicating subgroups, and then a number defin-
ing an individual isoform [132].
Section 1.5.1.2 CYP1 family
The P450s of this family are CYP1A1, CYP1A2 and CYP1B1. These enzymes are inducible by
many xenobiotics, including planar polyaromatic hydrocarbons (PAHs) and 2,3,7,8-tetrachlo-
rodibenzo-p-dioxin (TCDD) which is a highly potent inducer of CYP1A1 in particular [133].
As mentioned earlier, it is well documented that regulation of the CYP1 family is mediated by
the AhR and its nuclear translocator Arnt [3] [134] [20] [135]. Although the AhR is involved in
the regulation of all three CYP1 enzymes, it has been reported [96] that CYP1A1 is significantly
more inducible by TCDD than CYP1A2. Essentially, substrates of CYP1A1 are hydrophobic
and characterized as relatively planar PAH molecules comprised of two to four fused aromatic
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rings, which also tend to be rectangular in shape [136] [137].
The levels of these enzymes in the liver and other organs are variable and subject to chemical
induction, genetic variation and other factors relating to lifestyle, diet, age, sex and medical con-
ditions [138]. In humans, CYP1A2 is mainly expressed in liver, whereas CYP1A1 and CYP1B1
are expressed extrahepatically. In rodents, CYP1A1 is expressed in the liver [125].
Section 1.5.2  Phase II reactions: 
The oxidized products of phase I are made more polar by enzymes in phase II. All of them are
conjugation reactions which add various highly polar groups such as glucuronic acid and glu-
tathione. They also occur mainly in the liver.
Section 1.6 Phenylbenzothiazoles
Section 1.6.1  2-(4-aminophenyl)benzothiazoles (series 1)
Section 1.6.1.1 Discovery of non-fluorinated 2-(4-aminophenyl)benzothi 
azole analogues
Originally, the compound 2-(4-aminophenyl)benzothiazole CJM126 was discovered as an in-
termediate during the synthesis of hydroxylated 2-phenylbenzothiazoles as potential tyrosine
kinase inhibitors [139]. CJM126 exhibited a selective in vitro activity in MCF-7 (ER+) breast
carcinoma cell lines (GI50 < 0.001 PM). However, the growth curve displayed an unusual bi-
phasic dose response where the drug killed the cells at sub-nanomolar concentrations but was
inactive in the micromolar range [128].
Among the 3'-substituted congeners, 2-(4-aminophenyl-3-methylphenyl)benzothiazole (DF
203; NSC 674495) was originally selected as the lead compound for its superior in vivo activity
in human xenograft models and in vitro activity in specific breast, ovarian, renal, colon, melano-
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ma and non small cell lung cell lines [128] [129].
Section 1.6.1.2 Discovery of fluorinated 2-(4-aminophenyl)benzothiazole 
analogues
Metabolic studies on DF 203 showed that it was biotransformed by the drug metabolizing en-
zyme cytochrome P450 (CYP) 1A1 to 2-(4-aminophenyl-3-methylphenyl)-6-hydroxybenzothi-
azole (6-OH 203) in sensitive cells. 6-OH 203 (IH 130) was devoid of antitumour activity [140]
and reversibly inhibited CYP1A1 [141].
In attempts to overcome the metabolism of non-fluorinated analogues, the 5-fluoro isomer (5F
203) was synthesized. It was found to block selectively oxidative metabolism of the non-fluor-
inated counterpart DF 203 and restored the conventional dose-response curve [126]. Similar to
DF 203, 5F 203 potently and selectively inhibited the growth of renal, breast, and ovarian cancer
cell lines [141]. The prodrug, lysylamide dihydrochloride salt of 5F 203 (Phortress, NSC
710305) is in Phase I clinical trials under the auspices of Cancer Research UK [127]. 
Section 1.6.1.3 Mechanistic investigations
2-(4-aminophenyl)benzothiazoles showed a potent and selective antitumour profile, for in-
stance, MCF-7 and T-47 D breast carcinoma cells were sensitive and renal TK-10 or ovarian
IGROV1 cells had intermediate sensitivity, breast MDA-MB-435, ovarian SK-OV-3, and renal
CAKI I, were insensitive [128] [126]. It was reported that phenylbenzothiazole compounds may
modulate the activity of more than one receptor and may display cross-talk between pathways
[84]. The MCF-7 cells express both ERD and AhR [142] [143]. However, 5F 203 and DF 203
had cell growth inhibitory potency in human breast cancer cells irrespectively of the ER or
growth factor receptor status [128].
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It was postulated that the selectivity is due to metabolism of the drugs, where drug uptake and
biotransformation were observed only in sensitive cell lines, in contrast to little or no metabo-
lism in resistant cell lines [140]. Chua and colleagues (2000) reported that DF 203 induced and
was metabolized by CYP1A1 only in sensitive cell lines [141]. The major metabolite reported
is 6-OH 203 [140], whereas lysates prepared from untreated MCF-7 cells failed to catalyse the
6-hydroxylation of DF 203. Because CYP1A1 activity is known to be induced by AhR signal
transduction pathway, it was postulated that the receptor may mediate DF 203 action. Loaiza-
Perez and collaborators (2002) demonstrated that the AhR pathway was activated in MCF-7 cell
lines but not in MDA-MB-435 cells, resulting in CYP1A1 mRNA induction [253]. Moreover,
DF 203 binds to DNA and forms DNA adducts in sensitive but not resistant cells [140].
It was reported that the differential capacity of AhR to regulate CYP1A1 expression in different
cell types may underlie the sensitivity to DF 203. For instance, in DF 203-sensitive cells, AhR
translocation to the nucleus and binding to XRE sequences seems to occur after treatment,
whereas, in DF 203-resistant cells, AhR was found in cytoplasm and nucleus before and after
treatment with DF 203. Furthermore, protein complexes bound to XRE were not observed in
resistant cells and CYP1A1 expression was not detected at the mRNA nor the protein levels and
finally, adduct formation is negligible [253].
The general proposed mechanism of action of 5F 203 was described by Bradshaw and Westwell
(2004) [145]:
Water soluble Phortress is rapidly reverted to its hydrophobic parent 5F 203 drug that is readily
sequestered by sensitive cell lines only. Subsequently, 5F 203 binds cytosolic AhR and then
translocates to the nucleus. Like any classical mechanism of AhR activation, the complex AhR-
benzothiazole dimerizes with Arnt and complexes with XRE on the CYP1A1 promoter and ac-
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tivates gene transcrition. 5F 203 then binds to CYP1A1 and gets metabolized to reactive inter-
mediate(s). Highly electrophilic, intermediate(s) bind(s) DNA and form(s) DNA adducts and
single strands breaks leading ultimately to the cell death in vitro and in vivo. It appears from this
model that metabolism is essential for 5F 203 antiproliferative activity through DNA adduct
formation [253] [141] [146].
DNA adducts accumulated in MCF-7 cells treated with 1µM 5F 203 within 2 h and attained sat-
uration levels at 24 h. At concentrations > 100 nM, adducts were detected in DNA of MCF-7
cells treated with 5F 203. At 1 µM 5F 203, one major adduct and few minor adducts were
formed. Increasing the concentration to 10 µM led to the formation of a new dominant adduct
in MCF-7 cells [146].
Engagement of apoptotic machinery (CD95/FAS1, upregulation of P53 and P21, downregula-
tion of Bcl-2)[147] and detection of single-strand breaks has been observed in responsive mam-
mary carcinoma cells following treatment with benzothiazole analogues [148]. The drug
candidate 5F 203 also induced mRNA levels of IL-6, an NF-kappaB-responsive gene, in MCF-
Figure 1.8 Mode of action of Phortress.   (Adapted from [248]). See text for discussion.
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7 cells, but not in MDA-MB-435 cells, as determined by quantitative RT-PCR. Based on that,
it was suggested that 5F 203 activation of the NF-kappaB signaling cascade may contribute to
5F 203-mediated anticancer activity in human breast cancer MCF-7 cells [149]. Recently, with
the aim of characterising the pathways involved in 5F 203 toxicity, cDNA microarrays were
used to determine gene expression changes in both sensitive MCF-7 cells and resistant MDA-
MB-435 after treatment with 1 PM 5F 203 [150]. The results revealed that AhR-regulated
genes, DNA-damage responsible genes, and a PLAcental Bone morphogenetic (PLAB) gene (a
gene encoding for a member of TGF-E superfamily and encoding a proapoptotic protein) were
induced in MCF-7 but not in MDA-MB-435 cells. 5F 203 accumulates human breast cancer
MCF-7 cells in G1 and S phase, and induces the formation of DNA adducts.
Overall, AhR pathway activation then subsequently CYP1A1 induction seems to be essential
for 5F 203 metabolism. But whether metabolism and/or AhR activation are prerequisites for 5F
203 antitumour activity will be the subject for future studies.
Section 1.6.1.4 Structure-Activity Relationships (SARs)
Benzothiazole molecules contain a benzene ring fused to a thiazole ring [128]. Their optimised
structure is planar. Their antitumour profile is modulated by substitutions at specific positions
on the benzothiazole pharmacophore [140] [126]. Structure-activity relationships revealed that
compounds with a methyl group (DF 203) or halogen group (Cl, Br, or I) in the 3' position were
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Section 1.6.2  2-(3,4-Dimethoxyphenyl)benzothiazoles (series 2)
Section 1.6.2.1 Background
A new series of 2-phenylbenzothiazoles, the dimethoxyphenylbenzothiazoles, bearing oxygen-
ated substituents on the phenyl ring has been synthesized. The lead compound 2-(3,4-dimeth-
oxyphenyl)-5-fluorobenzothiazole (GW 610; NSC 721648) elicited superior antitumour
activity against a range of breast (e.g, MCF-7, MDA 468), colon (e.g. HCC2998, KM12), non-
small cell lung, ovarian and renal cell lines (GI50 values < 1 nM) [151]. 
Section 1.6.2.2 Mechanistic investigation
Mechanistically, like the series (1), activity of series (2) seems to be AhR-mediated. However,
their antitumour activity is not restricted to cell lines with inducible CYP1A1. 
GW 610 induced CYP1A1 transcription and protein expression in MCF-7 and MDA 468. Im-
portantly, this compound was found active in both CYP1A1 inducible and non-inducible cells
(e.g, colon cell line HCC2998). In comparison with DF 203 from series (1), GW 610 is active
in breast MCF-7 and MDA 468 variant cell lines with acquired resistance to DF 203, however,
MCF-7 and MDA 468 variant lines exhibiting acquired resistance to GW 610 displayed cross
resistance to DF 230 [151]. Exclusively in sensitive cell lines, GW 610 is rapidly depleted from
nutrient media, induces G2/M cell cycle arrest and DNA adducts. Overall, the activity of the
GW 610 is not CYP1A1-dependent [262]. 
Section 1.6.2.3 Structure-Activity Relationships (SARs)
Structure-activity relationships revealed that, unlike the series (1), the presence of a fluorine at-
om, at the position 5 in the benzothiazole ring, is essential for antitumour activity. For instance,
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its removal yields the inactive compound (AW 892). Moreover, shifting the fluorine atom from
position 5 to the position 4 or 6, resulted in an attenuated activity in colon cell lines but not in
breast and lung cancer cell lines. In the phenyl ring, the dimethoxy moiety was found essential
for activity in positions 3 and 4. For instance, an introduction of a methylenedioxy bridge at this
position, inactivates the compound (JMB 81). Finally, it seems that the compounds of this series
are very sensitive to substituent modifications [151].
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AIMS
The study described here was undertaken to establish the correlation between binding, induction
and growth inhibitory potency of the phenylbenzothiazoles (series 1 and 2) in rat and generate
a QSAR model on the binding affinity and the induction potency of the phenylbenzothiazoles
in order to elucidate the mechanism of action of these compounds.
The specific objectives were to:
- Characterize the binding (derived as inhibition constants Ki) of the phenylbenzothi-
azoles (series 1 and 2) to the AhR by means of a radioactive competitive binding assay in rat
cytosol.
- Characterize the induction potency of the phenylbenzothiazoles (series 1 and 2)
(EC50) for CYP1A1 mRNA in rat H4-II-E cells. 
- Characterize the growth inhibitory potency (GI50) of the phenylbenzothiazoles (se-
ries 1 and 2) in H4-II-E cells. 
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Chapter 2 Materials and Methods
Section 2.1 Materials 
Section 2.1.1 Animals
Male Wistar rats CRL:WI (2-3 weeks, 200-250g) were purchased from Life Sciences, Charles
River laboratories (251 Ballardvale Street, Wilmington, MA 01887-1000). The animals were
housed in cages under standard laboratory conditions (24°C, 60% humidity, 12 hours dark/light
cycle) and had access to standard laboratory chow and water ad lib. The animals were given 3
days to adapt to the standard laboratory conditions. These animals were used for cytosol prep-
aration following liver perfusion. 
Section 2.1.2  Cell lines and cell culture chemicals
Human Caucasian breast adenocarcinoma MCF-7 cat.no 86012803 
Rat hepatoma H4-II-E cat.no 85061112 
Minimum essential medium eagle (MEM) 100x cat.noM2279
Non essential amino acid solution (MEM) 100x cat.noM7145
Dulbecco's phosphate buffered saline cat.noD8537
Fetal bovine serum cat.no F7524
L-Glutamine-penicillin-streptomycin 100x solution  cat.noG1146
Trypsin-EDTA solution 10x cat.noT4174
Both cell lines were purchased from Sigma Ecacc and culture chemicals were purchased from
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Sigma (The Old Brickyard, New Road, Gillingham, SP8 4XT Dorset).
Section 2.1.3  Kits and reagents
Absolutely RNA® Miniprep kit (cat.no 400800), Affinity Script QPCR cDNA synthesis kit
(cat.no 600559) and Brilliant® multiplex QPCR Master Mix (cat.no 600553) were purchased
from Stratagene (Gebouw California, Hogehilweg 15, 1101 CB Amsterdam Zuidoost, The
Netherlands).
Quanti-iT TM Ribogreen® RNA assay kit (cat.no R11490) , Quanti-iT TM Pibogreen® dsDNA
assay kit (cat.no P7589) and DNA ladder 1kb plus (cat. no10488-085) were purchased from In-
vitrogen Molecular Probes (3 Fountain Drive, Inchinnan Business Park, Paisely, UK PA4 9RF).
ReddyMix PCR Master Mix conc.1.1x (cat.no AB-0575/LD/A) was purchased from ABgene
(ABgene House, Blenheim Road, Epsom KT19 9AP, UK).
Section 2.1.4  Compounds
CH-223191 (purity 95.71%) (cat.no 182705) was purchased from Calbiochem (or MERCK,
Padge Road, Beeston, Nottingham NG9 2JR, UK).
3-Methylcholanthrene (MC) (purity 98%) (cat.no 213942) was purchased from Aldrich. 
Tetrachlorodibenzo-p-dioxin (TCDD) (purity 99%) (cat.no ED-901-B) and Tetrachlorodiben-
zofuran (TCDF) (purity 98%) (cat.no EF-903-C) were purchased from Cerilliant Cambridge
isotope laboratories (LGC Promochem, Queens Road, Teddington Middlesex TW11 OLY,
UK).
Benzothiazole test chemicals were synthesized by the Cancer Research Laboratories at the Uni-
versity of Nottingham, UK and the Drug Synthesis and Chemistry Branch, NCI, following pub-
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lished methods [126]. Benzothiazole test chemicals and Camptothecin were kindly provided by
Dr Tracey Bradshaw. 
TCAOB was a gift from Dr. Andy Smith (MRC Toxicology Unit, Leicester). The compound 1c
was kindly provided by Astrazeneca and was synthesized following published methods [152].
Tetracholorophenothiazine (TCPT) compound was provided by Dr.Kristian Fried [196].
Compound structures were drawn using CDS/ISIS DRAW Program:
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C-Miscellaneous:
Section 2.1.5  Buffers
MN stock buffer (pH 7.5 at 4ºC) : 25 mM MOPS + 0.02 % Sodium Azide. 
MEN stock buffer (pH 7.5 at 4ºC) : MN buffer + 1 mM EDTA.
MDENG stock buffer (pH 7.5 at 4ºC) : MEN buffer + 10 % (w/v) glycerol + 1 mM dithioth-
reitol (DTT). (DTT is freshly supplemented to the buffer before the protein preparation).
TE buffer: 10 mM Tris-HCl, 1 mM EDTA, pH 7.5.
5x TBE buffer 














Compound 1c from Astrazaneca
3-Hydroxy-2-[4-(trifluoromethyl)phenyl)]-[1,2,3]-triazolo[1,5-a]quin-
olinium hydroxide.




0.25 % bromophenol blue
0.25 % xylene cyanol FF
1 mM ethylenediaminetetraacetic acid (EDTA)
10x DNase I Buffer
500 mM Tris-HCl (pH 7.5)
100 mM MgCl2
0.5 mg/ml nuclease-free bovine serum albumin (BSA)
10x MOPS buffer (pH 7.0): 
0.2 M MOPS (3-[N-morpholino] propanesulfonic acid
0.05 M sodium acetate
0.01 M (EDTA)
Loading buffer (100Pl total volume)
10 Pl 10x MOPS buffer
11.5 Pl RNase-free water
50 Pl of deionized formamide
17.5 Pl 37% formaldehyde solution
10 Pl 10x loading dye
1 Pl 10 mg/ml ethidium bromide
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Lysis buffer-E-ME: 7 Pl of E-ME to each 1 ml of Lysis Buffer (provided with Absolutely
RNA® Miniprep kit).
Section 2.1.6  Solutions
[3H]-TCDD 
The radioligand [3H]-TCDD (specific activity 34.7 Ci/mmol, 0.929 mCi/ml in toluene/CH3OH,
1 x 500 mCi) was from ChemSyn Laboratories (13605 W. 96th Terr, Lenexa, Kansas, U.S.A.,
66215-1297). The concentration of [3H]-TCDD was calculated 26 PM (SA = 29,77 Ci /mmole).
From this stock, a 535 nM top stock was prepared by diluting with p-Dioxane and stored at -
20°C. The radioligand was diluted to the working concentration (200 nM) immediately prior to
use. 
Cold TCDD 
The top stock solution of TCDD (155 PM) was prepared in DMSO and stored at room temper-
ature protected from light.
TCAOB 
It was prepared as 3 mM top stock dissolved in p-dioxane and stored at room temperature pro-
tected from light, and diluted to the working concentration (20 µM) for experimental proce-
dures. 
Phenylbenzothiazoles (PBT)
Stock solutions (20 mM) of phenylbenzothiazoles compounds were prepared in DMSO, and
stored protected from light at -20°C. Prior to experimentation, these test agents were diluted to
the desired working concentrations.
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TCDF 
Stock solution (20 mM) of TCDF compounds was dissolved in p-dioxane and stored at room
temperature protected from light. Prior to experimentation, TCDF was diluted to the desired
working concentrations.
Astrazeneca compound 1c and MC 
Stock solutions (20 mM) of TCDF and MC compounds was dissolved in p-dioxane and stored
at -20°C protected from light. Prior to experimentation, these drugs were diluted to the desired
working concentrations.
TCPT
Stock solution (1 mM) of TCPT was prepared in DMSO, and stored protected from light at -
20°C. Prior to experimentation, TCPT was diluted to the desired working concentrations
MTT solution
Thiazolyl Blue Tetrazolium Bromide, MTT chemical, (purity 98%), was purchased from Sigma
(cat.no M5655-1G). MTT stock solution was prepared in water at 2 mg/ml and stored at 4°C,
protected from light.  
Dextran-coated charcoal (DCC) stock suspension
DCC was purchased from Sigma (cat no. C-6241). It was prepared as follows: 0.67 g of char-
coal-dextran coated powder was resuspended in 10 ml of ice-cold MDENG for a final concen-
tration of 10 mg/ml (2 mg of charcoal /mg cytosolic protein) and stored at 4ºC, wrapped with
aluminium foil, at least one day prior to experiment.
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DNase solution 
50 Pl of DNase Digestion Buffer + 5 Pl of reconstituted RNase-Free DNase I (prepared accord-
ing to Stratagene’s instructions).
Abgenes PCR readyMix (1.3x) (per final 1x reaction)
0.625 units ThermoPrime Taq DNA polymerase
75 mM Tris-HCl (pH 8.8 at 25ºC)
20 mM (NH4)2SO4
1.5 mM MgCl2
0.01% (v/v) Tween® 20
0.2 mM each of dATP, dCTP, dGTP and dTTP
Section 2.1.7 Gels
1% agarose gel (100 ml)
1 g agarose
88 ml RNase-free water
10 ml 10x MOPS buffer
2.7 ml 37% formaldehyde
8% TBE gel (100 ml)
26.6 ml 30% Acrylamide
52.7 ml water
20 ml 1x TBE
0.7 Pl 10% APS
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50 Pl TEMED 
Section 2.1.8 Real-time RT-PCR primers and probes
Real-time RT-PCR primers and probes for human genes were designed using primer 3 (http://
frodo.wi.mit.edu/) and synthesized by the genomic company Eurofins MWG Operon for prim-
ers and probes synthesis. The rat primers and probes were designed by Dr Tao Jiang [153]. The
primer and probe sequences, the gene accession numbers, and the probe labels for rat and human
are listed in (Table 2.1 & Table 2.2) respectively. 
To avoid amplification from traces of possible contaminating DNA in the RNA isolation, one
of the two primers was placed at the junction between two exons (for rat, CYP1A1, ß-actin and
AhR genes and human ß-actin and AhR genes). Except for the human CYP1A1 gene, the probe
was designed to span the junction between two exons. Primers were checked for specificity by
Blast search using the relative NCI BLAST search. The human primer pairs give rise to PCR
products of 122 bp, 139 bp and 150 bp for CYP1A1, E-actin and AhR respectively. 








CCA CAG CAC CAT AAG AGA TAC AAG 
CCG GAA CTC GTT TGG ATC AC







GCA GCT TAT TCT GGG CTA CA
CAT GCC ACT TTC TCC AGT CTT A
TAT CAG TTT ATC CAC GCC GCT GAC ATG
 Af082124
HEX-BH2
Table 2.1 RT-PCR oligonucleotides primers for rat genes. The primers and probes are identified by letters
designating the forward (F) and, reverse (R) primer or the probe (P), and a number corresponding to the position of the base at
the 5' end of the positive strand of primer or probe in the reference sequence, according to gene bank accession number.
Sequences are given from 5’ĺ 3’'. The reporter dye is at the 5’ end of the oligonucleotide, and the quencher dye Black-Hole-
1 or -2 is at the 3’ end; FAM, iscarboxy fluorescein; Hex, hexachlorofluorescein; ROX, 5(6)-carboxy-X-rhodamine.
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Section 2.2 General laboratory methodology
Section 2.2.1  Receptor preparation
AhR was prepared from rat liver cytosol given it is rich in AhR proteins. The preparation re-
quires that all materials should be autoclaved and all work carried on ice. The rats were first ad-
ministered a single intra-peritoneal dose of 0.3 ml Dolethal (200 mg/ml) (purchased from
Vetoquinol Company) and then death confirmed by cervical dislocation. The livers were per-
fused immediately with cold 150 mM KCl, pH 7.4 via the hepatic portal vein. While perfusing,





CTG ACA GGA TGC AGA AGG AG
GAT AGA GCC ACC AAT CCA CA
CAA GAT CAT TGC TCC TCC TGA GCG
V01217
ROX-BH1








GTT GTG TCT TTG TAA ACC AGT G
CTC ACT TAA CAC CTT GTC GAT A







ATA CAG AGT TGG ACC GTT TG
CTT TCA GTA GGG GAG GAT TT







GAC ATG GAG AAA ATC TGG C
AGG TCT CAA ACA TGA TCT GG
ACA CCT TCT ACA ATG AGC TGC GTG T
NC_000007
ROX-BH1
Table 2.2 RT-PCR oligonucleotides primers for human genes. The primers and probes are identified by letters
designating the forward (F), and reverse (R) primer or the probe (P), and a number corresponding to the position of the base at
the 5’ end of the positive strand of primer or probe in the reference sequence, according to gene bank accession number.
Sequences are given from 5’ĺ 3’. The Reporter dye is at 5’ end of the oligonucleotide, and the quencher dye Black-Hole-1 or
-2 is at 3’ end. FAM, iscarboxy fluorescein; Hex, hexachlorofluorescein; ROX, 5(6)-carboxy-X-rhodamine




Table 2.1 RT-PCR oligonucleotides primers for rat genes. The primers and probes are identified by letters
designating the forward (F) and, reverse (R) primer or the probe (P), and a number corresponding to the position of the base at
the 5' end of the positive strand of primer or probe in the reference sequence, according to gene bank accession number.
Sequences are given from 5’ĺ 3’'. The reporter dye is at the 5’ end of the oligonucleotide, and the quencher dye Black-Hole-
1 or -2 is at the 3’ end; FAM, iscarboxy fluorescein; Hex, hexachlorofluorescein; ROX, 5(6)-carboxy-X-rhodamine.
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buffer in attempts to minimize contamination by endogenous proteases. Livers were quickly re-
moved, weighed, minced on a dish placed on ice with scissors in cold MDENG buffer, decanted
and homogenized in 5-volumes of MDENG (v/w) at 0ºC in a Potter-Elvehjem glass homoge-
nizer fitted with a Teflon pestle. The homogenate was centrifuged at 12,000 x g for 20 min at
4ºC in a Beckman J21-21 centrifuge. The supernatant was removed avoiding lipid layers on top
and subjected to ultracentrifugation at 440,000 x g for 25 min at 4ºC. Aliquots of this superna-
tant, referred as hepatic cytosol, were stored at -80ºC until use. 
Section 2.2.2  Determination of protein concentrations
Protein concentration was determined using the Bradford method using Bio-Rad reagents with
bovine serum albumin as the standard [155]. 
Section 2.2.3  [3H]-TCDD Binding assay
Section 2.2.3.1 Principle
The binding assay using radiolabeled [3H]-TCDD in liver cystosol was extensively used to de-
termine the binding affinities of several compounds relative to the TCDD's KD [164]  [66]  [157]
[158]  [67]  [159]. The radioligand [3H]-TCDD and non radioligand competitor (TCAOB) are
equilibrated with a preparation containing AhR receptor (hepatic cytosolic protein) for a certain
time sufficient to reach the binding equilibrium. Parallel experiments were run with an unla-
beled competitor (TCAOB) known to bind to the same receptor population. TCAOB was added
in excess concentration to define the non-specific binding of [3H]-TCDD.
The unbound radioligand was removed by adsorption to dextran-coated charcoal solution. The
assay is terminated by this step, and the radioactivity quantified. [3H]-TCDD remaining in the
cytosol after adsorption represents the total binding ("specific" and "nonspecific"). The sub-
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straction of the nonspecific binding from the total binding defines the specific binding of the
preparation. The radioactive signal corresponds to the concentration of radioligand bound to the
receptor. 
Section 2.2.3.2 Methodology
The radioligand binding assay described in this work is slightly modified from the classic assay.
The conditions of the binding assay were as described [164], except using tetrachloroazoxyben-
zene (TCAOB) [66] as a competitor. 
The frozen cytosolic aliquots from rat liver protein preparation were diluted in ice-cold
MDENG buffer to a concentration of 5 mg of protein /ml prior to each experiment. The general
procedure in binding assays consists of adding 1Pl of 200 nM [3H]-TCDD in p-dioxane to the
solution of proteins (rat liver cytosolic preparation or bovine serum albumin) to a final concen-
tration of 1 nM in 200 Pl total volume, unless indicated differently in the individual figure leg-
ends. In order to define the non specific binding (NSB) of [3H]- TCDD, the same experiment
was run in parallel with 1 Pl of unlabeled TCAOB (200-fold molar excess of [3H]-TCDD con-
centration). The tubes were incubated at 4ºC for 16 h. Each sample was analyzed in triplicate.
After the 16-18 h incubation, tubes were vortexed thoroughlly (~ 30 seconds) then centrifuged
at 1000 x g briefly to collect the solution from the top and the edges of the tubes. The assay was
terminated by the addition of 30 Pl dextran-coated charcoal (10 mg/ml in MDENG buffer), un-
less indicated differently in the individual figure legends, to remove unbound [3H]-TCDD.
Samples were vortexed vigorously and incubated on ice for 10 minutes, followed by centrifu-
gation at 20,000 x g at 4ºC for 10 min. A volume of 150 Pl of supernatant were transferred to
scintillation vials containing 5 ml scintillation fluid and mixed vigorously before counting.
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Parallel to each experiment, the total [3H]-TCDD in solution, was determined by the transfer of
a 30 Pl of aliquot to scintillation vials after the 16-h incubation (no charcoal-dextran is added to
these tubes). This step is an important control, for total radioactivity in solution. 
Radioactivity was determined by liquid scintillation counting using a Packard Tri-carb Model
2100 TR Liquid Scintillation analyser. Data were collected as d.p.m values, then, converted to
nM as follows [160]:
RL* = B / (V x SA x 2220) nM.
Where B is the radioligand bound (d.p.m) corrected for counter background, V is the volume of
radioligand assayed (ml), SA is the specific activity of the radioligand (Curies /mmole), and
2220 is the conversion factor from d.p.m to nanocuries.
Given the high [3H]-TCDD toxicity, a swipe test was performed regularly, to detect [3H]-TCDD
contamination. 
Section 2.2.3.3 [3H]-TCDD standard binding assay
The standard binding assays were processed essentially as described in binding assay method-
ology except with incubating 200 Pl of aliquots containing receptor preparation with a range of
concentration of [3H]-TCDD ± TCAOB (200-fold molar excess) for 16 h at 4ºC. 
Section 2.2.3.4 [3H]-TCDD competition assay
Section 2.2.3.4.1 Principle
The binding affinity constant of the radioligand [3H]-TCDD was determined from the saturation
experiment. The relative binding affinities, (or inhibition constant Ki) of the test compounds
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were calculated from the IC50, the concentration of the test compound which inhibits 50 % of
the specific binding of [3H]-TCDD in the absence of the competitor. Ki of test compounds are
calculated by GraphPad Prism 5.0 Software using the equation derived by Cheng and Prusoff
[161]:
Where, L is the concentration of the radioligand and KL is the IC50 value for [
3H]-TCDD.
Section 2.2.3.4.2 Methodology:
The competitive assays were run essentially under the same conditions as for [3H]-TCDD bind-
ing standard assay. In order to determine the IC50 of the competitor that displaces [
3H]-TCDD
from specific sites, four experiments were run in triplicate, each using 200 Pl cytosol and 1Pl
of either TCDD, TCAOB or test competitor, to define:
a) Total binding of [3H]-TCDD in the absence of test competitor: cytosols + 1 nM [3H]-TCDD.
b) Non-specific binding of [3H]-TCDD in the absence of test competitor: a) + 200 nM TCAOB.
c) Specific binding of [3H]-TCDD in the absence of competitor: a) - b).
d) Total binding of [3H]-TCDD in the presence of test competitor: a) + increasing concentra-
tions of competitor.
e) Non specific binding of [3H]-TCDD in the presence of competitor: b) + increasing concen-
trations of competitor.
f) Specific binding of [3H]-TCDD displaced from AhR by test competitor: d) - e).
Ki IC50  1 L> @ KL e+ e=
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[3H]-TCDD (1 nM) was added to 200 Pl cytosolic preparations ± TCAOB (200 nM) ± varying
concentration of unlabeled competitor dissolved in DMSO. Competitors were add first from 10-
30 minutes to allow equilibrium before the addition of [3H]-TCDD. Steps a), b) and c) are pos-
itive controls. Step e) was performed only once for each test competitor with the aim of verify-
ing that the the amount of [3H]-TCDD NSB is unchanged in the presence of increasing
concentrations of test competitor and to test whether the test competitor and [3H]-TCDD are
competiting for NSB sites. After validating that the NSB of [3H]-TCDD in the presence of test
competitor is similar to that in the absence of the test competitor, the step e) was replaced with
step b). Other controls are:
(a) Assay tubes were incubated with 1 Pl [3H]-TCDD + 1 Pl DMSO (0.5%).
(b) 30 Pl of triplicate samples were subjected to counting before treatment with charcoal to asses
the concentration of [3H]-TCDD in incubations. All the samples were performed in triplicate.
The assay was terminated by the charcoal adsorption as described in binding assay methodolo-
gy.
Section 2.2.4 Cell cultures
The H4-II-E and MCF-7 cells were cultured in modified Eagle's medium (MEM) containing so-
dium bicarbonate and supplemented with 10% fetal bovine serum, 1% (200 mM L-glutamine,
10,000 U penicillin and 10 mg/ml Streptomycin) solution 100x, 1% MEM nonessential amino
acid solution 100x. The cells were cultured in a humidified atmosphere with 5 % CO2 at 37°C.
Section 2.2.5 Cell growth curves
MCF-7 and H4-II-E cells were plated in triplicate in 96 well plates at the densities of 2.5 x 103
and 5 x 103 cells in 180 Pl per well of medium respectively for 7 consecutive days at 37°C/5 %
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CO2 to reach 90-95% confluence. On the third day, the old medium in cultures was replaced by
fresh medium. Each day, medium was removed, cells were washed with 150 Pl PBS, trypsinized
with 60 Pl Trypsin/EDTA and subjected to counting by hemocytometer. 
Section 2.2.6 Chemical treatment for the induction assay
Benzothiazole test chemicals and TCDD were prepared in dimethyl sulfoxide (DMSO) at 20
mM and 10 PM top stock solutions respectively. Prior to each experiment, concentrations were
prepared in DMSO then further diluted with fresh (first two experiments) or incubation medium
(all subsequent experiments) into the working concentrations at the final concentration of 0.1%
or 0.5 % immediately before use. 
The solubility of the top stock solutions and the incubation concentrations was assessed visually
by examining precipitation formation and solution turbidity. None of the chemicals used were
found insoluble at the concentrations mentioned above. However, that was not confirmed ana-
lytically.
All experiments were conducted using the same source of each benzothiazole test chemicals and
one top stock solution of TCDD that was aliquoted in Eppendorf tubes and stored at -20°C till
further use.
H4-II-E and MCF-7 cell cultures (90-95% confluent) were treated with 20 Pl of incubation me-
dium containing the test chemical and TCDD or vehicle DMSO. For experiments on TCDD and
test chemicals with 10 PM as the highest concentration, the final concentration of DMSO in the
cultures was 0.1%, whereas for experiments on test chemicals with 30 PM as the highest con-
centration, the DMSO final concentration was 0.15%. At these concentrations, DMSO was not
found toxic and did not increase the CYP1A1 expression above the constitutive basal levels.
MCF-7 and H4-II-E cultures were seeded in triplicate in 96 well plates at a cell density of 5 x
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104 and 1 x 105 cells per well respectively and incubated for 24 h at 37°C/5 % CO2 to reach 90-
95% confluency. Cell confluence was assessed visually at 24 h and the incubation medium was
replaced with the incubation medium containing the test chemical (indicated concentrations),
the positive control (TCDD 10 nM) or negative control (DMSO 0.1%) for 4 h. Untreated cells
were included as a negative control in all experiments. To compare the maximal inducing effect
for CYP1A1 mRNA for each chemical with that of TCDD, the concentration response curves
for all test-chemicals were generated relative to the maximally inducing concentration of TCDD
(10 nM) unless indicated differently in the individual figure legends.
Section 2.2.7 Preparing H4-II-E and MCF-7 cells before total RNA isola-
tion
Following incubation with the indicated chemical(s), medium containing the test chemical was
removed and cultures were washed with 100 Pl of phosphate buffered saline (PBS). The PBS
was then replaced with 60 Pl Trypsin/EDTA. When cells were detached, they were resuspend
in 120 Pl CMEM, then transferred to microcentrifuge tubes and centrifuged at 5000 x g for 5
min at 4°C. Cell pellets were resuspend in phosphate buffer saline and centrifuged for another
5 min at 5000 x g at 4°C. Cell pellets were frozen at -20°C until ready for total RNA isolation.
Section 2.2.8 RNA isolation
Total RNA from H4-II-E cells was isolated according to the Absolutely RNA protocol (Strata-
gene), with minor modifications.
The optimized protocol is the following:
1. For low-density cells (1 x 104 - 1 x 105 cell number), add 100 Pl Lysis buffer-E-ME
mixture to the cell pellet and vortex to homogenise. For high-density cells (1 x 105 - 1 x 106 cell
number), lyse with 200 Pl Lysis buffer-E-ME (prepared freshly).
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2. Add an equal amount of 70% ethanol to the lysates and vortex the tubes well.
3. Transfer the lysates in ethanol to an RNA binding spin cup and spin in a microcen-
trifuge at maximum speed for 1 minute at room temperature.
4. Discard the filtrate and add 400 Pl of 1x Low-Salt Wash Buffer and spin in a micro-
centrifuge at maximum speed for 1 minute at room temperature.
5. Add 50 Pl of DNase I solution (prepared freshly) onto the fiber matrix and incubate
the samples at 37°C for 15 minutes in a water incubator. 
6. Add 400 Pl of 1x High-Salt Wash Buffer and spin in a microcentrifuge at maximum
speed for 1 minute at room temperature.
7. Discard the filtrate and add 400 Pl of 1x Low-Salt Wash Buffer and spin in a micro-
centrifuge at maximum speed for 1 minute at room temperature.
8. Discard the filtrate and add 200 Pl of 1x Low-Salt Wash Buffer and spin in a micro-
centrifuge at maximum speed for 2 minutes at room temperature.
9. Transfer the spin cup to a 1.5 ml microcentrifuge tube and discard the receptacle
tube.
10. Add 30 Pl of Elution Buffer directly onto the centre of the fiber matrix inside the
spin cup and cap the spin cup. Incubate at room temperature. Spin the tube in a microcentrifuge
at maximum speed for 2 minutes at room temperature.
11. Store RNA in the Elution Buffer at -80°C.
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Section 2.2.9  Quantitation of total RNA
The quantity of total RNA was determined using a RiboGreen RNA quantitation kit (Molecular
Probes, Eugene, OR). It consists on measuring the fluorescence of RiboGreen, a fluorescent
RNA-binding probe, against a standard. The RiboGreen assay was prepared using high range
ribosomal RNA (rRNA) standard curve. The standard was generated from 2 Pg/ml rRNA using
five concentrations including the blank sample (final concentrations ranging from 10 to 500 ng/
ml) in a 200 Pl volume. 2 Pl of each RNA sample was diluted 50-fold with TE buffer. The Ri-
bogreen was diluted 200-fold before performing each standard and 100 Pl was added to both the
RNA standards and isolated samples. The concentration of total RNA in the samples was ex-
trapolated from the standard curve. The fluorescence was measured using a Wallac Victor2 plate
reader (Perkin Elmer) instrument set at 485 nm excitation and 510 nm emission. Once the con-
centration of RNA was determined, the quality of RNA was assessed by the relative intensities
of the 28S and 18S rRNA bands visualized by electrophoresis on 1% denaturing agarose gel af-
ter ethidium bromide staining. 
Section 2.2.10 cDNA synthesis
Total RNA was reverse-transcribed into first strand cDNA using AffinityScript QPCR cDNA
synthesis kit. The reverse transcription reaction was prepared from 50 ng total RNA as follows:
In 20 Pl total volume:
10 Pl of 2x cDNA synthesis master mix.
1 Pl of random primers (~100 ng).
1 Pl of oligo d(T) (~100 ng).
1 Pl of Reverse transcriptase (RT).
x Pl of RNAse free water.
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x Pl of total RNA (50 ng).
In addition, under the same conditions described above, a sample with no RT was run as a neg-
ative control for genomic DNA contamination. DEPC-treated water was substituted for RT. 
The reverse transcription reaction was initiated by running the samples under the following pro-
gram:
- 25 °C for 5 minutes.
- 42°C for 45 minutes.
- 95°C for 10 minutes.
Section 2.2.11 Quantitation of cDNA
The quantity of cDNA was determined using a picogreen DNA quantitation kit (Molecular
Probes, Eugene, OR). It consists of measuring the fluorescence of PicoGreen, a fluorescent
DNA-binding probe relative to a ȜDNA standard curve. The standard was generated from 2 Pg/
ml ȜDNA using five concentrations including the blank sample (final concentration ranging
from 10 to 200 ng/ml) in a 200 Pl volume. A volume of 5 Pl of each RNA sample was diluted
20-fold with TE buffer. The Picogreen was diluted 200-fold before performing each standard
and 100 Pl was added to both the DNA standards and cDNA samples. Concentration of un-
known cDNA in the samples was extrapolated from the standard curve. The fluorescence was
measured using Wallac Victor2 plate reader (Perkin Elmer) set at 485 nm excitation and 510 nm
emission.
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Section 2.2.12 Polymerase Chain Reaction PCR 
Before running the qRT-PCR on the cDNA samples, each set of primers and probes for individ-
ual genes were tested on the cDNA samples by amplification with a ordinary PCR reaction then
run on an 8% acrylamide TBE gel to test for the specificity of the primers and for genomic con-
tamination in the samples.
 
A negative control consists of substituting the DNA template with 1 Pl Nuclease-free water.
PCR products were then analyzed on a 8% TBE gel electrophoresis along with a DNA ladder.
Volume Final Concentration 1X
ReddyMix PCR Master Mix 22.6 Pl 1X
Primer forward (12.5 PM each) 0.7 Pl 0.35 PM
Primer reverse (12.5 PM each) 0.7 Pl 0.35 PM
Nuclease-free water variable
DNA template 1 Pl 1 ng
Total volume 25 Pl




Initial denaturation 94°C 2 min 1 cycle
Denaturation 94°C 1 min
Annealing 58 °C 30 sec 35 cycles
Extension 70°C 30 sec 
Final extension  70°C 10 min 1 cycle
Table 2.4 PCR thermal cycler programme. 
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Section 2.2.13 Quantitative Real-Time RT-PCR using TaqMan® probes
Section 2.2.13.1 Principle
TaqMan real-time PCR provides a fluorescence measurement of mRNA expression during each
cycle of a PCR protocol. It is a quantitative analysis of mRNA expression based on PCR cycling
threshold (Ct) values using MX4000 software. The TaqMan RT-PCR was used to assess the in-
ducibility of CYP1A1 and the expression of AhR and ß-actin. It allows study of changes in gene
expression by measuring messenger RNA (mRNA) levels in total RNA extracted from rat H4-
II-E and human MCF-7 cells. 
The Stratagene’s Brilliant® multiplex QPCR master mix allows more targets (up to four) to be
amplified with a normalizing gene in the same reaction by using probes with spectrally different
fluorophores for the detection of each amplicon. CYP1A1, AhR and ß-actin mRNA were run si-
multaneously in the same qRT-PCR reaction. CYP1A1, and AhR mRNA expression was quati-
tated by performing comparative Ct method for relative quantitation of gene expression using
TaqMan real-time Multiplex quantitative PCR technology with ß-actin as the endogenous con-
trol. The use of ß-actin as reference RNA, was based on the fact that ß-actin RNA measure-
ments in both H4-II-E and MCF-7 cells were unchanged at all treatment concentrations (finding
proven in the actual study in Chapter 3). The first step consists of evaluating the proticol by ad-
ministering TCDD to the H4-II-E cells. Once evaluated, the protocol was used for the rest of the
test compounds.
Section 2.2.13.2 Analysis
Gene expression analysis was performed using the relative quantitation method by Pfaffl (2001)
[162]. Quantitation of RNA copy number of the target gene was calculated from the experimen-
Rana Bazzi   Section 2.2.13
Page 75
tal Ct values. The threshold Ct value for each DNA was adjusted so that the Ct value is in the
exponential phase of the PCR reaction. The threshold was kept constant throughout the analysis
for all the experiments. That is for CYP1A1, ß-actin and AhR 2000, 200 and 200 respectively.
In each experiment, an independent control sample was included and run along with the sam-
ples. The Ct of this external control was used as a calibrator. Negative controls were run side by
side with samples for each RT-PCR reaction. These were no-RT and no-RNA samples.
First, the Ct of the target gene was normalized to that of the external control (RNA from rat tis-
sue liver homogenate treated with dioxin), for both treated (test) and vehicle (DMSO) samples:
ǻCt = Ct(target)-Ct(external control). The copy number of the test chemical, vehicle and untreated
samples was normalized to that of internal control (ß-Actin) as target/ ß-actin ratio. Then, the
ǻǻCt was converted to copy number after correcting for qRT-PCR efficiency for each target
according to the equation = E-ǻǻCt. Finally, the ratio was normalized to control untreated cells,
vehicle treated cells or 10 nM TCDD-treated cells according to the experiment. 
Section 2.2.13.3 Quantification by real-time RT-PCR
Once the quantity of cDNA was determined, 2 ng of cDNA was subjected to qRT-PCR ampli-
fication. Briefly, the Multiplex qRT-PCR reaction was set up using Brilliant® Multiplex QPCR
Master Mix (refer to Table 2.6) and amplified using a TaqMan thermal cycler (Mx4000). The
Multiplex real-time (RT-PCR) reactions were run under the conditions cited in Table 2.5.
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Section 2.2.13.4 qRT-PCR standard curves
To define the QPCR efficiency (E), a standard curve of the three genes, CYP1A1, ß-actin and
Number of cycles Time Temperature
1 10 min 95°C
40 20 sec
1 min; 30 sec
95°C
58°C
Table 2.5 qRT-PCR cycling protocol.  The conditions for the multiplex real-time PCR reactions were 
one cycle at 95 °C for 10 min, followed by 40 cycles at 95°C for 20 s, and 58°C for 90 s
qRT-PCR experimental reaction (12.5Pl rxn)
2.375 Pl Nuclease-free PCR-grade water H2O 
5.25 Pl of 2x master mix
2 Pl cDNA
 CYP1A1
0.25 Pl of FAM
0.125 Pl of reverse primer
0.125 Pl of forward primer
ß-Actin
0.5 Pl of ROX
0.25 Pl of reverse primer
0.25 Pl of forward primer
AhR
0.75 Pl of HEX
0.25 Pl of reverse primer
0.375 Pl of forward primer
Table 2.6 Multiplex real-time RT-PCR experimental reaction.  The volume of master 
mix, water, the pair of primers and the probes as indicated for each gene in 12.5 Pl of buffer solution 
qRT-PCR experimental reaction. 
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AhR was generated by stepwise dilutions of cDNA in both human and rat cell lines. Human and
rat cDNA samples used to generate the standard curves were prepared from MCF-7 and H4-II-
E cells treated with TCDD (10 nM) for 4 h respectively. cDNA at 2 ng/Pl initial concentration
was further diluted 5-fold to the final concentration of 16 pg/Pl. A duplicate of the four samples
(2000, 400, 80 and 16 pg/Pl) was subjected to Multiplex real time RT-PCR reaction. 
The standard curves for each dye were generated using the least mean squares curve fitting log-
arithm by MX4000. The R Squared (RSq) or regression value is determined for each standard
from the equation for the line [y = mlogx + b, where m is the slope of the line]. The RSq value
is an indicator of the quality of the fit of the standard curve to the Standard data points plotted.
The value will always be between 0 and 1. The closer the value is to 1, the better the fit of the
line. The slope of the curve is directly related to the average amplification efficiency throughout
the cycling reaction. The equation that relates the slope to amplification efficiency is according
to Pfaffl [162]:
PCR Efficiency = 10(-1/slope).
where PCR Efficiency corresponds to the proportion of template molecules that are doubled
every cycle. From this equation it follows that a reaction with 100% efficiency will result in a
slope of -3.322.
As negative controls, no RT and no template reactions were run in parallel. A sample of cDNA
from rat liver chronically treated with dioxin was included as a positive control. Amplification
efficiency was used to determine gene copy number as described in Section 2.2.13.2. 
Section 2.2.14 Induction protocol 
The general conditions consist of incubating H4-II-E cells and MCF-7 cells at 1 x 105 cells and
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5 x 104 cells per 180 Pl in 96 well plates respectively. The following day, cultures were treated
with vehicle control 0.1% DMSO as a negative control, TCDD (10 nM) as a positive control
and the test inducer at the indicated concentrations for 4 h. In the first two experiments, chem-
ical treatment consisted of diluting DMSO, TCDD or the test inducer in a fresh medium prior
to addition. In all subsequent experiments, chemicals were diluted into 200 Pl of incubation me-
dium, then 20 Pl of incubation medium containing the chemical was added into the well for a
total volume of 200 Pl. Untreated cultures were included as a negative control in all experiments
except for the first experiment (Section 3.2.5.1).
Section 2.2.15 Growth inhibitory assay: MTT assay
MTT assay measures the antiproliferative activity of test compounds. The general procedure is
essentially as described by [250]. MCF-7 and H4-II-E cells were seeded in triplicate into 96-
well microliter plates at a density of 2.5 x 103 cells /180 Pl and 5 x 103 /180 Pl respectively and
allowed 24 h to adhere before drugs were introduced (final concentration 0.1nM to 10 PM, n =
9). In parallel to each treatment, control triplicate cultures were seeded to assess the number of
viable cells at the time of the addition of the drugs (time zero, T0). Serial drug dilutions were
prepared in medium immediately prior to each assay. The following day, cultures were treated
with 20 Pl of the test drugs and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) was added to the T0 cultures. Cell viability was measured at the time of the drug addition
(time zero) and following 72 h exposure by MTT reduction. A volume of 50 Pl MTT was added
to each well (final concentration 400 Pg/ml). Incubation at 37°C for 4 h allowed reduction of
MTT by mitochondrial dehydrogenase to an insoluble formazan product. Well contents were
aspirated and formazan solubilized by addition of 150 Pl DMSO. Absorbance was read on Wal-
lac Victor2 plate reader (Perkin Elmer) instrument at 590 nm as a measure of cell viability. Cell
viability was assessed using DMSO treated cells as the 100% viable control.
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Camptothecin, a known toxic compound [163], was included as a positive control at varying
concentrations.
Section 2.2.16 Curve modelling and statistical analysis
All data are represented as mean ± SD. Statistical significance is tested by Student's t-test, paired
t-test, or one-way analysis of variance (ANOVA) followed by Dunett’s Multiple Range Test.
Groups were considered significantly different if p<0.05.
KD and Bmax were determined from non linear regression for single site binding hyperbola anal-
sysis by GraphPad Prism 5.0 Software (GraphPad Software Inc, San Diego, CA). 
[3H]-TCDD log concentration competition curves were fitted using non linear regression for
single site competitive binding analysis, IC50 values represent the concentrations of test com-
pound required to displace 50% of [3H]-TCDD specifically bound the Ah receptor. IC50 values
were determined using GraphPad Prism 5.0 Software (GraphPad Software Inc, San Diego, CA).
The concentration-response curves for the CYP1A1 mRNA induction were modelled using the
variable slope sigmoid Hill equation (GraphPad Prism 5.0 Software). The CYP1A1 mRNA
EC50 is the concentration at which the induced gene is halfway between the calculated bottom
and the top of each concentration-response curve. 
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Chapter 3  Results 
Section 3.1 Characterization of the binding to the rat hepatic Ah recep-
tor
This chapter aims to quantitate the binding of phenylbenzothiazole analogues to the AhR by vir-
tue of a [3H]-TCDD competitive binding assay. A conventional representation of the binding
affinity is the reciprocal of the ligand-receptor complex dissociation constant, and denoted KD.
In this work, the binding affinities will be indirectly presented as the equilibrium dissociation
constants for direct binding measurements or inhibition constants Ki for displacement measure-
ments. All experiments were carried - out assuming:
 A single binding site between the drug and the receptor.
 The experiment has reached equilibrium. 
 A stable concentration of drug/receptor.
 The binding is reversible and follows the law of mass action.
 There is no cooperativity.
 Receptors are either free or bound to ligand. No partial binding.
 The binding does not alter the ligand or receptor.
 Only a small fraction of ligand binds to the receptor to approximate the free concentration 
with the added concentration
The binding assay was developed as described [164], except using tetrachloroazoxybenzene
(TCAOB) [66] as a competitor. It was essential to optimise several aspects of the assay.
Section 3.1.1  Incubation time
It is essential to determine whether the binding of [3H]-TCDD to the AhR has reached equilib-
rium. To investigate this, the time course of specific binding of [3H]-TCDD to rat liver cytosol
was measured.
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Cytosolic protein preparations were incubated with [3H]-TCDD (1 nM) ± TCAOB (200 nM)
for different incubation times (0, 2, 4 and 16 h) ( time zero does not correspond really to time
zero, but it is estimated to be very few minutes). Charcoal was added to terminate the assay and
radioactivity measured as described in Materials and Methods (Section 2.2.3.2). BSA was used
in place of cytosolic protein as a negative control. 
In Figure 3.1 is shown the effect of time on [3H]-TCDD specific binding. The results show that
[3H]-TCDD binds specifically to rat liver cytosol quickly after addition of the radioligand (Fig-
ure 3.1). Maximal specific binding of [3H]-TCDD to rat cytosolic protein was detected after 2
Figure 3.1 Effect of incubation time on [3H]-TCDD specific binding to rat cytosolic protein. Rat liver cy-
tosol [Ɣ] and bovine serum albumin [ǻ] proteins were incubated at 4°C with 1nM [3H]-TCDD ± 200 nM unlabeled TCAOB
at varying times of incubation. At the specified time point, charcoal was added to remove unbound ligand and terminate the
assay and radioactivity in the resultant supernatant measured by liquid scintillation spectrometry. The radioactivity remaining
in the solution after adsorption with charcoal represents the total binding (“specific and “non specific”). The non specific bind-
ing is defined by the radioactivity remaining in solution in the tubes with TCAOB. The specific binding is calculated by sub-
stracting the non specific binding from the total binding. Radioactivity was converted to nanomolar concentrations. Each point
represents the average of mean ± S.D for triplicate samples, and is representative of results obtained from three experiments.
(* asterisk; p<0.01, t-test, n=3, [3H]-TCDD specific binding in CP compared to BSA for each time point). Ordinate: specific
binding of [3H]-TCDD (nanomolar concentration). Abscissa: Incubation time (0, 2, 4 and 16 h). 
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h of incubation and remained unchanged after that time (Figure 3.1). [3H]-TCDD specific bind-
ing to BSA was negligible, whereas [3H]-TCDD specific binding to rat cytosolic protein was
found to be high in three experimental repeats. The high specific binding of [3H]-TCDD to the
rat cytosolic proteins and the negligible binding to the BSA confirms that the [3H]-TCDD binds
specifically to a cytosolic protein, which has previously been shown to be the AhR [66], and the
specific binding protein will henceforth be referred to as the AhR. The time of incubation was
selected to be 16 h following the protocol described by Bradfield and Poland (1988) [164]. 
Section 3.1.2  Dextran-coated charcoal (DCC)
The Dextran-coated charcoal was used to separate the bound from the free ligand. So, it is es-
sential to have enough charcoal to adsorb loosely bound radioligand and free radioligand re-
maining in solution. However, a high amount of charcoal could also adsorb the specifically
bound radioligand. So it was important to optimise the amount of charcoal for a balance be-
tween decreasing [3H]-TCDD nonspecific binding and loss of specific binding to the receptor.
Cytosolic proteins (or BSA as a negative control) were incubated with [3H]-TCDD (1nM) ±
TCAOB (200 nM) and incubated at 4°C for 16 h. After the 16 h-incubation, protein samples
were incubated with 30Pl of different amounts of charcoal in suspension (0.06, 0.2, 0.6, 2 and
6 mg /mg protein) and the charcoal removed by centrifugation. Radioactivity in the resultant su-
pernatants was measured as described in Materials and Methods (Section 2.2.3.2). Figure 3.2
shows the effect of charcoal amount on the total, nonspecific and specific binding of [3H]-
TCDD to cytosol and BSA proteins. Figure 3.2 B reveals high nonspecific binding of [3H]- 




Figure 3.2 Effect of charcoal on [3H]-TCDD binding to rat cytosolic and BSA proteins.  [3H]-TCDD bind-
ing to BSA (A) and rat cytosol (B). Aliquots of cytosolic (CP) and bovine serum albumin (BSA) proteins (5 mg/ml, prepared
in MDENG buffer) were incubated with 1nM [3H]-TCDD ± 200 nM TCAOB for 16 h at 4ºC. Varied amounts of charcoal-
dextran in MDENG buffer (0.06, 0.2, 0.6, 2 and 6 mg /mg cytosolic protein) were then added to samples and incubated on ice
for 10 min. Charcoal-dextran was removed by centrifugation at 20,000 x g for 10 min, and the radioactivity measured. Total
and non-specific were measured and specific binding calculated as described in Figure 3.1 legend. Each point represents the
mean ± S.D for triplicate samples, and is representative of results obtained from three experiments. Ordinate: total, non-spe-
cific and specific binding of [3H]-TCDD to rat hepatic cytosolic and BSA (nanomolar). Abscissa: varying amount of charcoal
(mg/mg protein).
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TCDD to cytosolic proteins compared to the specific, particularly at low amounts of charcoal
(< 2mg/mg protein). It has been reported that this is partly due to the use of relatively high con-
centration of [3H]-TCDD (1 nM) which enhances [3H]-TCDD binding to non receptor compart-
ments [165]. Increasing amounts of charcoal decreased [3H]-TCDD non specific binding to
both cytosol and BSA. However, [3H]-TCDD specific binding was not affected with increasing
charcoal amount up to the amount tested (6 mg /mg protein). When BSA protein was used as a
negative control, no statistically significant specific binding of [3H]-TCDD was measured for
all charcoal amounts. Charcoal concentrations  2 mg/mg cytosolic protein did not alter the spe-
cific binding levels of [3H]-TCDD and further decreased the nonspecific binding of [3H]-TCDD
to cytosolic protein, therefore, a concentration of 2 mg of charcoal /mg cytosolic protein was
used in subsequent experiments.
Section 3.1.3  TCAOB concentration
The unlabelled competitor, TCAOB, was used to determine the non-specific binding of [3H]-
TCDD. In principle, the competitor is added in excess and will compete with [3H]-TCDD for
the high-affinity and saturable binding sites. However, at sufficiently high concentrations, it is
a possibility that the TCAOB could compete with [3H]-TCDD at non-specific sites [166].
Therefore, it was essential to optimise the concentration to be used throughout the binding as-
say. The experiment was conducted essentially as described in Materials and Methods (Section
2.2.3.2), except with a range of TCAOB concentrations (0-50-100-200-400 and 800 nM) for 16
h at 4°C. The same experiment was run on BSA as negative control. After the 16-h incubation
charcoal was added and radioactivity measured as described in Materials and Methods (Section
2.2.3.2). Figure 3.3 shows the total, non specific and specific binding of [3H]-TCDD to rat cy-
tosolic proteins and to BSA used as a negative control. The results show that the [3H]-TCDD
binds specifically to the cytosolic protein but does not specifically bind BSA. [3H]-TCDD spe-
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cific binding remains unchanged with increasing TCAOB concentrations for cytosolic protein
preparations (Figure 3.3). This experiment shows that the non-specific binding of [3H]-TCDD
to cytosolic proteins and BSA was unchanged up to the highest concentration tested (800 nM),
which proves that TCAOB is not competing with [3H]-TCDD at non specific sites. The TCAOB
concentration selected for the assay was 200 nM consistent with the literature [66].
Figure 3.3 Effect of TCAOB concentration on [3H]-TCDD binding to rat cytosolic proteins. [3H]-TCDD
total, non specific and specific binding was measured in rat liver cytosolic (CP) and bovine serum albumin (BSA) proteins after
incubating [3H]-TCDD (1 nM) ± varying concentration of the unlabeled competitor TCAOB (0-50-100-200-400 and 800 nM)
for 16 h at 4ºC as as described in Figure 3.1 legend. Each bar represents the mean ± S.D for triplicate samples, and is represen-
tative of results obtained from three experiments. Ordinate: total, non-specific and specific binding of [3H]-TCDD to rat hepatic
cytosolic and bovine serum albumin proteins (nanomolar). Abscissa: unlabeled TCAOB (nanomolar). 
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Section 3.1.4  Cytosolic protein concentration
Section 3.1.4.1 Effect of cytosolic protein concentration on [3H]-TCDD 
specific binding
One of the important parameters that could affect the specific binding of [3H]-TCDD is the pro-
tein concentration. It is known that at high receptor number, the ligand could be depleted by
binding to the receptors. As mentioned earlier in the introduction of this chapter, only a small
fraction of the [3H]-TCDD should bind to the receptor so that the system is not facing ligand
depletion by binding to receptors and thus the binding obeys to the law of mass action. There-
fore, it was important to investigate the effect of protein concentration on the specific binding
of [3H]-TCDD as well as the free concentration in solution. Initially, all experiments were con-
ducted using 5 mg/ml protein concentration [38] [67].
The experiment conducted here investigates the effect of a range of rat liver cytosolic protein
concentration on [3H]-TCDD specific binding. Therefore, 200 Pl cytosolic protein preparations
at different protein concentrations (0, 1, 3, 5 and 8 mg/ml) were incubated with [3H]-TCDD (1
nM) ± TCAOB (200 nM) at 4°C for 16 h. 
Figure 3.4 shows the effect of protein concentration on [3H]-TCDD specific binding. As seen
in Figure 3.4, as protein concentration increases, the specific binding of [3H]-TCDD increases
in a linear way up to 5 mg/ml protein concentration. Above 5 mg/ml, [3H]-TCDD specific bind-
ing deviates from linearity. At 5 mg/ml, only around 20% of [3H]-TCDD is specifically bound
to the AhR. As the aim is to select conditions for high [3H]-TCDD specific binding (high signal-
to-noise ratio) while the response is still in the linear part, a protein concentration of 5 mg/ml
protein was within these criteria, thus subsequent work will be carried out, as previously, using
this protein concentration.
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Section 3.1.4.2 Effect of cytosolic protein concentration on [3H]-TCDD in 
solution
A technical problem is the limited solubility of TCDD in aqueous solutions [167]. This experi-
ment was conducted to examine the effect of protein concentration on [3H]- TCDD actual con-
centrations in the solutions. The best conditions consist of selecting the protein concentration at
which more [3H]-TCDD is retained in solution.
The concentration of [3H]-TCDD that remained in solution was examined, before and after a
16-h incubation, as a function of a range of concentrations of the cytosolic protein preparation,
and is shown in Figure 3.5. No charcoal was added in this experiment as the aim is to assess the
total (free), but not bound, radioligand concentration. 
Figure 3.4 Effect of cytosolic protein concentration on [3H]-TCDD specific binding to rat cytosolic pro-
tein.  [3H]-TCDD (1 nM) was incubated with 200 Pl of varying concentrations of cytosolic protein (0, 1, 3, 5 and 8 mg/ml
prepared in MDENG buffer) ± 200 nM TCAOB for 16 h at 4ºC. After 16 h, total and non specific binding were determined
after washing with charcoal and specific binding of [3H]-TCDD was calculated as described described in Figure 3.1 legend.
Each point represents the average of mean ± S.D for triplicate samples, and is representative of results obtained from three ex-
periments. Ordinate: specific binding of [3H]-TCDD (nanomolar). Abscissa: cytosolic protein concentration (mg/ml). 
Rana Bazzi   Section 3.1.4
Page 88
As shown in Figure 3.5, in preparations containing no protein, ~ 50 % of free [H]-TCDD was
depleted from solution immediately after the addition [3H]-TCDD (no incubation time) and ~
86% was depleted after 16-h incubation. The addition of protein retains more total [3H]-TCDD
in solution with and without 16-h incubation ± 200 nM TCAOB. [3H]-TCDD concentration was
significantly higher in protein incubations than observed in no protein incubations (p<0.01, t-
test, n=3). At protein concentrations of 3 mg/ml or greater, more total [3H]-TCDD was found in
solution before (~ 99%) and after incubation (78%), and these concentrations were significantly
different from no-protein incubations (p< 0.01, One-way ANOVA followed by Dunnett’s Mul-
tiple Comparison test, n=3). That is true for samples with or without 200 nM TCAOB. The low-
er value of [3H]-TCDD concentration in solution after the 16-h incubation is not surprising, a
similar depletion of ligand has been reported [164]. Although maximum solubility was achieved
at a cytosolic protein concentration of 3 mg/ml, at 5 mg/ml higher specific binding of [3H]-
TCDD was observed (Figure 3.4), moreover, it seems to increase the solubility of competing
ligands when performing competition assays. In the light of these results, we confirmed that un-
der the conditions of incubating cytosolic proteins (5 mg/ml) with 1 nM [3H]-TCDD and 200
nM TCAOB for 16-h incubation at 4ºC, ~ 20% of ligand is depleted from solutions. This was
not considered problematic, since ligand depletion within this limit is acceptable and does not
affect the displacement curves when performing competition studies [165]. 
Taken together, the results of the two experiments shown in Figure 3.4 & Figure 3.5, the con-
centration of 5 mg/ml cytosolic protein was used for subsequent experiments.
In parallel, TCAOB (200 nM) was added to test its effect on [3H]-TCDD solubility. The values
in the absence of TCAOB are very similar to those with TCAOB, which shows that TCAOB
has no effect on [3H]-TCDD solubility. 
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Section 3.1.5  Effect of [3H]-TCDD concentration on [3H]-TCDD in solu-
tion
As for Section 3.1.4.2, the concern is the limited solubility of [3H]-TCDD in aqueous solutions.
The aim is to select the concentration of [3H]-TCDD added at which [3H]-TCDD remains in
solution after 16-h incubation. The experiment investigates the concentration of [3H]-TCDD
that remains in solution, after the 16-h incubation, as a function of a range of [3H]-TCDD con-
centrations added in solution and is presented in Figure 3.6. The experiment was performed by
incubating 200 Pl of cytosolic protein with varying concentrations of [3H]-TCDD ± 200-fold
molar excess of TCAOB for each [3H]-TCDD concentration. No charcoal was added. The assay
Figure 3.5 Effect of cytosolic protein concentration on [3H]-TCDD solubility.  [3H]-TCDD (1 nM) was incu-
bated for 16 h at 4ºC with varying concentrations of the receptor preparation (0, 1, 3 and 5 mg/ml cytosolic protein prepared
in MDENG buffer) in the presence (ǻ) or absence (ż) of the non-radioligand TCAOB (200 nM). In parallel, the same exper-
iment was run without incubation in the presence (ź) or absence (Ɣ) of TCAOB (200 nM). Before and after the 16-h incu-
bation, the total [3H]-TCDD in solution was measured by counting radioactivity in 150 Pl of samples with no charcoal added.
Radioactivity data was converted into nanomolar concentrations. Each point represents the average of mean ± S.D for tripli-
cate samples, and is representative of results obtained from three experiments. (*; asterisk; p<0.01; one-way ANOVA fol-
lowed by Dunnett’s Multiple Comparison test; n=3, [3H]-TCDD concentrations in solution of protein incubations compared
to no protein incubations at the specified concentrations). Ordinate: total [3H]-TCDD in solution (nanomolar). Abscissa: cy-
tosolic protein concentration (mg/ml). 
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was terminated by transferring 150 Pl for liquid scintillation counting.
  
As seen in Figure 3.6, the concentration of [3H]-TCDD remaining in solution after incubation
versus the initial concentration added was almost linear up to 1 nM [3H]-TCDD, at which ~ 20%
of the [3H]-TCDD was depleted from solutions. Above 1 nM [3H]-TCDD, much less [3H]-
TCDD remains in solution after incubation. This could be problematic for analyzing binding as-
says under these conditions, since above 1 nM, the concentration of TCDD varies by two-fold
over the course of the 16-h incubation. This experiment was repeated three times with consistent
results.
To rule out the possibility of TCAOB affecting the [3H]-TCDD solubility at high concentra-
Figure 3.6 Concentration of [3H]-TCDD in solution.  Aliquots of 200 Pl cytosolic protein was incubated with a
range off increasing concentrations (0-2.6 nM) of [3H]-TCDD in the presence [Ɣ] or absence [ż] of 200-fold molar excess
unlabeled TCAOB for 16 h at 4ºC. The concentration of [3H]-TCDD in solution was measured after the 16-h incubation by
transferring 150 Pl for liquid scintillation counting. Radioactivity data was converted into nanomolar concentration. Each point
represents the average of mean ± S.D for triplicate samples, and is representative of results obtained from three experiments.
Ordinate: [3H]-TCDD in solution (nanomolar). Abscissa: added [3H]-TCDD (nanomolar).
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tions, in each experiment, samples were incubated for 16 h with and without 200-fold excess
molar TCAOB with varying concentration of the [3H]-TCDD (0, 0.1, 0.33, 0.99, 1.6, 1.98 and
2.6 nM). The results showed no effect of TCAOB addition on [3H]-TCDD solubility in p-diox-
ane for all [3H]-TCDD initially added concentrations, which is consistent with previous finding
(Figure 3.5). In all experiments, the final [3H]-TCDD concentration used was 1 nM, and as the
Figure 3.6 shows, at this concentration, most of the radioligand was in solution.
Section 3.1.6 Binding assay standard
Saturation analysis of [3H]-TCDD binding experiments to rat liver cytosol was used to charac-
terize the binding of [3H]-TCDD quantitatively and determine the apparent affinity constant
(KD) and the maximum concentration of specific binding sites, Bmax. 
[3H]-TCDD standard binding assay was performed by incubating aliquots of cytosolic protein
with several concentrations of [3H]-TCDD (0-2.6 nM) with and without 200-fold molar excess
TCAOB for 16-h incubation at 4ºC. The assay was terminated by addition of charcoal (2 mg/
mg protein) after the 16-h incubation and radioactivity measured as described previously.
The simultaneous measurement of [3H]-TCDD binding in the presence of excess TCAOB per-
mits experimental estimation of the nonspecific binding. The binding parameters were deter-
mined from nonlinear regression for single site binding hyperbola analysis using GraphPad
Prism version 5. The saturation binding isotherm of [3H]-TCDD to the preparation of liver cy-
tosol is shown in Figure 3.7 A. [3H]-TCDD specific binding to rat cytosol was saturable at  1
nM. The data in Figure 3.7 B shows that the non specific binding of [3H]-TCDD is linear with
increasing concentrations of [3H]-TCDD (as indicated in Figure 3.7 B legend). The apparent KD
for specific binding of [3H]-TCDD to rat liver cytosol and the concentration of binding sites,
Bmax were 0.37± 0.08 nM (74 fmol/mg) and 0.19 ± 0.01 nM (~40 fmol/mg) respectively. The  
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standard binding assay was repeated three times with increasing numbers of [3H]-TCDD con-
A
B
Figure 3.7 The binding standard of [3H]-TCDD to rat liver cytosol.  A. Radioactivity for total [Ɣ] and non-
specific binding [Ƒ] of [3H]-TCDD was determined for each sample and [3H]-TCDD specific binding was calculated as de-
scribed in (Figure 3.1) legend. B. The standard binding curve for [3H]-TCDD specific binding [ż] generated from substracting
non-specific from total binding in curves in (A). 200 Pl aliquots cytosolic protein (5mg/ml) were incubated with varying con-
centrations of [3H]-TCDD (0, 0.1, 0.33, 0.99, 1.6, 1.98 and 2.6 nM) ± 200-fold molar excess TCAOB for 16 h at 4°C. The
assay was terminated by the addition of charcoal-dextran (2 mg/mg protein). The standard assay was analyzed for one site bind-
ing by using GraphPad Prism version 5.00 for windows. Each point represents the average of mean ± S.D for triplicate samples,
and is representative of results obtained from three experiments. Ordinates: binding of [3H]-TCDD (nanomolar). Abscissa:
added [3H]-TCDD (nanomolar). 
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centrations, each in triplicate, and the average of the apparent KD and the concentration of bind-
ing sites, Bmax were 0.37 ± 0.06 nM (74 fmol/mg) and 0.23 ± 0.06 nM (~40 fmol/mg)
respectively (Table 3.1). These data show reproducibility of the binding assay with the coeffi-
cients of variation of assay Ki and Bmax values are 16% and 26% respectively. The results of the
current binding assay are in good agreement with earlier results where apparent dissociation
constants for TCDD AhR were determined (Table 3.2).
The binding assay was generated successfully and proves saturable and high-affinity specific
binding of [3H]-TCDD to the Ah receptor, and thus the KD of [
3H]-TCDD will be used in the
competitive binding assays to determine the binding affinities of the test compounds.
Experiments
KD [nM] (95% 
confidence intervals)
Bmax [nM] (95% 
confidence intervals)
(1) 0.37 (0.1-0.9) 0.19 (0.2-0.4)
(2) 0.45 (0.2-0.6) 0.3 (0.17-0.2)
(3) 0.33 (0.1-1) 0.2 (0.1-0.3)
Average ± S.D 0.37 ± 0.06 0.23 ± 0.06
Table 3.1 Summary of binding kinetics of [3H]-TCDD to rat hepatic cytosol from three
independent experimental trials.  KD and Bmax were determined from three standard binding assays using
non linear regression for one site binding equation (GraphPad Prism 5.0). Each standard assay was performed on
different concentrations of [3H]-TCDD conducted in triplicates. The average and S.D values represent the mean
and the standard deviations of binding kinetics from three trials.
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Section 3.1.7 Displacement of [3H]-TCDD by cold TCDD
In order to validate the [3H]-TCDD binding assay, [3H]-TCDD binding was assessed by the
ability of the unlabelled TCDD to displace [3H]-TCDD from specific sites via a competitive
binding assay. Therefore, 200 Pl cytosolic protein (5 mg/ml) was incubated with 1 nM [3H]-
TCDD ± 200 nM TCAOB ± a range of nine concentrations of cold TCDD for 16 h at 4°C and
Table 3.2 Comparison with literature for binding kinetics of TCDD for AhR.  These data, along with
those reported from this study, were generated from different binding assays in Wistar rat, Sprague-Dawley rat and C57BL/
6J mice liver cytosols.KD is the dissociation constant and the value is inversely proportional to binding affinity. KD values
from literature were determined using Scatchard analysis, whereas the KD value determined in the present study was








































Wistar rat 6 [3H]-TCDD;
50-52
1.25 100 [170]
Wistar rat 5 [3H]-TCDD;
34.7
1.45 40.6 [38]
Wistar rat 5 [3H]-TCDD;
29.77
0.37 40 current study
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specific binding of [3H]-TCDD displaced by competitor was calculated as described in Materi-
als and Methods (Section 2.2.3.4.2).
The aim is to determine the concentration of TCDD at which 50% of [3H]-TCDD (IC50) is dis-
placed from the specific binding sites. Figure 3.8 shows the log concentration-curve for [3H]-
TCDD against unlabelled TCDD. From Figure 3.8, the IC50 value extrapolated from the com-
petitive displacement curve was 1.65 nM (95% CI, 0.66 - 4.1), and thus calculated Ki for cold
TCDD was 0.44 nM (95% CI, 0.18-11.1).
This is in agreement with the results of the saturation binding assay (KD 0.37 nM). This finding
Figure 3.8 Competitive displacement of hot TCDD by cold TCDD.  Cytosolic protein (5 mg/ml) was incubated
for 16 h at 4°C with 1nM [3H]-TCDD ± increasing concentration of TCDD ± (200 nM) TCAOB. At each specified TCDD
concentration, [3H]-TCDD total binding and non specific binding was measured experimentally and specific binding of [3H]-
TCDD displaced by cold TCDD (Ÿ) was calculated as described in Section 2.2.3.4.2. The specific binding of [3H]-TCDD in
the absence of cold TCDD (ǻ) was included as a positive control. The competitive binding curve was analyzed for one site
competition by using GraphPad Prism version 5.00 for windows. Each point represents the average of mean ± S.D for triplicate
samples, and is representative of results obtained from one single experiment. Ordinate: specific binding of [3H]-TCDD to cy-
tosolic protein (nanomolar). Abscissa: logarithms of molar concentrations of unlabeled TCDD. 
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confirms that the conditions under which the displacement experiment is conducted are stable
and yield reproducible results as compared to the standard binding assay. 
Section 3.1.8  Displacement of [3H]-TCDD by test competitors
To investigate the strength of the interactions between the test compounds and the AhR, com-
petitive assays were conducted as described in Materials and Methods (Section 2.2.3.4.2).
  
The binding of 5F 203 was determined by adding different concentrations of 5F 203 to a 1 nM
solution of [3H]-TCDD in rat liver cytosol ± 200 nM TCAOB. Figure 3.9 shows the log con-
centration curve for [3H]-TCDD displacement by 5F 203. The concentration of 5F 203 that dis-
placed 50% of [3H]-TCDD, IC50 was 9 nM (95% CI, 4.6-17.3). Given that the [
3H]-TCDD
Figure 3.9  Competitive displacement of [3H]-TCDD by 5F 203.  Cytosolic protein (5 mg/ml) was incubated
with 1nM [3H]-TCDD and increasing concentrations of 5F 203 ± (200nM) TCAOB for 16 h at 4°C. At each specified 5F 203
concentration, [3H]-TCDD total binding and non specific binding was measured experimentally and specific binding of [3H]-
TCDD displaced 5F 203 was calculated as described in Section 2.2.3.4.2. The specific binding of [3H]-TCDD in the absence
of 5F 203 (ź) was included as a positive control. The competitive binding curve was analyzed for one site competition by
using GraphPad Prism version 5.00 for windows. Each point represents the average of mean ± S.D for triplicate samples, and
is representative of results obtained from three experiments. Ordinate: specific binding of [3H]-TCDD to cytosolic protein
(nanomolar). Abscissa: logarithms of molar concentrations of 5F 203. 
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concentration utilized is 1nM and the apparent KD 0.37nM, the Ki of 5F 203 was calculated as
described in Materials and Methods (Section 2.2.3.4.2) to be 2.4 nM (95% CI, 1.3-4.7). Thus,
this study identifies 5F 203 as a new potent high-affinity ligand for AhR.
Competitive displacement curves for a variety of phenylbenzothiazole analogues were generat-
ed under the same conditions. The 5F 203 Ki value represents the average of three separate ex-
periments. Nanomolar concentrations of Ki and their 95% confidence intervals for
phenylbenzothiazole analogues, TCDD, TCAOB, TCDF, TCPT and compound 1c are dis-
played in (Table 3.3). 
The binding affinities for TCAOB and TCDF, two PAHs known to potent ligands for AhR, are
very similar to literature reports [66] [6], which further validates the [3H]-TCDD competitive
assay .
Of the 24 compounds tested for their binding avidity to the AhR, 22 were found to be ligands
for AhR with low nanomolar Ki values. 2-(4-amino-3-methylphenyl)-6-hydroxybenzothiazole,
(IH 130) and 2-(3-hydroxy-methoxyphenyl)-5- fluorobenzothiazole (JP-2) were low-affinity
ligands, with Ki value > 1PM. Interestingly, the tetrachlorophenothiazine (TCPT) and the com-
pound 1c from Astrazeneca were found high-affinity ligands for the AhR ligands with potency
similar to (TCPT, Ki = 400 pM) or greater (1c, Ki= 40 pM) than TCDD’s (Table 3.3).












2,3,7,8- Tetrachlorodibenzo-p-dioxin TCDD 0.44 (0.18-1)
Tetrachlorophenothiazine TCPT 0.4 (0.08-2.2)
Tetrachlorodibenzofuran TCDF 0.5 (0.2-1.6)





 IH 445* 0.9 (0.05-16.9)
Table 3.3 Binding affinities of TCDD, TCAOB, TCDF, TCPT, astrazeneca compound 1c and
benzothiazole analogues in rat liver cytosol.  The affinity of the test compounds for the Ah receptor was measured by
their ability to compete with the specific binding of [3H]-TCDD. Concentrations of compounds that inhibited 50% of [3H]-
TCDD specific binding (IC50) from Ah receptor, were determined (by Prism 5.0) from the curves and their relative inhibition
constants (Ki) were calculated according to [
3H]-TCDD's KD. All values reported are the average of two independent
experiments, except for 5F 203, the data are the average of three independent trials, each conducted in triplicate. (*) to




































 5F 203 2.8 (2-5)
2-(4-amino-3-bromophenyl)-5- fluo-
robenzothiazole 
IH 277*  2.8 (1.4-5.5)
2-(4-amino-3-methylphenyl)-5-bro-
mobenzothiazole 
 IH 318 8 (5.5-12)
2-(4-amino-3-methylphenyl) benzothi-
azole
DF 203 9.9 (5.3-18.7)
2-(4-amino-3-chlorophenyl) benzothiaz-
ole 
DF 229* 10 (1.6-68)
2-(4-amino-3-methylphenyl)-6-fluo-
robenzothiazole 
 IH 168 13 (3-59)
2-(4-amino-3-methylphenyl)-5,6- diflu-
orobenzothiazole






Table 3.3 Binding affinities of TCDD, TCAOB, TCDF, TCPT, astrazeneca compound 1c and
benzothiazole analogues in rat liver cytosol.  The affinity of the test compounds for the Ah receptor was measured by
their ability to compete with the specific binding of [3H]-TCDD. Concentrations of compounds that inhibited 50% of [3H]-
TCDD specific binding (IC50) from Ah receptor, were determined (by Prism 5.0) from the curves and their relative inhibition
constants (Ki) were calculated according to [
3H]-TCDD's KD. All values reported are the average of two independent
experiments, except for 5F 203, the data are the average of three independent trials, each conducted in triplicate. (*) to




















































 IH 220 30 (3-300)
2-(4-amino-3-methylphenyl)-5-iodo-
benzothiaoleaole 
 IH 278* 32 (11-95)
2-(4-amino-3-cyanophenyl)-5-fluo-
robenzothiazole
 IH 352 36.6 (11-119)
2-(4-amino-3-hydroxymethylphenyl)-5-
fluorobenzothiazole 
 IH 353* 98 (48.3-199)
2-(4-amino-3-hydroxymethylphe-
nyl)benzothiazole
 IH 224* 149 (123-182)
2-(4-amino-3-methylphenyl)-5-
hydroxybenzothiazole 
IH 186*  175 (54-571)






Table 3.3 Binding affinities of TCDD, TCAOB, TCDF, TCPT, astrazeneca compound 1c and
benzothiazole analogues in rat liver cytosol.  The affinity of the test compounds for the Ah receptor was measured by
their ability to compete with the specific binding of [3H]-TCDD. Concentrations of compounds that inhibited 50% of [3H]-
TCDD specific binding (IC50) from Ah receptor, were determined (by Prism 5.0) from the curves and their relative inhibition
constants (Ki) were calculated according to [
3H]-TCDD's KD. All values reported are the average of two independent
experiments, except for 5F 203, the data are the average of three independent trials, each conducted in triplicate. (*) to


























































 GW 610 6.8 (1.5-30)
2-(3,4-dimethoxyphenyl) benzothiazole  AW 892 9.8 (4.4-22)
2-(3,4-dimethoxyphenyl)-4- fluoroben-
zothiazole 
 4F 610 14 (3.2-62)
2-(3-methyl-4-methoxyphenyl)-5- fluo-
robenzothiazole 
 JP-1 26 (2.3-284)
2-(4-aminocarboxymethoxy-3-meth-
ylphenyl)- 5- fluorobenzothiazole 
 IH 128* 47 ( 37-61)
2-(3,4-dimethoxyphenyl)-6- fluoroben-
zothiazole






Table 3.3 Binding affinities of TCDD, TCAOB, TCDF, TCPT, astrazeneca compound 1c and
benzothiazole analogues in rat liver cytosol.  The affinity of the test compounds for the Ah receptor was measured by
their ability to compete with the specific binding of [3H]-TCDD. Concentrations of compounds that inhibited 50% of [3H]-
TCDD specific binding (IC50) from Ah receptor, were determined (by Prism 5.0) from the curves and their relative inhibition
constants (Ki) were calculated according to [
3H]-TCDD's KD. All values reported are the average of two independent
experiments, except for 5F 203, the data are the average of three independent trials, each conducted in triplicate. (*) to
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Section 3.1.9 Structure-Activity Relationships (SARs) 
The structures of the compounds tested are displayed in Section 2.1.4 under Materials and
Methods. The results from the binding data show differences in binding potency between com-
pounds. Structure-activity relationship analysis for binding of these test compounds revealed
that the binding affinities were substituent-dependent and varied over 3 orders of magnitude.
AhR binding was weakened by polar groups, such as hydroxyl- or methylenedioxy-significantly
reduced the binding. Importantly, the effect of hydroxylation was position-dependent. For ex-
ample, the 3’-hydroxylation in the phenyl ring (IH 224) or the 6-hydroxylation in the benzothi-
azole ring  (IH 130) inhibited the binding affinity whereas the 5-hydroxylation in the
benzothiazole ring (IH 186) only decreased the binding but retained nanomolar values. 
The 5-fluorination in the phenyl ring was not essential for the binding activity, as the fluorinat-
ed-(5F 230) and the non-fluorinated (DF 203) analogues have binding affinities within ~3-fold
for the AhR. Importantly, the 3' position in the phenyl moiety seems to be required for binding,
2-(3,4-methylenedioxyphenyl)-5- fluo-
robenzothiazole
 JMB 81 613 (195-1932)
2-(3-hydroxy-4-methoxyphenyl)-5- flu-
orobenzothiazole 







Table 3.3 Binding affinities of TCDD, TCAOB, TCDF, TCPT, astrazeneca compound 1c and
benzothiazole analogues in rat liver cytosol.  The affinity of the test compounds for the Ah receptor was measured by
their ability to compete with the specific binding of [3H]-TCDD. Concentrations of compounds that inhibited 50% of [3H]-
TCDD specific binding (IC50) from Ah receptor, were determined (by Prism 5.0) from the curves and their relative inhibition
constants (Ki) were calculated according to [
3H]-TCDD's KD. All values reported are the average of two independent
experiments, except for 5F 203, the data are the average of three independent trials, each conducted in triplicate. (*) to











Rana Bazzi   Section 3.1.9
Page 103
as the CMJ 126 has 33-fold lower Ki than that of 5F 203. Furthermore, it was observed that the
presence of a hydrophobic group on this position enhanced the binding. This is the case when
the carbon at the 3' position is occupied by a bromine atom > acetylene group > chlorine atom
or methylene group> methoxy or cyanide compared to the hydrogen atom at this position (CJM
126). 
Under the conditions of the current binding assay, two compounds emerged as AhR high-affin-
ity ligands with potency similar to TCDD’s (TCPT, Ki = 400 pM) or greater (1c, Ki=40 pM)
(Table 3.3). These compounds bear some structural similarities toTCDD, in that they have pol-
yaromatic structures. Interestingly, the compound 1c, in contrast to TCPT, does not fit the clas-
sic model for the ligand binding pocket of a rectangle with a maximal dimension of (14 x 12 x
5 Å) generally described for AhR ligands [40]. Moreover, both compounds are not planar like
TCDD.
The data for the compound 1c, along with the phenylbenzothiazole analogue structures, seems
to suggest that there is promiscuity of the binding domain of this receptor that deviates from the
known ligand binding model [9].
Originally, the aim of quantifying the interactions of the phenylbenzothiazole analogues with
the AhR was to establish a quantitative structure activity relationship (QSAR) analysis and gen-
erate a model for their binding. However, such quantitative analysis requires a significant num-
bers of compounds (at least 50), and this study was constrained by the limited number of the
compounds available, the lack of some substituent groups essential for elucidating the QSAR
and the time involved in generating the data. 
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Section 3.2 Characterization of CYP1A1 induction
Section 3.2.1  Cell growth curves
It is essential to characterize the growth of the cells, and to determine accurately the character-
istic growth rate for each cell line and when exactly the cells reach high confluence. Therefore,
growth curves for both cell lines were generated.
Figure 3.10 shows growth curves for H4-II-E and MCF-7 cell lines over seven days of culture.
90-95% cell confluence was achieved at concentrations of ~ 2 x 105 cells / well or 6.25 x 105
cells /cm2 and ~1 x 105 cells / well or 3 x 10 5 cells/cm2 (96 well plates, 0.32cm2/well) for H4-
II-E and MCF-7 cells respectively. H4-II-E cells grow twice as fast as MCF-7 cells, but the lat-
ter cells reach confluence at lower density. These growth characteristics were similar to the lit-
erature in that H4-II-E cells had a doubling time between 18 and 24 h [171]. From these growth
Figure 3.10  Growth curves of H4-II-E and MCF-7 cells.  H4-II-E and MCF-7 cells were cultured respectively in
triplicate in 96 well plates initially at a density of 3 x 103 and 2.5 x 103 cells/well in 180 Pl culture medium and cultured for 7
days at 37°C. The old medium was replaced with a fresh medium every three days. At each time point, cells were washed with
PBS, trypsinized and counted by hemocytometer as described under Materials and Methods Section 2.2.5. Each point represents
the average of mean ± S.D for triplicate samples, and is representative of results obtained from three experiments. Ordinate:
cell count x 103 /cm2. Abscissa: time (days). 
Rana Bazzi   Section 3.2.2
Page 105
curves, the concentrations for which high confluence will be achieved after 24 h for MCF-7 and
H4-II-E cells were 5 x 104 cells/well and 1 x 105cells/well respectively.
Section 3.2.2 Testing the primers and probes for specificity 
It was important to test the primers and probes for specificity and susceptibility to any genomic
contamination.
For the human and rat CYP1A1, ß-actin and AhR genes, the primers were tested on cDNA sam-
ples from 4-h-TCDD-treated H4-II-E and MCF-7 cells by performing firstly endpoint PCR
analysis and then by real-time PCR. One single band of the expected size was found for each
gene with no additional bands showing genomic contamination, except for the human CYP1A1,
where genomic contamination was found (data not shown). For this gene, the probe, but not
primers, was designed to span the junction between two exons as described in Materials and
Methods (Section 2.1.8). As expected, when tested by real-time qRT-PCR this genomic con-
tamination was not detected, as shown in no reverse transcriptase controls. No signal was de-
tected in no template controls (no Ct), indicating no contamination of any assay reagents (data
not shown). The results revealed no primer-dimers or genomic amplification and that all ampli-
cons were at the expected size. Thus, the specificity of the primers and probes was confirmed,
and found suitable for use in qRT-PCR measurements.
Section 3.2.3 Assessmemt of RNA quality 
The quality of RNA was assessed by the relative intensities of the 28S and 18S rRNA bands
visualized by electrophoresis on 1% denaturing agarose gel after ethidium bromide staining.
The results in Figure 3.11 show that the RNA extracted were of a high quality with two distinct
bands corresponding to the 28S and 18S rRNA. . 
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Section 3.2.4  qRT-PCR probe/ primer efficiency
In order to accurately measure the levels of mRNA in qRT-PCR, it is essential to validate the
use of Pfaffl’s method, which is derived from the ǻǻCt method and corrects for efficiency, by
determining the amplification efficiency (E) for each gene and demonstrating equal efficiency
between the target and the reference genes. 
Standard curves for human and rat CYP1A1, ß-actin and AhR genes were determined by ampli-
fying 5-fold serial dilutions of cDNA from H4-II-E and MCF-7 cells. Figure 3.12 shows con-
centrations of the template versus the Ct (threshold cycle). A least mean squares curve fitting
algorithm is used to generate the standard curves displayed. Curves are displayed for each gene.
Efficiency, slope and regression (RSq) of the standard curve fits for rat and human ß-actin,
CYP1A1 and AhR genes are listed in Table 3.4 and Table 3.5 respectively. 
Standard curves for all six genes had a regression coefficient close to 1, with real-time PCR ef-
ficiency of >100% (Table 3.4 and Table 3.5), with a slope close to 1, for which applied E=(10-
1/slope). An ideal PCR reaction will have an amplification efficiency of 100 (+/- 10%). The ef-
a b c d e f
28S
18S
Figure 3.11 An agarose gel showing the integrity of the total RNA as assessed by the relative intensities
of the 28S and 18S RNA bands.  RNA were randomly selected from different experiments and were loaded on the gel.
The first lane at the left represents DNA ladder (1kb+). Lanes a, b and c: 100 ng, 300 ng, and 600 ng respectively of total RNA
extracted from high-confluent H4-II-E cells treated with 10 nM TCDD for 4 h. Lanes d, e and f: 100 ng, 1 Pg and 2 Pg respec-
tively of total RNA extracted from tissue rat liver treated chronically with 10 nM TCDD included as an external control for
real-time RT-PCR analysis.
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ficiencies determined from the standard were not significantly different from this range, and
they were not significantly different from each other, except for human E-actin, where the PCR
efficiency was 125%. However, since the PCR efficiency for the all genes was less than 140%,
that was considered acceptable (http://www.dddmag.com/reliability-of-qPCR-data.aspx). 
Therefore, the Pfaffl’s method can be applied and ß-actin reference gene was used for normal-
isation. Gene copy number will be calculated from the efficiencies determined for each set of
TaqMan primers/probes as described in Materials and Methods (Section 2.2.13.2). 




Figure 3.12 Amplification efficiencies for CYP1A1, E-actin and AhR.  The cDNA from H4-II-E (A) and MCF-7
cells (B) was serially diluted and amplified with ß-actin (ROX) (red triangles), CYP1A1(FAM) (blue squares) and AhR (HEX)
primers (green circles) and detected with TaqMan probe with real-time RT-PCR. After 4-h incubation with TCDD (10 nM),
cells were washed with 1x PBS, trypsinized then RNA isolated and reverse transcibed into cDNA. Serial dilutions of cDNA
were amplified with qRT-PCR reaction for three genes ß-actin, CYP1A1 and AhR as described in Materials and Methods (Sec-
tion 2.2.13.4). Standard curves were generated by using the least mean squares curve fitting algorithm by Mx4000 from indi-
vidual experiments. Each point represents the average of mean for duplicate samples obtained from one experiment. Ordinates:
Ct values. Abscissae: concentrations of cDNA (pg/Pl). 
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Section 3.2.5 CYP1A1 induction assay in H4-II-E cells
Section 3.2.5.1 Effect of confluence 
This experiment investigates the effect of cell density on CYP1A1 mRNA basal expression and
inducibility in response to inducer, TCDD, in H4-II-E cells and aims to select the conditions un-
der which there is optimal induction of CYP1A1 mRNA and the response to TCDD is linear over
the time course. H4-II-E cells were plated at a density of 1 x 104 cells/well. When cells attained 
Gene
Slope (Ct x pg-1 
x Pl-1) Efficiency (%) Regression
CYP1A1 -2.9 119 0.988
E-actin -3.1 109 0.994
AhR -3 114 0.996
Table 3.4 Quantitation data of qRT-PCR for rat genes.  Slope, efficiencies and regression of
CYP1A1, E-actin and AhR. Efficiencies are derived as percentages. The R Squared (RSq) or regression
(Pearson’s correlation coefficient) value was determined for each standard from the equation of the line.
The slope is directly related to the average amplification efficiency throughout the cycling reaction. The
amplification efficiency of the reaction is derived from the slope according to Pfaffl [162]: PCR
effciency=10(-1/slope).The quantification data was generated by MX4000 Software using the least mean
squares curve fitting as described under Materials and Methods Section 2.2.13.4
Gene
Slope (Ct x pg-1 
x Pl-1) Efficiency (%) Regression
CYP1A1 -2.95 118 0.996
E-actin -2.83 125 0.997
AhR -3.1 110 0.982
Table 3.5 Quantitation data of qRT-PCR for human genes.  Slope, efficiencies and
regression of CYP1A1, E-actin and AhR. Efficiencies are derived as percentages. The R Squared (RSq) or
regression (Pearson’s correlation coefficient) value was determined for each standard from the equation of
the line. The slope is directly related to the average amplification efficiency throughout the cycling
reaction. The amplification efficiency of the reaction is derived from the slope according to Pfaffl [162]:
PCR effciency=10(-1/slope).The quantification data was generated by MX4000 Software using the least
mean squares curve fitting as described under Materials and Methods Section 2.2.13.4.
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either 20-30% confluence (24 h, low-density; 5.6 x 104/well) or 90-95% confluence, (72 h,
high-density; 18 x 104/well), the cells were treated by replacing the medium in cultures with
fresh medium containing either 0.5% DMSO (vehicle control) or 10 nM TCDD and then incu-
bated for 4, 8, 12 and 24 h. RNA was extracted from the cultures, transcribed into cDNA and
subjected to qRT-PCR analysis essentially as described in Materials and Methods (Section
2.2.7, Section 2.2.8, Section 2.2.10, Section 2.2.13.2 and Section 2.2.13.3).
The measurements of mRNA use normalization against ß-actin mRNA to correct for loading
differences, so it was essential to test that ß-actin mRNA expression is not affected by any treat-
ment at any time of the induction. An additional reference gene used in this study was the AhR
mRNA. 
Figure 3.13 D and Figure 3.13 E show ß-actin and AhR/ß-actin mRNA ratios relative to vehicle
control at 4 h. The results show that the ß-actin mRNA levels and AhR/ß-actin mRNA ratios
were stable after all treatments, except for the ß-actin mRNA for DMSO-treated cultures at 8
and 12 h, where the decreased levels were found to be significantly different from control at 4
h. However, this result may be due to insufficient input of cDNA in these samples, which was
a consistent problem in low-density cultures. ß-actin mRNA and the AhR/ß-actin mRNA ratios
were more stable in high-density cultures. Thus, in high-density cultures, they are suitable to
use as a reference genes. This finding proves that the induction of CYP1A1 mRNA relative to
controls was not due to sample variability as there was no corresponding change in the two con-
trol genes. The stable expression of reference genes over time and treatments, makes the anal-
ysis for CYP1A1 mRNA more robust.






Figure 3.13 Effect of cell density on CYP1A1 mRNA in H4-II-E cells over time course.  A. Low- (5.6 x
104cells/well) and B. high- (18 x 104 cells/well) density cultures were incubated with fresh medium containing 10 nM TCDD
or 0.5% DMSO for 0, 4, 8, 12 and 24 h at 37ºC, then harvested at the specified time. Total RNA was extracted and reverse-
transcribed. 2 ng cDNA was amplified and Ct levels of CYP1A1 and E-actin were determined by RT-PCR. The relative gene
expression levels were normalized to those of E-actin and calculated from E-ǻǻCt, as described in Material and Methods (Sec-
tion 2.2.13.2). Each point represents the average of mean ± S.D of four replicate determinations and is representative of results
obtained from two experiments. Each qRT-PCR reaction was performed twice. In ordinates: (A, B and C) CYP1A1/E-actin
mRNA ratios relative to vehicle control at 4 h, (D) E-actin mRNA relative to vehicle control at 4 h, (E): AhR/E-actin mRNA
ratios relative to vehicle control at 4 h. The figure (E) is missing one data point, the DMSO-treated low-density cells at 4 h.
(*, asterisks; p<0.05, t-test, n=4, comparison of TCDD-treated cultures at each time point with vehicle controls at correspond-
ing time points). E-actin mRNA and AhR/E-actin mRNA ratios at different time points for each treatment were not signifi-
cantly different from vehicle-treated cultures at 4 h (p>0.05, one-way ANOVA analysis followed by Dunnett’s Multiple
Comparison test), except for E-actin mRNA for DMSO-treated low-density cells at 8 and 12 h (*) (p<0.05, one-way ANOVA
analysis followed by Dunnett’s Multiple Comparison test).
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It was important to examine CYP1A1 mRNA levels in the control cultures, and determine if
these were perturbed. Figure 3.13 C shows the results for DMSO-treated cultures displayed in-
Figure 3.13 A and B, but on a different scale. Figure 3.13 C shows that CYP1A1/ß-actin mRNA
ratios were increased in vehicle controls in low-density cells at all time points relative to 4 h
(p<0.05, n=4; one way-ANOVA analysis followed by Dunnett’s Multiple Comparison test). In
high-density cells, CYP1A1/ß-actin mRNA ratios are induced at 8 and 12 h (p<0.05, n=4; one
way-ANOVA analysis followed by Dunnett’s Multiple Comparison test) but decreased at 24 h
(p>0.05, n=4; one way-ANOVA analysis followed by Dunnett’s Multiple Comparison test)
treatment relative to 4 h levels (Figure 3.13 C). This is in agreement with findings reported by
Kocarek et al (1993) [172], where the P450 1A1 RNA levels were increased 1 to 2 h after a me-
dium change, reached maximum level at 6 h and declined to baseline by 24 h.
Figure 3.13 A and Figure 3.13 B reveal that the increase in CYP1A1 mRNA levels by TCDD
was observed as early as 4 h in both low- and high-density cells (4 h, p<0.01, t-test, n=4, com-
pared to vehicle controls at 4 h). In high- and low-density cells, maximal levels of induced
CYP1A1 mRNA were achieved from 12 h and were maintained until 24 h. The mean and S.D
for CYP1A1/ß-actin mRNA (% vehicle control at 4 h) induced by TCDD in high density cells
at 8 and 12 h were, 5300 ± 1200 and 9000 ± 3000 respectively). Whereas, the mean and S.D for
CYP1A1/ß-actin mRNA ratios (% vehicle control at 4 h) by TCDD in low-density cells, at 8 and
12 h were, 2200 ± 560 and 5000 ± 800 respectively. The maximal induced levels were 90-fold
and 60-fold above controls for high- and low-confluent H4-II-E cells respectively. These results
confirmed inducibility of the CYP1A1 mRNA in low-(Figure 3.13 A) and high-(Figure 3.13 B)
density H4-II-E cells by TCDD as previously reported [173] [58] [174] [175] [176] with 3-fold
greater induction observed in high-compared with low-density cells (p<0.05, t-test; n=4, for
TCDD-treated high density cultures over TCDD-treated low-density cultures at each time
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point). In high and low density cells, the CYP1A1/ß-actin mRNA ratios in response to TCDD,
were still increasing till 12 h. Thus, working at early time points, such as 4 h, insures linearity
of the response which deviates from linearity at 12 h and onward. 
Given the higher induction levels of CYP1A1/ß-actin mRNA by TCDD in high-density cells
coupled with increased RNA yield, and the more stable expression of RNA of reference genes,
high-density conditions were used subsequently. Throughout all experiments, unless indicated
elsewhere in the text, cultures were seeded at a density of 1 x 105 cells/ well in 96 well plates
so that they reach high-density by 24 h (Figure 3.10). After 24 h, inducing compounds were add-
ed at the indicated concentrations and cultures incubated for 4 h. 
Section 3.2.5.2 Effect of varying the treatment time
The CYP1A1/ß-actin mRNA ratios increased linearly till 12 h in response to 10 nM TCDD (Fig-
ure 3.13 B). However, TCDD is resistant to metabolism [61], and it is not known whether a met-
abolically labile compound, such as 5F 203 [146], would show a different time-course of
induction of CYP1A1. The aim is to select the time at which the CYP1A1/ß-actin mRNA ratios
prove linear for both TCDD and 5F 203. The following experiment was conducted to examine
the time-course profile of the induction of CYP1A1/ß-actin mRNA ratios by 5F 203 under the
same conditions applied for TCDD on H4-II-E cultures (Section 3.2.5.1). The experiment also
seeks to examine the effect of DMSO on the CYP1A1/ß-actin mRNA ratios H4-II-E cells over
time course. 
H4-II-E cells were incubated with 1 PM 5F 203 for 0, 2, 4, 6 and 8 h at 37ºC. In parallel, cultures
were incubated with 10 nM TCDD as a positive control or 0.1% DMSO as a negative control
for 4 h. All treatments were added to cultures in fresh medium. Untreated cultures were not sub
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jected to medium change and were included as a negative control. CYP1A1 mRNA induction
by TCDD (10 nM), 5F 203 (1 PM) or 0.1% DMSO at different time points is shown in Figure
3.14 A.
Figure 3.14 B shows the time-response curve for the CYP1A1/ß-actin ratios in response to
DMSO (0.1%). A significant increase in CYP1A1 mRNA was observed in vehicle-treated cells 
A
Figure 3.14 Time course of induction of CYP1A1 mRNA by 5F 203 in H4-II-E cells.  H4-II-E cultures were
treated with fresh medium containing 1 PM 5F 203 (black diamonds) or 0.1% DMSO (blue triangles) for 0, 2, 4, 6 and 8 h or
TCDD (10 nM) (red circle), used as a positive control at 4 h. CYP1A1/E-actin mRNA ratios were determined as described in
Figure 3.13 legend. Each point represents the average of mean ± S.D for four replicate determinations, and is representative of
results obtained from two experiments. Each qRT-PCR reaction was performed twice. Ordinates: (A and B) CYP1A1/E-actin
mRNA ratio relative to untreated H4-II-E cells at 0 h, with (C) showing the DMSO-treated cultures displayed in (A) but on
adifferent scale. (C) E-actin mRNA relative to untreated H4-II-E cells at 0 h, (D) AhR/E-actin mRNA ratios relative to untreated
H4-II-E cells at 0 h. (*, asterik, difference between means of DMSO-treated cultures at each time point and untreated cultures
at 0 h were greater than two standard deviations). E-actin mRNA and AhR/E-actin mRNA ratios at different time points for
each treatment were not significantly different from untreated H4-II-E cells at 0 h (p>0.05, one-way ANOVA analysis followed
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from 2 h up to 8 h consistent with the previous experiment (Figure 3.13 C). The increase of
CYP1A1/ß-actin mRNA in DMSO-treated cultures from these results is in apparent contrast
with literature reports of low basal hydroxylase activity in the H4-II-E cell line [173] [58] [177]
or that DMSO at concentrations of 0.5% or less in the medium has no effect on aryl hydrocarbon
hydroxylase induction in H4-II-E cell [171].
The expression of RNA in reference genes was first analysed. Figure 3.14 C and D characterize
the expression of endogenous ß-actin and AhR mRNA. As seen from these results, the expres-
sion of both ß-actin and AhR mRNA was stable at all treatments at all time points. Thus the ex-
periment proves that CYP1A1/ß-actin mRNA ratios do not reflect an artifact of sample loading
or preparation.
A rapid and significant increase in CYP1A1/ß-actin mRNA ratio by 5F 203 was observed as ear-
ly as 2 h (200-fold above 0-h untreated cells), before attaining maximal induction around 6-8 h.
CYP1A1/ß-actin mRNA ratios achieved by 5F 203 were increasing over the period of 2-6 h and
saturate at 6 h (Figure 3.14 A). The results confirmed that 5F 203 can induce CYP1A1 mRNA.
The relationship between CYP1A1/ß-actin mRNA ratios and time of treatment with 5F 203 was
linear till 6 h. At 4 h of treatment with either TCDD or 5F 203, the induction of CYP1A1/ß-actin
mRNA ratio was high enough to be measured reliably and was linear for both compounds.
Therefore, further experiments will be conducted at 4 h treatment. 
DMSO and inducers (TCDD and 5F 203) were added to the cell cultures by replacing the me-
dium with fresh medium containing compound. A striking difference in the levels of CYP1A1/
ß-actin mRNA in TCDD- treated cells was observed comparing the results of Figure 3.14 A
with Figure 3.13 B. For example, in Figure 3.14 A, the levels of CYP1A1 mRNA induced by
TCDD after 4-h incubation were 780-fold above control (untreated cells at 0 h) as opposed to
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only 30-fold above control (0.1% DMSO at 4 h) in Figure 3.13 B. It is important to note that the
controls used in these two experiments are different. Figure 3.14 presents the data relative to
untreated cells (negative control), which were not subjected to any medium change, whereas
Figure 3.13 presents the data relative to vehicle-treated cells, which were subjected to replace-
ment of the old medium with fresh medium containing DMSO. The magnitude of CYP1A1
mRNA induction depends on the controls, since the data are presented relative to corresponding
controls. Therefore, it was essential to control the background levels for CYP1A1 in controls.
This issue will be addressed in detail in the following experiment. 
Section 3.2.5.3 Effect of medium on CYP1A1 mRNA induction
The induction levels achieved by TCDD in the H4-II-E cells varied significantly between Fig-
ure 3.13 and Figure 3.14. Moreover, control CYP1A1 levels were higher in Figure 3.13, than in
Figure 3.14. One hypothesis is that fresh medium can induce CYP1A1 mRNA. An alternative
possibility is that DMSO caused the induction of CYP1A1 mRNA.
To investigate these hypotheses, H4-II-E cultures were incubated for 24 h. After 24 h, high-den-
sity cultures were subjected to treatments (0.1% DMSO or 10 nM TCDD) by either:
a) Replacing the incubation medium with pre-incubated (day-old) medium.
b) Replacing the incubation medium with fresh medium.
c) Adding 20 Pl of day-old medium to each well (to a final volume of 200Pl).
d) Adding 20 Pl of fresh medium to each well (to a final volume of 200Pl).
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Figure 3.15 shows the effect of medium and DMSO on CYP1A1 mRNA basal expression and
on TCDD-induced CYP1A1 mRNA levels. The expression of ß-actin mRNA and AhR/ß-actin-
mRNA ratios are shown in Figure 3.15 C and D. The results prove that the constitutive expres
A
Figure 3.15 Effect of medium change on CYP1A1 mRNA expression in H4-II-E cells:  incubation medium
(white bars), fresh medium (light gray bars), 20 Pl incubation medium (dark gray bars) or 20 Pl fresh medium (black bars) was
added to untreated, vehicle (0.1% DMSO) or 10 nM TCDD-treated H4-II-E cultures for 4 h incubation at 37ºC. CYP1A1/E-
actin mRNA ratios were determined as described in Figure 3.13 legend. Each bar represents the average of mean ± S.D for
triplicate samples, and is representative of results obtained from one of three experiments. Each qRT-PCR reaction was per-
formed once. Ordinates: (A) CYP1A1/E-actin mRNA ratios as absolute values on logarithmic scale, (B) CYP1A1/E-actin
mRNA ratios relative to no-vehicle cultures in pre-incubated medium on a linear scale, (C) E-actin mRNA relative to no-ve-
hicle cultures, (D) AhR/E-actin mRNA ratios relative to no-vehicle cultures.(*; p<0.01; t-test, n=3 for comparing no vehicle-,
vehicle- or TCDD-treated cultures in fresh medium with those in pre-incubated medium, in parallel for comparing no vehicle-
, vehicle- or TCDD-treated cultures with addition of 20 Pl fresh medium with those subjected to 20 Pl pre-incubated medium,
**; p<0.05; t-test, n=3 for comparing DMSO-treated cultures in fresh medium with no-vehicle treated cultures in pre-incubated
medium set as control).
B
C D
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sion of the reference genes is stable after all treatments, except for ß-actin in DMSO-treated cul-
tures in fresh medium, which was found significantly different from no-vehicle treated control
cultures in pre-incubated medium (p<0.05, t-test, n=3). However, this latter result was not re-
produced in other experiments. Overall, the mRNA levels for the reference genes were found to
be relatively stable at all treatments, which provides reliability for the results and analysis of this
experiment.
Figure 3.15 A shows the CYP1A1/ ß-actin mRNA ratios as absolute values on a logarithmic
scale, whereas in Figure 3.15 B, the data are normalised relative to vehicle control on a linear
scale. Low but detectable basal levels of CYP1A1/ ß-actin mRNA were observed in no vehicle-
cultures not subjected to any fresh medium. The CYP1A1/ ß-actin mRNA ratios were 2.8 ± 1.0
x 10-5 and 6 ± 2 x 10-5 for the no vehicle-cultures incubated with day-old medium or subjected
to addition of 20 Pl of pre-incubated medium respectively. The CYP1A1/ ß-actin mRNA ratios
were 2 ± 0.9 x 10-4 and 1 ± 0.1 x 10-4 for the no vehicle-cultures incubated with fresh medium
or subjected to addition of 20 Pl of fresh medium respectively. CYP1A1/ ß-actin mRNA ratios
were significantly increased when medium was replaced with fresh medium or when cultures
were exposed to 20 Pl of fresh medium (p<0.05, t-test, n=3). The level of CYP1A1 mRNA in
no-vehicle cultures incubated with fresh medium was 8-fold above no vehicle-cultures with pre-
incubated medium. The level of CYP1A1 mRNA in no vehicle-treated cultures subjected to ad-
dition of 20 Pl fresh medium were 5-fold above no vehicle-cultures subjected to 20 Pl pre-incu-
bated medium (p<0.01, t-test, n=3). No significant difference was observed for no vehicle-
cultures subjected to addition of 20 Pl incubation medium compared to untreated cells in incu-
bation medium. The CYP1A1/ß-actin mRNA levels were significantly higher in cultures treated
with fresh or subjected to addition of 20 Pl fresh medium containing DMSO over vehicle-treat-
ed cultures with pre-incubated medium containing DMSO (p<0.05, t-test, n=3). Therefore,
Rana Bazzi   Section 3.2.5
Page 119
fresh medium is causing induction of CYP1A1 mRNA (Figure 3.15 A). Addressing the possi-
bility of DMSO as an inducer of CYP1A1 mRNA, the results of Figure 3.15 A show that the
addition of DMSO (0.1%) to cultures did not induce CYP1A1/ß-actin mRNA significantly over
corresponding no vehicle-cultures (p>0.05, t-test, n=3). This finding rules out the possibility
that DMSO was an inducer of CYP1A1 mRNA in this cell line. This is consistent with previous
findings [178] [173] [179] [171].
CYP1A1/ß-actin mRNA ratios were increased by TCDD in all cultures (in pre-incubated medi-
um, fresh medium or subjected to 20 Pl either pre-incubated medium or fresh medium) with
similar absolute ratios (Figure 3.15 A). When these data were normalised to no-vehicle controls,
CYP1A1/ß-actin mRNA ratio induced by 10 nM TCDD was 440-fold greater in cultures in pre-
incubated medium compared to those with fresh medium (55-fold) (p<0.01, t-test, n=3) (Figure
3.15 B). Similar levels of CYP1A1/ß-actin mRNA expression were observed in vehicle-treated
cultures in pre-incubated medium and those subjected to addition of 20 Pl pre-incubated medi-
um containing DMSO. This is also true for TCDD-treated cultures, where no difference was
found in cultures in pre-incubated medium containing TCDD compared with cultures subjected
to addition of 20 Pl pre-incubated medium containing TCDD (Figure 3.15 A). 
To summarize, the results from Figure 3.15 A showed significant differences in the levels of
CYP1A1/ ß-actin mRNA in cells depending on the medium in which the drugs were diluted and
subsequently cells were incubated. Consequently, the fold-induction of CYP1A1/ß-actin mRNA
levels induced by TCDD was markedly affected depending on the corresponding controls (Fig-
ure 3.15 B). The results suggest that the factor that was affecting the CYP1A1/ß-actin mRNA
background levels in the previous experiments (Figure 3.13 C and Figure 3.14 B) was the fresh
medium and this problem was controlled by treating the cells with drugs diluted in a pre-incu-
bated medium. Furthermore, these findings provide an explanation for the variability of the in-
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duced levels by TCDD for the two experiments (Figure 3.13 and Figure 3.14). Thus, in
subsequent experiments, cultures will be exposed to chemicals, added in 20 Pl of pre-incubated
medium for a total volume of 200 Pl per well. This is consistent with earlier observations in this
study (Figure 3.13 B & Figure 3.14) and provides explanation for the high background for the
CYP1A1/ß-actin mRNA in controls (Figure 3.14 B).
Section 3.2.6 Effect of time on the dose response curves for TCDD
Figure 3.13 B showed that the induction of CYP1A1 mRNA expression in H4-II-E cells as a
function of time of exposure to TCDD was linear up to 12 h when the response starts to saturate. 
It is possible that assaying dose-response relationships under non-linear conditions could dis-
place the EC50 for induction of CYP1A1 [180]. This experiment investigates the effect of time
on TCDD log concentration-response curves in H4-II-E cultures, by comparing induction at lin-
ear (4 h) and non linear (24 h) response.
H4-II-E cultures were treated with TCDD for 4 and 24 h and CYP1A1 mRNA expression was
determined by qRT-PCR as described in Materials and Methods (Section 2.2.13.3).
Expression of the ß-actin and AhR mRNA ratios was analysed in parallel to the quantitation of
CYP1A1 mRNA induction in each experiment. Figure 3.16 B and Figure 3.16 C show the ex-
pression of ß-actin and AhR/ß-actin mRNA ratios. The results prove that the constitutive ex-
pression of the reference genes is stable after TCDD treatment at all concentrations, at both 4
and 24 h. 
Figure 3.16 A shows a significant induction of CYP1A1/E-actin mRNA ratios over vehicle-
treated H4-II-E cells from 10 pM TCDD at 4 h (p<0.01, t-test; n=3). The maximal levels of
CYP1A1/E-actin mRNA ratios were achieved by 100 pM TCDD. 
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From 100 pM onward, the maximal saturated CYP1A1/E-actin mRNA ratios (percentage of 4 h
DMSO) induced by TCDD were 23 x 103 % (95% CI, 18-27) and 33 x 103 % (95% CI, 26- 41),
at 4 and 24 h respectively. TCDD’s EC50 values were 40 pM (95% CI, 12-140) and 13 pM (95%
CI, 2.8-57) at 4 h and 24 h respectively. This experiment showed no significant difference of 
A
B C
Figure 3.16 Effect of time on the concentration-response curves for CYP1A1 mRNA induction by TCDD in
H4-II-E cells.  Cultures were exposed to DMSO (0.1%) or TCDD (at the indicated concentrations) for 4 h [Ɣ] and 24 h [ż].
CYP1A1/E-actin mRNA ratios were determined as described in Figure 3.13 legend. Each point represents the mean ± S.D for
triplicate samples from one experiment. Each qRT-PCR reaction was perfomed once. The mean and S.D for CYP1A1/E-actin
mRNA absolute ratios for untreated and vehicle-treated H4-II-E cells were 2.2 ± 0.7 x 10-5 and 4.3 x 10-5 respectively. Curves
were fitted using the variable slope sigmoid Hill equation (GraphPad 5.0 Software). Ordinates: (A) CYP1A1/E-actin mRNA
ratios relative to 4 h DMSO, (B) E-actin mRNA relative to 4 h DMSO, (C) AhR/E-actin mRNA ratios relative to 4 h DMSO.
Abscissae: logarithms of molar concentrations of TCDD. E-actin mRNA and AhR/E-actin mRNA ratios for vehicle-treated
cultures at 4 h were represented by zero molar concentrations. E-actin mRNA and AhR/E-actin mRNA ratios at different time
points for each treatment were not significantly different from vehicle-treated cells at 4 h (p>0.05, one-way ANOVA analysis
followed by Dunnett’s Multiple Comparison test). 
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time treatment (4 and 24 h) with TCDD on the EC50 values for induction of CYP1A1 mRNA in
H4-II-E cells (as the difference between means of EC50 at 4 and 24 h, were less than two stand-
ard deviations).
The effect of time on TCDD log concentration-response curves is expected to be higher than
observed. However, the effect was not detected given that the 95% confidence intervals of the
mean were very large (> 10-fold) and overlapping. Based on earlier observations that the levels
of CYP1A1/E-actin mRNA ratios induced by TCDD at 4 h were 3-fold lower than those at 24
(Figure 3.13 B), the magnitude of the effect desired is expected to be at least 3-fold, in order to
be considered significant. However, given the large size of variation, the powers of the experi-
ment were limited and so the ability to detect a small effect as 3-fold was masked. Overall, the
EC50 of TCDD is more likely to be affected by the time, but the experiment failed to detect it
(this is called type II error). Thus, this experiment needs to be repeated in the future, including
more concentrations between 10-12 M and 10-10 M, in order to reduce the 95% confidence in-
tervals. 
Section 3.2.7  Induction of CYP1A1 mRNA by 3-methylcholanthrene (MC) 
The nonhalogenated aromatic hydrocarbon, MC, exhibits similar binding to AhR as TCDD in
rat [67] but is 30,000-fold less potent at inducing AHH in rat liver in vivo [181]. It was suggested
that the reduced potency of nonhalogenated aromatic hydrocarbons is influenced by their more
rapid metabolism [180] in comparison with the poorly metabolized TCDD [61]. The aim was
to see whether the EC50 for the induction of CYP1A1 mRNA of a compound, known to be me-
tabolized, such as MC, can be determined under the conditions of the current assay. The ability
of MC and TCDD to induce CYP1A1 mRNA was investigated in H4-II-E cells. Cultures of H4-
II-E cells were exposed to increasing concentrations of MC, the positive control TCDD or the 
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negative control DMSO (0.1%) for 4 h. The positive control TCDD produced maximal CYP1A1
mRNA induction at 10 nM, which was set at 100%. The expression of ß-actin mRNA and AhR/
ß-actin mRNA ratios was examined for stability. It was essential that these reference genes
proved unchanged over treatments, so that the results will be considered reliable and analysis
for CYP1A1 mRNA will be performed. As shown in Figure 3.17 B and C, generally, the expres-
sion was found stable with less than two-fold variation, thus the experiment proves that
CYP1A1/ß-actin mRNA ratios do not reflect an artifact of sample loading or preparation. Figure
3.17 shows that TCDD and MC have similar maximal levels of CYP1A1 mRNA induction in
H4-II-E cells, as previously reported [180] [177]. The maximum CYP1A1/ß-actin mRNA levels
attained by TCDD and MC relative to 10 nM TCDD were 117 for MC (95% CI, 109-124) and
100 for TCDD (95% CI, 94-113). 
EC50 values for TCDD and MC were 60 pM (95% CI, of 33-100) and 9 nM (95% CI, 7-13) re-
spectively. The log concentration-response curves in Figure 3.17 A show that MC is ~150-fold
less potent than TCDD in H4-II-E cells. These results prove the potency of MC for inducing
CYP1A1 mRNA in H4-II-E cells. This compound was found much less potent in rat liver in vivo
[181] compared to TCDD. In the present study, MC was 150-fold more potent compared with
the 30,000-fold from literature report [181]. This could be due to the possibility that, in the cur-
rent assay, CYP1A1 mRNA was measured in H4-II-E cells under conditions where metabolism
of MC would be minimal (4 h by qRT-PCR) as opposed to in vivo at 24 h [181]. In the light of
these results, the current induction assay proves useful tool to measure the EC50 for the induc-
tion of CYP1A1 mRNA for compounds prone to self-metabolism, such as phenylbenzothiazole
compounds [182]. 
The induction assays for CYP1A1 mRNA by TCDD in H4-II-E cells were conducted on differ-
ent occasions and EC50 values for TCDD are displayed in Table 3.6.  




Figure 3.17 Effect of TCCD and MC on CYP1A1 mRNA in H4-II-E cells.  Cultures were treated with DMSO
(0.1%), TCDD [Ɣ] or MC [ż] (at the indicated concentrations) for 4 h. CYP1A1/E-actin mRNA ratios were determined as
described in Figure 3.13 legend. Each point represents the average of mean ± S.D for triplicate samples, and is representative
of results obtained from one of two experimental trials (for MC) and four for (TCDD). Each qRT-PCR reaction was performed
once. The mean and S.D for CYP1A1/ß-actin basal ratios attained by untreated cultures and vehicle controls was 3.8 ± 1.4 x
10-6 and 1.78 ± 1.23 x 10-5 respectively. The mean and S.D for CYP1A1/ß-actin ratios for 10 nM TCDD-treated cultures was
0.15 ± 0.004. Curves were fitted using the variable slope sigmoid Hill equation (GraphPad Prism 5.0 Software). Ordinates: (A)
CYP1A1/E-actin RNA ratios relative to 10 nM TCDD, (B) E-actin mRNA ratios relative to 10 nM TCDD, (C) AhR/E-actin
mRNA ratios relative to 10 nM TCDD. Abscissae: logarithms of molar concentrations of TCDD and MC. E-actin mRNA and
AhR/E-actin mRNA ratios at different time points for each treatment concentration were not significantly different from 10
nMTCDD-treated cells at 4 h (p>0.05, one-way ANOVA analysis followed by Dunnett’s Multiple Comparison test), except
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These data show reproducibility of the induction assay; note that the coefficient of variation of
assay EC50 valuesis 32.5%.
Section 3.2.8  Induction of CYP1A1 mRNA by 5F 203 
5F 203 was found to be a high-affinity ligand for rat AhR (Section 3.1.8; Figure 3.9). This com-
pound is expected to be a potent inducer of CYP1A1 mRNA in rat H4-II-E cells. To assess the
agonistic activity of 5F 203, cultures of H4-II-E cells were exposed to increasing concentrations
of 5F 203. CYP1A1 mRNA levels are expressed relative to the maximal induced level, which is
arbitrarily obtained using 10 nM TCDD. The positive controls TCDD were included from an-
other experiment (see Section 3.2.7; Figure 3.17), to compare the EC50 for both compounds. It
was not possible to test higher concentrations of 5F 203, because of the insolubility of the 5F
203 at concentrations higher than 30 PM. The log concentration response-curves of TCDD and
5F 203 for CYP1A1 mRNA in H4-II-E cells are shown in Figure 3.18.





Average ± S.D 40 ± 13
Table 3.6 Summary for the EC50 values of TCDD for the induction of CYP1A1 mRNA in
H4-II-E cells.  EC50 values were determined from log concentration-response curves using the variable
slope Hill sigmoidal equation (GraphPad Prism 5.0). Each trial was conducted on a range of concentrations,
each in triplicate samples. The average and S.D represent the mean and standard deviations of EC50 values
from four independent experiments.
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The expression ß-actin mRNA and AhR/ß-actin mRNA ratios was examined for stability. As
shown in Figure 3.18 B and C, generally, the expression was found stable within less than two
Figure 3.18 Concentration-response curves for CYP1A1 mRNA induction by TCDD and 5F 203 in H4-II-
E cells.  Cultures were treated with DMSO (0.1%), 10 nM TCDD [Ɣ] or 5F 203 [ż] (at the indicated concentrations) for 4 h.
CYP1A1/E-actin mRNA were determined as described in Figure 3.13 legend. Response curves were combined from two sep-
arate experiments. Log concentration-response curve for TCDD is the same displayed in Figure 3.17. Each point represents the
average of mean ± S.D for triplicate samples, and is representative of results obtained from one experiment (for 5F 203) and
four experiments (for TCDD). Each qRT-PCR reaction was performed once.The mean and S.D for CYP1A1/ß-actin ratios were
1.9 ± 1.3 x 10-5 and 4.6 ±1.3 x 10-5 for the untreated- and DMSO-treated cultures. The mean and S.D for CYP1A1/ß-actin ratios
for 10 nM TCDD-treated cultures was 0.02 ± 0.004. Curves were fitted using the variable slope sigmoid Hill equation (Graph-
Pad Prism 5.0 Software). Ordinates: (A) CYP1A1/E-actin RNA ratio relative to 10 nM TCDD, (B) E-actin mRNA relative to
10 nM TCDD, (C) AhR/E-actin mRNA ratio relative to 10 nM TCDD. Abscissae: logarithms of molar concentrations of TCDD
and 5F 203. E-actin mRNA and AhR/E-actin mRNA ratios at different time points for each treatment concentration were not
significantly different from 10 nM TCDD-treated cells at 4 h (p>0.05, one-way ANOVA analysis followed by Dunnett’s Mul-
tiple Comparison test), except for the E-actin mRNA treated with 30 nM 5F 203 (*, p<0.05, one-way ANOVA analysis fol-
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fold variation, thus the experiment proves that CYP1A1/ß-actin mRNA ratios do not reflect an
artifact of sample loading or preparation.
As seen in Figure 3.18 A, 5F 203 increased the levels of CYP1A1 mRNA in a concentration-
dependent manner. Increased levels were observed from a concentration of 1 PM, up to the
maximum concentrations tested. The EC50 for 5F 203 was 3 PM (95% CI, 1.3-7.7) whereas
EC50 for TCDD was 60 pM (95% CI, 33-100). 5F 203 was able to induce CYP1A1 mRNA but
with ~50,000-fold less potency than TCDD. The 5F 203 log concentration-response curve
shows that a maximal response was achieved from 10 PM and the maximal levels of the
CYP1A1 mRNA induced by 5F 203 were 99% (95% CI, 77-120) compared with 100% by
TCDD (95% CI, 94-113). These results show that 5F 203 can induce CYP1A1 mRNA to a sim-
ilar level as that seen with TCDD. Based on that, 5F 203 is a full agonist but is much less potent
than TCDD.
Section 3.2.9  Induction of CYP1A1 mRNA by IH 445, DF 203, GW 610, 
AW 892 and IH 318
In Section 3.1.8 (Table 3.3), DF 203, GW 610, AW 892, IH 318 and IH 445 compounds were
found to be potent AhR ligands with the latter having the highest binding affinity (Ki § 1nM).
These compounds were expected to be potent inducers for CYP1A1 mRNA in H4-II-E cells. The
ability of these compounds for inducing CYP1A1 mRNA was examined in H4-II-E cells. The
induction assay was conducted essentially as described in Materials and Methods (Section
2.2.14). In Figure 3.19 are shown the log concentration-response curves for CYP1A1 mRNA in-
duction by DF 203, GW 610, AW 892, IH 318 and IH 445 in H4-II-E cells. 
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A
Figure 3.19 Concentration-response curves for the induction of CYP1A1 mRNA by TCDD, IH 445, DF
203, GW 610, AW 892 and IH 318 in H4-II-E cells.  Cultures were treated with DMSO (0.1%), 10 nM TCDD [Ɣ], IH
445 [Ƒ], DF 203 [Ŷ], GW 610 [ż], AW 892 ['] or IH 318 [ź] (at the indicated concentrations) for 4 h. CYP1A1/E-actin
mRNA were determined as described in Figure 3.13 legend. Response curves were combined from separate experiments. Each
point represents the average of mean ± S.D for triplicate samples, and is representative of results obtained from one of two
experimental trials for (IH445) and four for (TCDD). For the rest of the compounds, the results were obtained from a single
experiment. Each qRT-PCR reaction was performed once. Log concentration-response curve for TCDD is the same displayed
in Figure 3.17. Curves were fitted using the variable slope sigmoid Hill equation (GraphPad Prism 5.0 Software). Ordinates:
(A) the CYP1A1/E-actin mRNA ratios relative to 10 nM TCDD, (B) E-actin mRNA relative to 10 nM TCDD, (C) AhR/E-actin
mRNA ratios relative to 10 nM TCDD. Abscissae: logarithms of molar concentrations of inducers. E-actin mRNA and AhR/E-
actin mRNA ratios at different time points for each treatment concentration were not significantly different from 10 nM TCDD-
treated cells at 4 h (p>0.05, one-way ANOVA analysis followed by Dunnett’s Multiple Comparison test).
B
C
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The expression of ß-actin mRNA and AhR/ß-actin mRNA ratios was examined for stability. As
shown in Figure 3.19 B and C, the expression was generally found to be stable with less than
two-fold variation, thus the experiment proves that CYP1A1/ß-actin mRNA ratios do not reflect
an artifact of sample loading or preparation.
Because the EC50 and the maximal levels for CYP1A1/ß-actin mRNA ratios are compared be-
tween the test compounds and TCDD across experiments in some occasions, it was essential to
examine whether the controls used across experiments did not change significantly. Negative
(untreated- and vehicle-treated cultures) and positive control levels for CYP1A1/ß-actin mRNA
ratios for Figure 3.19 are shown in Table 3.7. These values fall in within 2-3 fold of variability,
which is acceptable, and thus the results on these test compounds were reliable. 
The EC50 for induction of CYP1A1/ß-actin mRNA by IH 445 was 4 nM (95% CI, 2-10), which
is 67-fold less potent than that of TCDD (EC50 = 60 pM with 95% CI, 33-100). The maximal
CYP1A1/ß-actin mRNA ratios were 60% of that seen with 10 nM TCDD. The apparent lower
maximal levels by IH 445 will be discussed further (see below Figure 3.29). Higher concentra-
tions of IH 445 were not tested due to the insolubility of the compound in the medium. Impor-
tantly, in this assay, this compound was 800-times more potent than 5F 203. 
The EC50 values and maximal induced levels (as percentage of 10 nM TCDD) for the phenyl-
benzothiazole compounds tested are listed in Table 3.8. From these results, the EC50 values for
DF 203, GW 610, AW 892 and IH 318 are all in the micromolar concentrations. DF 203 and
AW 892 displayed similar potency as 5F 203 for inducing CYP1A1 mRNA, i.e, they are much
less potent (>50,000-fold) than TCDD. However, GW 610 and IH 318 were 2- and 3-fold less
potent than 5F 203. Importantly, the IH 318 compound elicited TCDD supermaximal levels.
However, saturated levels could not be obtained because of the insolubility of the IH 318 at con
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centrations higher than 30 PM. Given that the response-curve for CYP1A1 mRNA induction by
IH 318 was not complete (Figure 3.19 A), the actual EC50 determined was an estimation and
was not considered as an accurate measurement value. However, although saturated levels by
IH 318 were not achieved, it is clear that this compound is not a potent inducer for CYP1A1 mR-
NA. Interestingly, all these compounds were found to be full agonists for the induction of
CYP1A1 mRNA, given that they all achieve levels of induction similar to those achieved by
TCDD. Overall, under the conditions of the current CYP1A1 induction assay, the IH 445 was









IH 445 1.5 ± 0.7 x 10-5 2.7 ± 0.9 x 10-5 0.024 ± 0.0028
DF 203 5.6 ± 1.8 x 10-5 6.6 ± 2.2 x 10-5 0.01 ± 0.002
GW 610 2 ± 1.3 x 10-5 4.6 ± 1.3 x 10-5 0.02 ± 0.004
AW 892 1.6 ± 0.7 x 10-5 2.8 ± 0.9 x 10-5 0.01 ± 0.002
IH 318 6.4 ± 1.6 x 10-5 1.4 ± 0.5 x 10-4 0.02 ± 0.005
Table 3.7 Control levels for CYP1A1/E-actin mRNA ratios by phenylbenzothiazole
compounds in H4-II-E cultures.  The mean and S.D for CYP1A1/ß-actin ratios for untreated, vehicle or 10






(% 10 nM TCDD)
IH 445 4 (2-10) 60 (53-66)
DF 203 3000 (900-13000) 105 (67-144)
GW 610 6500 (3700-11000) 110 (90-130)
AW 892 2000 (300-14000) 102 (56-147)
IH 318 9000 (2500-35000) 230 (138-326)
Table 3.8 CYP1A1 mRNA induction by IH 445, DF 203, GW 610, AW 892 and IH 318.
Maximum response achieved Emax by inducers as well as the concentrations that produce half-maximal
response EC50 were obtained from log concentration-response curves for CYP1A1 mRNA induction shown in
Figure 3.19.
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Section 3.2.10 Estimation of intrinsic efficacy and fractional receptor 
occupancy 
The data for AhR binding affinity (Table 3.3) and potency for induction of CYP1A1 mRNA
(Table 3.8) for the phenylbenzothiazole analogues tested, except for IH 445, showed significant
disparity between the two measures. For a quantitative understanding of this discrepancy, it was
essential to determine the intrinsic efficacy of the compounds as well as the number of receptors
that have to be occupied for a given stimulus. 
It is anticipated that the quantitative difference between these two measures could be due, but
not limited, to the low intrinsic efficacy of the phenylbenzothiazole compounds relative to
TCDD’s, i.e, to their inability to activate the AhR to the same extend as TCDD’s, after binding.
Based on the AhR binding affinities of the compounds (Table 3.3), the number of receptors (Ta-
ble 3.2) from the binding studies and the additional knowledge of EC50 values for CYP1A1
RNA induction (Table 3.9), relative intrinsic efficacy (Ke) of AhR ligands and fractional recep-
tor occupancy at 50% response were calculated and listed in Table 3.10 assuming same KD and
Rt as determined in rat binding system.
As seen from Table 3.10, TCDD, displays the highest intrinsic efficacy. Only ~14 % of Ah re-
ceptors have to be occupied by TCDD to elicit 50% response. The compound 1c, found to be a
high-affinity AhR ligand and a potent agonist with a full induction capacity has an intrinsic ef-
ficacy which is only 2-fold lower than TCDD and has to occupy only 23% of the receptors.
Compound 1c has only ~ 3-fold higher binding than induction potency. However, MC had ap-
proximately 11-fold higher binding potency than induction and requires much higher fractional
receptor occupancy, 92%.
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IH 445, a potent AhR ligand and inducer, has 5-fold higher binding than the induction potency. 
Inducer
Emax [% 10 nM TCDD] 
(95% confidence 
intervals)







TCDD 100 (94-113) 0.06 (33-100) 0.37 (0.18-1) 6.2
MC 117 (109-125) 9 (7-13) 1§ 0.09
AZI 111 (104-118) 0.1 (0.09-0.18) 0.04 (0.01-0.1) 0.4
IH 445 60 (53-66) 4 (2-10) 0.9 (0.05-17) 0.2
5F 203 99 (77-120) 3000 (1300-7700) 2.8 (2-5) 0.00093
DF 203 100 (67-140) 3400 (900-13000) 9.9 (5-19) 0.003
GW 610 100 (89-130) 6500 (4000-12000) 6.8 (2-30) 0.001
AW 892 100 (56-147) 1900 (300-14000) 9.8 (4-22) 0.005
Table 3.9 Data for CYP1A1 mRNA induction and AhR binding in rat.  Maximum response achieved Emax
by inducers as well as the concentrations that produce half-maximal response EC50 were obtained from log concentration-
response curves for CYP1A1 mRNA induction. Inhibition dissociation constant (Ki) were obtained from the log








IH 445 33 82
5F 203 40 99.9
DF 203 39.9 99.7
GW 610 40 99.9
AW 892 39.8 99.5
Table 3.10 Intrinsic efficacy and fractional receptor occupancy at 50% of AhR ligands in H4-
II-E cells.  a Ke (constant of intrinsic efficacy) represents the concentration of the agonist-receptor complex that
produces 50% response. bR50 values are the fraction of receptors that must be occupied to elicit a 50% response or
[A.R] / [Rt]. Ke and R50 values were calculated assuming the same Rt as determined in binding assay using rat
cytosols according to equation [4] (appendix).
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At 50% maximal response, 85% of the receptors have to be occupied by IH 445. 5F 203 was
1000-fold more potent for binding AhR than for inducing CYP1A1 mRNA. Importantly, for 5F
203 to elicit the same response as TCDD at 50% response, 99.9% of the AhR have to be occu-
pied. As seen in Table 3.10, DF 203, GW 610 and AW 892, all have similar intrinsic efficacy
as 5F 203 with similar receptor occupancy levels. These compounds bind AhR avidly but are
much less efficient at eliciting the response after receptor binding. So higher concentrations are
required to activate the receptor and produce TCDD-response levels. 
This study suggests that IH 445 is a relatively high-efficacy agonist whereas 5F 203, DF 203,
GW 610 and AW 892 are low-efficacy agonists.
Section 3.2.11 Inhibition of TCDD-induced CYP1A1 mRNA by 5F 203 
Section 3.2.10 suggests that 5F 203 has a low intrinsic efficacy, with 50,000-fold lower potency
than TCDD for inducing CYP1A1 mRNA (Figure 3.18 A). Since a low-intrinsic efficacy com-
pound has properties of both agonist and antagonist, it should exhibit a concentration-dependent
inhibitory effect on the action of the high-intrinsic efficacy ligand [217]. The alternatives are
that 5F 203 is metabolized or excreted. The prediction of antagonism would partially exclude
the alternative possibilities resulting in lower intracellular concentrations of 5F 203. To test this
prediction, the inhibitory activity of 5F 203 on TCDD was assessed by co-incubating TCDD
with and without 1 PM 5F 203 in H4-II-E cells.
The concentration of 5F 203 in mixtures with TCDD could severely affect TCDD log concen-
tration-response, and thus TCDD potency (EC50). The rationale of this experiment was based
on the observation that at 1 PM, 5F 203 increased CYP1A1 mRNA (8% of 10 nM TCDD max-
imal response) (Figure 3.18 A). Below 1 PM 5F 203, there was no detectable response. If 5F
203 has an antagonistic activity, this will be observed when working at 1 PM, where 5F 203
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induces CYP1A1 mRNA to 8% of TCDD maximal response. At 3 PM, 5F 203 increased the
CYP1A1/ß-actin mRNA ratio to 50% of the maximum response. As a result, the bottom and a
top levels of the log concentration-response curve obtained for these mixtures would be very
close to each other, and the EC50 would not be determined accurately. 
It is possible to predict the EC50 of TCDD in the presence of 1PM 5F 203 (A’), given the knowl-
edge of the KB (or Ki) value for 5F 203 (2.8 nM) from competitive displacement assay (Table
3.3), TCDD’s KD, TCDD’s EC50 in the absence of 5F 203 (A) and the concentration of 5F 203
(1 PM). At 50% maximal response, both equations [6] and [7] (appendix) are equal, and yield
an [A’] value of 22 nM, and thus the shift of TCDD response curve would be anticipated to be
360-fold to the right.
Figure 3.20 shows the log concentration-response curves for the levels of CYP1A1 mRNA by
TCDD alone (10-14-10-8 M) and in combination with 1 PM 5F 203. 
The effect of the treatments on the reference genes was investigated by examining ß-actin
mRNA and the AhR/ß-actin mRNA ratios. Figure 3.20 B and Figure 3.20 C prove that the levels
of the reference genes varied within a ~ two-fold range, but no points were statistically signifi-
cantly different from control (10 nM TCDD set at 100%). The results of this analysis prove that
equal amounts of sample DNAs have been analysed, and that there is no significant variation in
reference genes. Thus variation in CYP1A1 levels does not reflect an artifact of sample loading
or preparation. 
The CYP1A1/ß-actin mRNA ratios (~8% of maximal response) observed below 10 pM TCDD
represent levels in response to 1 PM 5F 203 alone, as the CYP1A1/ß-actin mRNA ratios in re-
sponse to TCDD was not detected below 10 pM TCDD (Figure 3.20 A) (p=0.001, t-test, n=3,
comparing CYP1A1/ß-actin mRNA ratios induced by 10 pM TCDD above vehicle control lev-
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els). 
From the log concentration-response curves shown in Figure 3.20 A, TCDD's EC50 value in the
absence of 1 PM 5F 203 was 46 pM (95% CI, 13-160) whereas it was 5 nM (95% CI, 2-12) in
the presence of 1 PM 5F 203. At 1 PM, the 5F 203 shifted the concentration-response curve for
TCDD to the right by 100-fold. This is a significant effect of antagonism by 5F 203 on TCDD's
potency. This is within ~ 4-fold difference from the predicted value of 360-fold, which could be
due to some loss of the drug by metabolism, cellular uptake or excretion, such that the actual
concentration of 5F 203 at the receptor sites is less than the concentrations added. Moreover,
the effect of 5F 203 was completely reversed by TCDD (Figure 3.20 A).
Maximal levels achieved by TCDD were slightly depressed by 5F 203 though not significantly
different (Figure 3.20 A; p>0.05; t-test comparing response by 10 nM TCDD in the presence of
1 PM 5F 203 with TCDD alone). These results provide compelling evidence that 5F 203 inhib-
ited TCDD-CYP1A1 induction in H4-II-E cells. Moreover, this experiment provides powerful
evidence for excluding the possibility that metabolism of the 5F 203 could be the major reason
behind the large quantitative difference in potency between 5F 203 and TCDD, given its antag-
onistic activity on TCDD. If much of the 5F 203 were metabolized, one would expect that most
of the drug would be depleted and there would be no change in potency of TCDD. 
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As a conclusion, the lower potency of 5F 203 for inducing CYP1A1 mRNA in H4-II-E cells
compared to TCDD, was shown to be a result of its low intrinsic efficacy and antagonistic ac-
tivity and not due to metabolism of the drug.
A
Figure 3.20 Inhibition of TCDD-induced CYP1A1 mRNA by 5F 203 in H4-II-E cells.  Cultured H4-II-E cells
were exposed to a range of increasing concentrations of TCDD alone [Ɣ] or in combination with 1 PM 5F 203 [ż] for 4 h. 5F
203 (1 PM) alone [Ƒ] was included as a positive control. CYP1A1/E-actin mRNA were determined as described in Figure 3.13
legend. Each point represents the average of mean ± S.D for triplicate samples from one experiment. Each qRT-PCR reaction
was performed once. Mean and S.D for CYP1A1/ß-actin ratio for untreated- and vehicle treated cultures, were 1.2 ± 8.3 x10-6
and 2.5 ± 9.5 x 10-6 respectively. Mean and S.D for CYP1A1/ß-actin mRNA ratios for cultures treated with 10 nM TCDD, was
0.2 ± 0.007. The mean and S.D for induced CYP1A1/ß-actin mRNA ratios (% of maximal response) for cultures treated with
1PM 5F203 alone, was 7.5 ± 2.8. Curves were fitted using the variable slope sigmoid Hill equation (GraphPad Prism 5.0 Soft-
ware). Ordinates: (A) the CYP1A1/E-actin mRNA ratios relative to 10 nM TCDD, (B) E-actin mRNA relative to 10 nM TCDD,
(C) AhR/E-actin mRNA ratios relative to 10 nM TCDD. Abscissae: logarithms of molar concentrations of TCDD. E-actin
mRNA and AhR/E-actin mRNA ratios at different time points for each treatment concentration were not significantly different
from 10 nM TCDD-treated cells at 4 h (p>0.05, one-way ANOVA analysis followed by Dunnett’s Multiple Comparison test).
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Section 3.2.12 Competitive antagonism of 5F 203 on TCDD-induced 
CYP1A1 mRNA
The results from Figure 3.20 proved that 5F 203 inhibited TCDD-induced CYP1A1 mRNA and
suggests that the nature of the inhibition is a reversible competitive antagonism. To confirm this
hypothesis, the following experiment was conducted and Schild regressions (non linear and lin-
ear) analyses were performed. The aims of the Schild regressions are i) to investigate if the an-
tagonism is competitive (if the regression proves linearity with a Schild slope of 1), ii) to
determine the equilibrium dissociation constant (KB) of the complex [antagonist-AhR] and iii)
to investigate whether the system is under equilibrium. 
H4-II-E cultures were treated with a range of concentrations of TCDD in the presence of three
concentrations of 5F 203. The EC50 of TCDD for CYP1A1 mRNA induction was measured at
each concentration of 5F 203.
From the experiment in Section 3.2.11, at 50% maximal response, the KB calculated from equa-
tions [6] and [7] (appendix) was 12 nM. Using this KB value, [A’]=EC50 values of TCDD in the
presence of 1 PM, 300 nM or 100 nM, were predicted to be 5, 2 and 0.6 nM respectively.
Before measuring the CYP1A1/ß-actin mRNA ratios induced by TCDD alone or in mixtures
with different concentrations of 5F 203, it was essential to verify that the ß-actin mRNA and the
AhR/ß-actin mRNA ratios were not affected by any of the treatments. Figure 3.21 B and Figure
3.21 C prove that these ratios were within 2-fold variation, and did not change significantly
throughout the different treatments (except for few individual points). Thus the CYP1A1/ß-actin
mRNA ratios will not be affected by sample loading artifacts. 
The increase of CYP1A1/ß-actin mRNA ratios observed at TCDD low concentrations (<10 pM)
corresponds to those induced by 5F 203 alone. No increase in the CYP1A1/ß-actin mRNA ratios  
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was seen below 10 pM TCDD. The EC50 for TCDD in the absence of 5F 203 was 30 pM (95%
CI, 5-166), whereas in the presence of 100 nM 5F 203, the EC50 was increased to 200 pM (95%
Figure 3.21 Competitive inhibition of TCDD-induced CYP1A1 mRNA by 5F 203 in H4-II-E cells.  Cul-
tures were cotreated with varying concentrations of TCDD and 1PM, 300 nM or 100 nM of 5F 203. 5F 203 at 100 nM, 300
nM and 1PM alone were included as positive controls. CYP1A1/E-actin mRNA were determined as described in Figure 3.13
legend. Each point represents the average of mean ± S.D for triplicate samples from one experiment. Each qRT-PCR reaction
was performed once. Mean and S.D for CYP1A1/ß-actin ratios for untreated and vehicle-treated cultures, were 7.8 ± 1.9 x 10-
6 and 18 ± 8.8 x 10-6 respectively. Mean and S.D for CYP1A1/ß-actin mRNA ratios for cultures treated with 10 nM TCDD,
was 0.02 ± 0.0006. Mean and S.D for CYP1A1/ß-actin mRNA ratio (as % of maximal response) induced by 5F 203 alone at
each concentration 1 PM, 300 nM or 100 nM, were 27 ± 2.8, 8 and 2.1 (the last two concentrations are missing one of the
triplicates). Curves were fitted using the variable slope sigmoid Hill equation, (with the Hill slope of unity for all curves)
(GraphPad Prism 5.0 Software). Ordinates: (A) the CYP1A1/E-actin mRNA ratios relative to 10 nM TCDD, (B) E-actin
mRNA relative to 10 nM TCDD, (C) AhR/E-actin mRNA ratios relative to 10 nM TCDD. Abscissae: logarithms of molar
concentrations of TCDD. E-actin mRNA and AhR/E-actin mRNA ratios at different time points for each treatment concentra-
tion were not significantly different from 10 nM TCDD-treated cells at 4 h (p>0.05, one-way ANOVA analysis followed by
Dunnett’s Multiple Comparison test), except for E-actin mRNA treated with (TCDD+100 nM or 300 nM 5F 203) and (100
nM or 300 nM 5F 203 alone) (*, p<0.05, one-way ANOVA analysis followed by Dunnett’s Multiple Comparison test) .
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CI, 56-765). A further increase was obtained in the presence of 300 nM 5F 203, with an EC50
of 500 pM (95% CI, 300-700). At 1 PM 5F 203, TCDD’s EC50 was 3 nM (95% CI, 2-4). This
latter finding is consistent with EC50 value of 5 nM for TCDD in the presence of 1 PM 5F 203
(Figure 3.20 A).
Non linear Schild regressions were performed on Figure 3.21 A using a global fit analysis (with
no constraints on the bottom and top, i.e, these parameters are not shared among the curves).
Non linear Schild regressions global analysis on the curves in Figure 3.21 A demonstrated a
Schild slope of ~ 1 (95% CI, 0.5-1.8). The KB for 5F 203 was 23 nM (95% CI, 4-139). The value
of K% was within 2-fold difference from the value calculated from the experiment in Section
3.2.11
Figure 3.22 Schild regression.  TCDD EC50 values in the presence of each concentration of 5F 203 were determined
from the curves in Figure 3.21 and used for regressions . Equiactive concentration ratio r is calculated according to equation
[8] (appendix). Ordinate: logarithm of (r-1). Abscissa: logarithms of molar concentrations of 5F 203.
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For illustration, a linear plot of the Schild regressions from the EC50 for TCDD at each concen-
trations of 5F 203 is shown in Figure 3.22. The EC50 concentration-ratios (cr) or (r) of TCDD
was defined as [EC50 in the presence of 5F 203] / [EC50 in the absence of 5F 203]. This ratio
was determined experimentally at each concentration of 5F 203 from Figure 3.21 A. 
The results in Figure 3.22 prove that the regression of log (cr-1) on log [5F 203] is linear and
had a slope of 1.2 ± 0.17, which is not significantly different from 1. This furnishes further ev-
idence that the antagonism of 5F 203 on TCDD is competitive; i.e, 5F 203 and TCDD compete
for the same sites of receptor. This is consistent with our previous results (Figure 3.9, Figure
3.20 A & Figure 3.21 A). Furthermore, given the slope is ~ 1, that could imply that the system
is under equilibrium.
Having found that the regression is linear and the slope is of unity, then the equilibrium disso-
ciation constant of the antagonist-receptor complex, represented by pKB can be estimated from
the intercept with x abscissa which yields -log KB or pKB. The value for pKB was 7.6, so that
KB=25 nM. This is consistent with the non linear regression analysis. This KB value is within
~9-fold difference from the equilibrium dissociation constant of 5F 203 derived from the radi-
oactive competitive assay (Ki = 2.8 nM, Table 3.3). This difference could be due to difference
in nature of the two assays. Given that this experiment was performed once, in order to ensure
reproducibility of the results and validate the KB derived for 5F 203, this experiment should be
repeated in the future.
Section 3.2.13 Effect of IH 445 on TCDD-induced CYP1A1 mRNA
The high-affinity AhR ligand IH 445 (Ki=0.9 nM) is a potent agonist for the induction of
CYP1A1 mRNA in H4-II-E cells (Figure 3.19). From these data, it is anticipated that IH 445
would have no any antagonistic activity on TCDD-induced CYP1A1 mRNA in these cells. In
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order to confirm this hypothesis, the following experiment was conducted. 
The rationale of the experiment is based on the data obtained from the competitive binding assay
(Table 3.3), where 100 nM IH 445 displaced [3H]-TCDD specific binding by 100%. At 3 nM
IH 445, 50% of [3H]-TCDD specific binding was displaced. In order to investigate the antago-
nistic activity of IH 445, there is a need to work under concentrations of IH 445 at which, sig-
nificant amount of TCDD will be inhibited. However, very high concentrations of IH 445 could
result in a additive response, and consequently, the top and bottom levels of TCDD response
will be very close, and EC could not be determined. From Figure 3.19 A, a concentration of
3 nM IH 445, offers a balance between significant competition with TCDD at the receptor sites
and an induction level less than 50% of maximal response. If the IH 445 is a partial antagonist,
from equations [6] and [7] (appendix), at equal responses (50% maximal response), it is expect-
ed to shift the log concentration-response of TCDD only by 4-fold when co-incubated at the
concentration of 3 nM with TCDD. Whereas, if the IH 445 is a potent agonist for inducing
CYP1A1 mRNA, the EC50 of TCDD will not be affected.
H4-II-E cells were co-treated with a range of concentrations of TCDD ± 3 nM IH 445 for 4 h.
Figure 3.23 shows the log concentration-response curves for increasing concentrations of
TCDD alone or combined with 3 nM IH 445.
The RNA ratios of the reference genes were examined to ensure stability against the various
treatments. Figure 3.23 B and Figure 3.23 C show that ß-actin mRNA and AhR/ß-actin mRNA
ratios were unchanged by any treatment (except for one point, E-actin mRNA treated with mix-
tures of 300 pM TCDD and 3 nM IH 445). Consequently, the CYP1A1/ß-actin mRNA ratios
will not be affected by sample loading artifacts. 
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In Section 3.2.9 (Figure 3.19), IH 445 increased the CYP1A1/ß-actin mRNA ratio in a concen
A
Figure 3.23 Effect of IH 445 on TCDD response in H4-II-E cells.  Cultured H4-II-E cells were exposed to a range
of increasing concentrations of TCDD alone [ż] or in combination with 3 nM IH 445 [Ɣ] for 4 h. 3 nM IH 445 alone was
included as a positive control [Ƒ]. CYP1A1/E-actin mRNA were determined as described inFigure 3.13 legend. Each point
represents the mean ± S.D of triplicate determinations from one experiment. Each qRT-PCR reaction was performed once. For
controls, mean and S.D for CYP1A1/ß-actin basal ratios for untreated and vehicle-treated cultures, were 4.6 ± 4.4 x 10-5 and 7
± 5 x 10-5 respectively. For 10 nM TCDD-treated cultures, the mean and S.D for CYP1A1/ß-actin mRNA ratios was 8.7 ± 5.6
x 10-5. The mean and S.D for for the induced levels of CYP1A1/ß-actin mRNA ratios (% 10 nM TCDD) by 3 nM IH 445 alone
was 50 ± 6.3. Curves were fitted using the variable slope sigmoid Hill equation (GraphPad Prism 5.0 Software).Ordinates: (A)
the CYP1A1/E-actin mRNA ratios relative to 10 nM TCDD, (B) E-actin mRNA relative to 10 nM TCDD, (C) AhR/E-actin
mRNA ratios relative to 10 nM TCDD. Abscissae: logarithms of molar concentrations of TCDD. E-actin mRNA and AhR/E-
actin mRNA ratios at different time points for each treatment concentration were not significantly different from 10 nM
TCDD-treated cells at 4 h (p>0.05, one-way ANOVA analysis followed by Dunnett’s Multiple Comparison test), except for
E-actin mRNA treated with mixtures of 300 pM TCDD and 3 nM IH 445, which was siginificantly different from 10 nM
TCDD-treated cells at 4 h (*, p<0.05, one-way ANOVA analysis followed by Dunnett’s Multiple Comparison test).
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tration-dependent manner. At 3 nM, the increased levels were ~20% those of the maximal re-
sponse. However, the data from Figure 3.23 A shows that IH 445 at 3 nM (shown in the black
triangle) induced ~50% of the maximal response. This difference is within ~2.5-fold between
experiments. When cultures were co-exposed to increasing concentrations of TCDD, the
CYP1A1 mRNA induced levels were ~60% those of the maximal response at low TCDD con-
centrations (< 30 pM). These levels are due to an additive effect of IH 445 on TCDD. The top
levels induced by TCDD in the absence or the presence of 3 nM IH 445 were 125% (95% CI,
71.18-178) and 193% (95% CI, 155.4 to 229.9) respectively, which was considered not statis-
tically significant. The maximal levels induced by TCDD did not vary significantly between ex-
periments, (given that the 95% confidence limits were overlapping). The EC50 for CYP1A1
mRNA induction by TCDD was 30 pM (95% CI, 2-400) in the absence of 3 nM IH 445, and 60
pM (95% CI, 12-294) in the presence of 3 nM IH 445. This minor effect was considered not
significant given the 95% confidence limits are overlapping. 
Under the conditions of the current CYP1A1 induction assay, the results of this experiment iden-
tified IH 445 as a potent agonist for inducing CYP1A1 mRNA with no detectable antagonistic
activity on TCDD in H4-II-E cells. In the light of this finding, phenylbenzothiazole analogues
showed different agonism/antagonism pattern, and thus the antagonism is a specific property of
certain analogues. 
Section 3.2.14CYP1A1 induction assay in MCF-7 cells
Section 3.2.14.1 Concentration-response curves of TCDD
CYP1A1 in MCF-7 cells is known to be inducible by TCDD [183] [11] [12]. In order to confirm
that TCDD induces CYP1A1 mRNA in MCF-7 cells and compare the induction of CYP1A1
mRNA by TCDD in MCF-7 with H4-II-E cells, the experiment was performed essentially as
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described in Section 3.2.8 under the same conditions, i.e, the same cell confluence (90-95%),  
and 4 h-treatment in MCF-7 cells. The RNA levels of the reference genes were examined to en-
Figure 3.24 Comparison between the log concentration-response curves for CYP1A1 mRNA induction by
TCDD in H4-II-E and MCF-7 cells.  Cultures were treated with DMSO (0.1%) or TCDD (at the indicated concentra-
tions) for 4 h in H4-II-E [Ƒ] and MCF-7 [Ŷ] cells. CYP1A1/E-actin mRNA ratios were determined as described in Figure 3.13
legend. Response curves were combined from two separate experiments. Each point represents the average of mean ± S.D for
triplicate samples, and is representative of results obtained from one of two experiments (for MCF-7 cells) and four experiments
(for H4-II-E cells). Each qRT-PCR reaction was performed once. The mean ± S.D for CYP1A1/E-actin mRNA ratios for un-
treated and vehicle treated H4-II-E cells were 2.2 x 10-5 and 4.3 x 10-5 as absolute ratios respectively. Those in MCF-7 cells
were 7 ± 6 x 10-4 and 8 ± 8.6 x 10-4, for untreated and vehicle treated cells respectively. Curves in (A) were fitted using the
variable slope sigmoid Hill equation (GraphPad Prism 5.0 Software). (A) Ordinate: the CYP1A1/E-Actin mRNA ratios relative
to 4 h DMSO. Abscissa: logarithms of molar concentrations of TCDD. Ordinates (B): E-actin mRNA relative to 4 h DMSO,
(D) AhR/E-actin mRNA ratios relative to 4 h DMDO. Abscissae: logarithms of molar concentrations of TCDD. E-actin mRNA
and AhR/E-actin mRNA ratios for vehicle-treated cutures at 4 h were represented by zero molar concentration. E-actin mRNA
and AhR/E-actin mRNA ratios at different time points for each treatment concentration were not significantly different from
vehicle-treated cells at 4 h (p>0.05, one-way ANOVA analysis followed by Dunnett’s Multiple Comparison test).
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sure stability during the various treatments. Figure 3.24 B and Figure 3.24 C show that there
was no significant difference in ß-actin mRNA and AhR/ß-actin mRNA ratios during all treat-
ments. Therefore, the CYP1A1/ß-actin mRNA ratios do not reflect an artifact of sample loading
or preparation. 
Figure 3.24 A shows the log concentration-response curves for CYP1A1 mRNA induction by
TCDD in H4-II-E and MCF-7 cells. The maximal levels for CYP1A1 mRNA induction achieved
by TCDD in MCF-7 were 4-fold higher than that in H4-II-E cells. The maximal levels for
CYP1A1 mRNA induction achieved by TCDD above vehicle controls were 14 x 104 % (95%
CI, 9.8-16) and 2.9 x 104 % (95% CI, 2.5-3.2) in MCF-7 and H4-II-E cells respectively. This is
in good agreement with previous findings, where maximal levels for EROD activity were found
significantly lower (10-fold) in H4-II-E than MCF-7 cells [184]. The results confirm inducibil-
ity of CYP1A1 in MCF-7 cells by TCDD. Thus, the AhR in these cells is functional and not de-
fective.
The EC50 value for TCDD was 194 pM (95% CI, 65-574) in MCF-7 cells, which is ~ 3-fold
greater than that in H4-II-E cells, 60 pM (95% CI, 33-102). There was no significant difference
in TCDD potency in MCF-7 and H-4-II-E cells. In Table 3.11 are summarized the EC50 values
for TCDD for inducing CYP1A1 mRNA in MCF-7 cells from two independent trials. The EC50
value for TCDD for inducing CYP1A1 mRNA were comparable with previously reported values
(Table 3.12).
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Section 3.2.14.2 Induction of CYP1A1 mRNA by 5F 203 
5F 203 was shown previously to induce CYP1A1 mRNA in MCF-7 cells [182]. The aim is to
determine a quantitative measurement of the potency (EC50) of 5F 203 for the induction of




Table 3.11 EC50 values for the induction of CYP1A1 mRNA by TCDD in MCF-7 cells.
EC50 values were determined from log concentration-response curves using the variable slope Hill
sigmoidal equation (GraphPad Prism 5.0). Each trial was conducted on a range of concentrations, each in
triplicate samples. The average represents the mean of EC50 values from two independent experiments.
Cell line CYP1A1 Assay EC50 (pM) Time of treatment References
H4-II-E cells EROD 0.6-1 24 hours [175]
10 72 hours [183] 
6 Not specified [184]
96 72 hours [185]
AHH 150 Not specified [184]
230 1 hour [186]
50 ± 0.013* 48 hours [187]
80 72 hours [185]
MCF-7 cells EROD 400 72 hours [183]
30 Not specified [184]
94 24 hours [13]
AHH 100 Not specified [184]
380 24 hours [13]
Table 3.12 Literature values for the EC50 of TCDD for inducing ethoxyresorufin O-deethylase
(EROD) and aryl hydrocarbon hydroxylase (AHH) at in H4-II-E and MCF-7 cells.  The assays were run as 
described in the corresponding references and the time of the assay treatments is indicated. * EC50 values ± S.D.
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CYP1A1 in MCF-7 cells.
MCF-7 cells were treated with 5F 203 at a range of concentrations for 4 h and potency is com-
pared with that of TCDD. The RNA ratios of the reference genes were examined to ensure sta-
bility under the various treatments. Figure 3.25 B and Figure 3.25 C show that ß-actin mRNA
and AhR/ß-actin mRNA ratios were relatively stable against all treatments, except for one
point, the ß-actin mRNA from cells treated with 300 pM 5F 203, which was found significantly
different from the control (10 nM TCDD set as 100%). However, when repeated in another ex-
periment, this was not reproduced. Therefore, the CYP1A1/ß-actin mRNA ratios do not reflect
an artifact of sample loading or preparation.
From Figure 3.25 A, the positive control, TCDD, increased CYP1A1 mRNA. The fold induction
of CYP1A1 mRNA level by 5F 203 was ~1600-fold above vehicle control compared to ~1700-
fold for TCDD, though at 30-fold higher concentration (300 nM). The 5F 203 increased
CYP1A1 mRNA to a level similar to 10 nM TCDD. The log concentration-response curve of the
5F 203 showed that the levels of CYP1A1 mRNA induced saturate approximately at 10 nM. The
maximal levels induced by 5F 203 are significantly higher than those reported in literature
[182]. 
The EC50 value for TCDD was 0.2 nM (95% CI, 0.07-0.6), whereas for 5F 203, the EC50 value
was 2 nM (95% CI, 0.9-5). 5F 203 is only 10-fold less potent than TCDD in MCF-7 cells. More-
over, 5F 203 achieved maximal levels similar to TCDD. 
Figure 3.26 illustrates the difference in the magnitude of response (displayed as percentage of
vehicle control) to 5F 203 in MCF-7 and H4-II-E cells. In comparison with MCF-7 cells (Figure
3.25 A), in H4-II-E cells, maximal levels (99%) were achieved by 5F 203 at 1000-fold higher
concentrations (Figure 3.18 A). 5F 203 was found to be 50,000-less potent than TCDD in H4-
Rana Bazzi   Section 3.2.14
Page 148
II-E cells but only 10-fold less potent in MCF-7 cells. The quantitative differences (4.5-fold) for
maximal levels observed for the 5F 203 (Figure 3.26) are consistent with the 4-fold difference 
A
Figure 3.25 Induction of CYP1A1 mRNA by TCDD and 5F 203 in MCF-7 cells.  Cultures were treated with
DMSO (0.1%), increasing concentrations of TCDD [Ɣ] or 5F 203 [ż] (at the indicated concentrations) for 4 h. CYP1A1/E-actin
mRNA were determined as described in Figure 3.13 legend. Each point represents the average of mean ± S.D for triplicate
samples, and is representative of results obtained from one of two experiments. Each qRT-PCR reaction was performed once.
TCDD log concentration-response curve is from Figure 3.24. Mean and S.D for CYP1A1/ß-actin ratios for untreated and ve-
hicle-treated cultures, were 60 x 10-4 and 5 x 10-4 respectively. Mean and S.D for CYP1A1/ß-actin ratios for cultures treated
with 10 nM TCDD was 1.3 ± 0.17. Curves were fitted using the variable slope sigmoid Hill equation (GraphPad Prism 5.0
Software). Ordinates: (A) the CYP1A1/E-actin mRNA ratios relative to 10 nM TCDD, (B) E-actin mRNA relative to 10 nM
TCDD, (C) AhR/E-actin mRNA ratios relative to 10 nM TCDD. Abscissae: logarithms of molar concentrations of TCDD and
5F 203. E-actin mRNA and AhR/E-actin mRNA ratios at different time points for each treatment concentration were not sig-
nificantly different from 10 nM TCDD-treated cells at 4 h (p>0.05, one-way ANOVA analysis followed by Dunnett’s Multiple
Comparison test), except for the E-actin mRNA treated with 300 pM 5F 203 which was siginificantly different from 10 nM
TCDD-treated cells at 4 h) (*, p<0.05, one-way ANOVA analysis followed by Dunnett’s Multiple Comparison test).
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observed with TCDD (Figure 3.24).The results of this experiment reveal 5F 203 to be 1500-fold
more potent in MCF-7 cells than in H4-II-E cells.
Section 3.2.14.3 Effect of 5F 203 on TCDD-induced CYP1A1 mRNA 
5F 203 was found to be a potent agonist in MCF-7 cells (Section 3.2.14.2, Figure 3.25 A). It
was anticipated that this compound would not have an antagonistic activity on TCDD in MCF-
7 cells. To verify this hypothesis, the antagonistic activity of 5F 203 was investigated in MCF-
7 cells by co-exposing cultures to increasing concentrations of TCDD ± 500 pM 5F 203. The
reason this concentration of 5F 203 was selected, is because this concentration offers a balance
between a significant levels of CYP1A1/ß-actin mRNA ratios above vehicle controls (p<0.01, 
Figure 3.26 Comparison between the log concentration-response curves for CYP1A1 mRNA induction by
5F 203 in H4-II-E and MCF-7 cells.  Cultures were treated with DMSO (0.1%) or 5F 203 (at the indicated concentra-
tions) for 4 h in H4-II-E [ż] and MCF-7 [Ɣ] cells. CYP1A1/E-actin mRNA ratios were determined as described in Figure 3.13
legend. Response curves were combined from two separate experiments. Each point represents the average of mean ± S.D for
triplicate samples, and is representative of results obtained from one of two experiments (for MCF-7 cells) and a single exper-
iment (for H4-II-E cells). Each qRT-PCR reaction was performed once. Curves were fitted using the variable slope sigmoid
Hill equation (GraphPad Prism 5.0 Software). Ordinate: the CYP1A1/E-Actin mRNA ratio relative to 4 h DMSO. Abscissa:
logarithms of molar concentrations of 5F 203.
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t-test, n=3, 5F 203 treatment) (Figure 3.25 A), and a significant difference between top and bot-
tom levels of response, so that EC50 would be determined accurately.
The expression of reference genes mRNAs were analysed before proceeding further with the
determination of CYP1A1/ß-actin mRNA ratios and analysis of the results. Figure 3.27 B and
Figure 3.27 C show that the ß-actin mRNA and the AhR/ß-actin mRNA ratios were generally
stable at all treatments (except for E-actin mRNA treated with mixtures of 10 pM TCDD and
500 pM 5F 203), thus the experiment proves that CYP1A1/ß-actin mRNA ratios do not reflect
an artifact of sample loading or preparation. 
As shown in Figure 3.27 A, at TCDD levels  30pM, no induction of CYP1A1 mRNA was de-
tected. The increase in CYP1A1/ß-actin mRNA ratios was observed from 100 pM to reach max-
imal saturated levels at 1 nM. The increased CYP1A1/ß-actin mRNA ratios observed at TCDD
concentrations below 100 pM TCDD, correspond to the levels induced by 5F 203 alone. For
mixture cultures, maximal levels were not significantly different from those in TCDD-treated
cultures alone.
The EC50 for TCDD in the absence of 500 pM 5F 203 was 300
 pM (95% CI, 98-930] whereas
in the presence of 500 pM 5F 203, the EC50 for TCDD was 400 pM (95% CI, 250-700), which
was not significant. Under the conditions of the induction assay in this study, 5F 203 had no
detectable antagonistic activity on TCDD in MCF-7 cells, and thus the 5F 203 was identified as
a potent agonist.
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Section 3.2.14.4 Induction of CYP1A1 mRNA by CH-223191 
It was reported that the (CH-223191) is an AhR pure antagonist in human hepatoma HepG2
A
Figure 3.27 Effect of 5F 203 on TCDD response in MCF-7 cells.  Cultured MCF-7 cells were exposed to a range
of increasing concentrations of TCDD alone [Ɣ] or in combination with 500 pM 5F 203 [ż] for 4 h. 5F 203 (500 pM) alone
[Ƒ], was included as a positive control. CYP1A1/E-actin mRNA were determined as described in Figure 3.13 legend. Each
point represents the average of mean ± S.D for triplicate samples, and obtained from one experiment. Each qRT-PCR reaction
was performed once. For controls, mean and S.D for CYP1A1/ß-actin ratios for untreated and vehicle-treated cultures, were
4.9 x 10-4 and 6 ± 3 x 10-3 respectively. For TCDD-treated cultures, the mean and S.D for for CYP1A1/ß-actin ratios was 1.3
± 0.08. Curves were fitted using the variable slope sigmoid Hill equation (GraphPad Prism 5.0 Software). Ordinates: (A) the
CYP1A1/E-actin mRNA ratios relative to 10 nM TCDD, (B) E-actin mRNA relative to 10 nM TCDD, (C) AhR/E-actin mRNA
ratios relative to 10 nM TCDD. Abscissae: logarithms of molar concentrations of TCDD. E-actin mRNA and AhR/E-actin
mRNA ratios at different time points for each treatment concentration were not significantly different from 10 nM TCDD-
treated cells at 4 h (p>0.05, one-way ANOVA analysis followed by Dunnett’s Multiple Comparison test), except for E-actin
mRNA treated with mixtures of 10 pM TCDD and 500 pM 5F 203, which was considered significantly different from 10 nM
TCDD-treated cells at 4 h (*, p<0.05, one-way ANOVA analysis followed by Dunnett’s Multiple Comparison test). 
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cells [188]. This experiment aims to examine the potency of CH-223191 for the induction of
CYP1A1 mRNA in MCF-7 and verify that this compound is devoid of any agonistic activity. To
assess the agonistic activity of (CH-223191) on the AhR in MCF-7, cultures were incubated
with increasing concentrations of the (CH-223191) (Figure 3.28), TCDD (10 nM) as a positive
control or 0.1% DMSO as a negative control for 4 h. Untreated cells were included as another
negative control. 
In Figure 3.28 are shown the log concentration-response curve for (CH-223191) relative to 10
nM TCDD. The log concentration-response curve for TCDD was used from a separate experi-
ment for the sake of comparison. Up to the highest concentrations tested (30 PM), the (CH-
223191) was unable to induce CYP1A1 mRNA in MCF-7 cells which verifies that this com-
pound has no agonistic activity in these cells. This is consistent with previous findings where
this compound failed to induce mRNA up to the highest concentration tested (10 PM) in HepG2
cell [188].
Figure 3.28 Studies on CYP1A1 mRNA induction by CH-223191 in MCF-7 cells.  Cultures were treated with
DMSO (0.1%), 10 nM TCDD [ż] or CH-223191 [Ɣ] (at the indicated concentrations) for 4 h. CYP1A1/E-actin mRNA were
determined as described in Figure 3.13 legend. Response curves were combined from two separate experiments. Each point
represents the average of mean ± S.D for triplicate samples from one of experiment. log concentration-response curve for
TCDD is the same as in Figure 3.25. Each qRT-PCR reaction was performed once. For controls, mean and S.D for CYP1A1/
ß-actin basal ratios for untreated and vehicle-treated cultures, were 55 ± 40 x 10-5 and 64 ± 18 x 10-5 respectively. For 10 nM
TCDD-treated cultures, the mean and SD for CYP1A1/ß-actin mRNA ratios was 1.1 ± 0.052. Curves were fitted using the vari-
able slope sigmoid Hill equation (GraphPad Prism 5.0 Software). Ordinate: the CYP1A1/E-actin mRNA ratios relative to 10
nM TCDD. Abscissa: logarithms of molar concentrations of TCDD and CH-223191. 
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Section 3.3 Growth inhibitory activity in H4-II-E cells
Section 3.3.1  Growth inhibitory activity of 5F 203 in H4-II-E cells
It was suggested that the activation of the AhR mediates sensitivity of MCF-7 cells to anticancer
benzothiazoles [141] and that cell sensitivity to the 2-(4-aminophenyl)benzothiazoles, series (1)
of benzothiazoles, seems to be CYP1A1-dependent. The model proposed for 5F 203 mechanism
of action consists of activation of the AhR and subsequent induction of CYP1A1 which metab-
olizes the 5F 203 into reactive species that then damage DNA. In agreement with this hypothe-
sis, CYP1A1 was not induced in resistant cells [189]. 
This study revealed that (5F203, DF203, GW 610, IH 318 and AW 892) had high-affinity for
the AhR but had low potency for inducing CYP1A1, whereas IH 445 was found to be a high-
affinity ligand for the AhR and a potent inducer of CYP1A1 mRNA in H4-II-E cells. One of the
aims of this project is to examine the anticancer activity of phenylbenzothiazole analogues in
H4-II-E cells. Taking into consideration the hypothesis mentioned above, we addressed the
question whether the rat cell line could be relatively nonresponsive to the anticancer activity of
these compounds, given their lower induction potency in these cells. That was addressed by test-
ing first the growth inhibitory activity of the 5F 203 in H4-II-E cells with the use of the cell vi-
ability assay (MTT assay). Camptothecin was used as a positive control [163]. TCDD, a potent
agonist for AhR known to be relatively resistant to metabolism [61], was included to examine
whether the activation of the AhR has any inhibitory activity. DMSO-treated cultures at zero
time (T0) and after 72 h, were included as negative controls. Culture viability was assessed by
measuring the metabolic conversion of MTT to the formazan product for each chemical treat-
ment as described in Materials and Methods (Section 2.2.15).
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Figure 3.29 shows that DMSO-treated cultures at 72 h, showed high levels of cell growth.
Camptothecin, at concentrations  100nM decreased cell growth to levels below To control lev-
els, and was thus found to be cytotoxic with a GI50 of 67 nM (95% CI, 12-386). The use of the
controls, DMSO and Camptothecin, showed that the MTT did not affect the cell growth and thus
validates the assay. 
As seen in Figure 3.29, TCDD did not inhibit culture viability at any concentration tested in H4-
II-E cells, as cell viability in TCDD-treated cultures was not significantly different from DMSO
controls. 5F 203 failed to inhibit the growth of the cells up to 10 µM. On the other hand, this
shows that the induction of CYP1A1 by 5F 203 (Figure 3.18 A) was not affected by any cyto-
toxicity of this compound. In contrast, IH 445 was found to be a potent inhibitor of cell growth,
with a GI50 value of 100 nM (95% CI, 40-248). The cytostatic effect by IH 445 was observed
from  30 nM. These data could provide explanation for the lower CYP1A1 mRNA levels in-
Figure 3.29 Growth inhibitory activity of 5F 203, IH 445 and TCDD in H4-II-E cells.  Cells were plated at
seeding densities of 5000/well and incubated for one day. The next day, cells were treated with 5F 203 [Ŷ ], TCDD [ż], IH
445 [ź], Camptothecin [Ɣ] (at the indicated concentrations) or 0.1% DMSO [*] for 3 days. Parallel to the addition of the drugs,
MTT was added to a triplicate of cultures to assess the cell viability at the day of the treatment (T0; shown by a horizintal
dashed line). After 3 days exposure, MTT was added to cells and measured using a Wallac Victor2 plate reader. Each point
represents the average of mean ± S.D for triplicate samples, and is representative of results obtained from one of three exper-
iments (5F 203), one experiment (IH 445), one experiment (Camptothecin) and two experiments (TCDD). Curves were fitted
using the sigmoidal response equation (GraphPad Prism 5.0 Software). Ordinate: absorbance at 590nm. Abscissa: logarithms
of molar concentrations of the compounds tested.
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duced by IH 445 (60% those of 10 nM TCDD), previously shown in Figure 3.19 A. 
That TCDD showed no effect on cell viability at all concentrations tested, revealed that the ac-
tivation of AhR in H4-II-E cells, without additional factors, does not result in inhibition of cell
growth.
The inhibitory activity of DF 203, GW 610, AW 892 and IH 318 was assessed against H4-II-E
cells by an MTT assay. The GI50 values, along with Ki and EC50 values, are summarised in Ta-
ble 3.13.
 
From Table 3.13, DF 203, GW 610 and IH 318 had weak inhibitory potency in H4-II-E cells.
Only AW 892 had a sub micromolar GI50 value, which reveals a relatively higher inhibitory po-
tency. Overall, the MTT assay was validated and showed that, with the exception of the IH 445
Compound
Ki [nM] (95% 
confidence intervals)
EC50 [nM] (95% 
confidence intervals)
GI50 [nM] (95% 
confidence intervals)
TCDD 0.44 (0.18-1) 0.06 (33-100) ND*
Camptothecin - - 67 (12-386)
IH 445 0.9 (0.05-16.9) 4 (2-10) 100 (40-248)
5F 203 2.8 (2-5) 3000 (1300-7700) ND*
DF 203 9.9 (5.3-18.7) 3400 (900-13000) ND*
GW 610 6.8 (1.5-30) 6500 (4000-12000) 1400 (450-4300)
AW 892 9.8 (4.4-22) 1900 (300-14000) 223 (133-373)
IH 318 8 (5.5-12) ND¶ >10000
Table 3.13 Summary for binding to AhR (rat cytosol), CYP1A1 mRNA induction and growth
inhibitory potency of compounds in H4-II-E cells.  To assess growth inhibitory activity of the compounds,
cultures were plated for 24 h then treated with varying concentrations of each of the compouns listed. Cell viability was
assessed by MTT assay after 3 days exposure. Curves were fitted using the sigmoidal response equation (GraphPad Prism
5.0 Software) and compound concentration that inhibited the growth of cells by 50% (GI50) was determined. (ND*) these
compounds did not decrease the viability of the cells below the control levels (To) significantly. (ND¶) the EC50 for IH
318 could not be accurately measured given the superinduction of CYP1A1 mRNA and the absence of a clear plateau. (-)
Camptothecin was not subjected to competitive assays nor to CYP1A1 mRNA induction analyses. EC50 and Ki values are
obtained from the competitive assays and the CYP1A1 mRNA induction assays. 
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and AW 892, all the phenylbenzothiazoles tested were devoid of anticancer activity in H4-II-E
cells. 
Section 3.3.2 Effect of TCDD on 5F 203 cytostatic effect in H4-II-E cells
Based on the original hypothesis for 5F 203 [182] anticancer activity that consisted of increased
induction of CYP1A1 would result in more metabolism and thus cytostatic effect in MCF-7
cells. It was hypothesized that sensitising H4-II-E cells by treating with TCDD and subsequent-
ly inducing CYP1A1 enzymatic activity could enhance the anticancer activity of the compounds
in H4-II-E. 
H4-II-E cultures were pre-treated with 10 nM TCDD for 24 h. The following day, TCDD was
removed and cells were washed with PBS without perturbing the cells, then subjected to 5F 203
treatment in an MTT assay as described under Materials and Methods Section 2.2.15. The re-
sults in Figure 3.30 showed no inhibitory activity of 5F 203 against untreated cultures for con-
centrations below 1 PM. A modest inhibitory activity was observed from 1 PM up to 10PM.
The same effect was observed when cells were pre-treated with TCDD for 24 h, however, with
a minor decrease in maximal cell growth levels. The results showed no significant difference
for 5F 203 GI50s between H4-II-E cultures pretreated with 10 nM TCDD, 0.6PM (95% CI, 0.08-
4.7) and those untreated, 1.8 PM (95% CI, 0.98-3.3). The H4-II-E cells were found relatively
more responsive to 5F 203 in this experiment compared to Figure 3.29. The 5F 203 in the cur-
rent experiment inhibited the cell growth by 60%, thus the GI50 values could not be measured
accurately. 
Overall, activation of AhR by TCDD (10 nM) did not significantly enhance the sensitivity of
the H4-II-E cells toward the cytostatic activity of 5F 203 under the conditions of the assay. In
the light of these results, it does not seem that AhR-mediated induction of CYP1A1 is involved
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in mediating the anticancer activity of 5F 203 in these cells, and thus the hypothesis previously
mentioned [141] [182] does not apply in H4-II-E cells.
Section 3.3.3 Growth inhibitory activity of 5F 203 in MCF-7 cells
The responsiveness of MCF-7 cells to phenylbenzothiazole analogues has been characterized
[126] [182] [141]. This experiment seeks to address several issues: i) to verify the growth inhib-
itory potency of 5F 203 and thus confirm the responsiveness of the MCF-7 cell line used in this
study, ii) to examine whether the activation of AhR, without the involvement of the enzymatic
activity of CYP1A1, would have any inhibitory effect on cell growth by testing whether TCDD
has any inhibitory activity and iii) to examine whether the inhibition of AhR, would have any
inhibitory effect on cell growth by testing whether the AhR antagonist, CH-223191 has any in-
hibitory activity. 
That was addressed by incubating cultures with varying concentrations of 5F 203, TCDD, or
CH-223191 and then tesing the growth inhibitory activity in MCF-7 cells with the use of the
Figure 3.30 Effect of TCDD on the growth inhibitory activity of 5F 203 against H4-II-E cells.  Cells were
plated at seeding densities of 5000/well and incubated ± TCDD (10 nM) for one day. The next day, medium containing TCDD
was removed and replaced with a medium containing 5F 203 [Ƒ] (at the indicated concentrations). In parallel, 0.1% DMSO
(*) or 5F 203 was added to cultures without 10 nM TCDD[Ŷ], for 3 days. MTT was added and cell growth determined as desci-
bed in Figure 3.29 legend. Each point represents the average of mean ± S.D for triplicate samples, and is representative of
results obtained from one experiment. Curves were fitted using the sigmoidal response equation (GraphPad Prism 5.0 Soft-
ware). Ordinate: absorbance at 590 nm. Abscissa: logarithms of molar concentrations of 5F 203.
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cell viability assay (MTT assay). 0.1% DMSO-treated cultures were included as a negative con-
trol.
Figure 3.31 shows growth response curves in MCF-7 cells. 5F 203, decreased growth in a con-
centration-dependent manner, with a GI50 value of 18 nM (95% CI, 8.7-39], which confirms the
responsiveness of the MCF-7 cell line in this study. TCDD treatment did not affect cell growth
viability at any concentration. This confirms that TCDD has no inhibitory activity in MCF-7
cells. This is in good agreement with previous findings [190] [191] [192]. This finding provides
evidence that the activation of the AhR by itself is not sufficient for cell growth inhibition, by
the fact that TCDD, an AhR agonist, but not CYP1A1 substrate, had no effect on the growth
curve.
On the other hand, the AhR pure antagonist, CH-223191 [188] also inhibited the growth of the
Figure 3.31 Growth inhibitory activity of 5F 203, CH-223191 and TCDD against MCF-7 cells.  Cells were
plated at seeding densities of 2500/well and incubated for one day. The next day, cells were treated with 5F 203 [Ƒ], TCDD
[ż], CH223191[Ÿ] (at the indicated concentrations) or 0.1% DMSO (*) for 3 days. MTT was added and cell growth deter-
mined as descibed in Figure 3.29 legend. Each point represents the average of mean ± S.D for triplicate samples, and is rep-
resentative of results obtained from one of four experiments (for 5F 203), one experiment (for TCDD), one experiment (for
CH223191) and one experiment for the co-treatment of 5F 203 and CH223191. Curves were fitted using the sigmoidal re-
sponse equation (GraphPad Prism 5.0 Software). Ordinate: absorbance at 590 nm. Abscissa: logarithms of molar concentra-
tions of the compounds tested.
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cells in a concentration-dependent manner, with a GI50 value of 420 nM (95% CI, 173-1029].
In the light of these results, we could not conclude whether the cytostatic effect observed by CH-
223191 is a result of the AhR antagonism or via different mechanism of action. We went further
to delineate this latter issue.
Section 3.3.4 Effect of TCDD on 5F 203 and CH-223191 growth inhibitory 
activity in MCF-7 cells
Figure 3.31 showed that the AhR antagonist CH-223191 had a cytostatic effect on MCF-7 cells.
This experiment aims to investigate whether this cytostatic effect is AhR-mediated. It was pos-
tulated that AhR activation is important for the anticancer activity of 5F 203 in MCF-7 cells.
Based on this hypothesis, this experiment also aims to investigate the involvement of AhR in
mediating the activity of 5F 203. This will be addressed by confirming that the cytostatic effect
of 5F 203 is not due to AhR antagonism.The rationale of this hypothesis is the following: if 5F
203 or CH-223191 inhibits the cell growth by antagonizing AhR, competition with sufficiently
high TCDD concentrations will displace the compound with TCDD leading to agonism, and the
inhibitory effect will be lost. This will be addressed by incubating MCF-7 cultures with increas-
ing concentrations of TCDD ± 500nM CH-223191 or TCDD ± 50nM 5F 203. 
The choice of 5F 203 or CH-223191 concentrations was based on the fact that, at these concen-
trations, ~50% cell growth inhibition was observed (Figure 3.31). CH-223191 (500 nM) and 5F
203 (50 nM) were included as positive controls.
As shown previously (Figure 3.31), TCDD did not affect the growth of MCF-7 cells at any con-
centration tested (Figure 3.32). CH-223191 and 5F 203 at single concentrations, inhibited cell
growth by ~ 50% and 40% respectively. Addition of 500 nM CH-223191 to TCDD, resulted in
a biphasic dose-response curve, where at low concentration of TCDD (< 100 pM), CH-223191 
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decreased cell growth to levels similar to those achieved by 500 nM CH-223191 alone. Higher
TCDD concentrations (100 pM), restored some of the cell loss to a extent of ~ 30% (comparing
mixtures of TCDD and CH-223191 with TCDD-treated cultures in the absence of CH-223191)
(Figure 3.32). 
This effect would be best explained by the agonistic effect of TCDD competing with CH-
223191 at sufficiently high TCDD concentrations, where TCDD competes with CH-223191 for
AhR and displaces it [188]. However, the addition of TCDD at high concentrations did not re-
store the cell growth up to control levels, but only by 30%. That could suggest that the cytostatic
effect of CH-223191 is partly mediated by AhR (~30%). Therefore, another mechanism of
growth inhibition is involved, other than AhR [188]. However, it is also possible that the CH-
223191 is partly metabolically inactivated by the TCDD-induced CYP1A1 protein and other
Figure 3.32 Growth inhibitory activity of TCDD ± 5F 203 or ± CH-223191 against MCF-7 cells.  Cells
were plated at seeding densities of 2500/well and incubated for one day. The next day, cells were treated with varying con-
centrations of TCDD alone [ż] (at the indicated concentrations) or co-inubated with 50 nM 5F 203 [Ŷ] or 500 nM CH-
223191[Ÿ]. As controls, cultures were exposed to 0.1% DMSO (*), 50 nM 5F 203[ź] or 500 nM CH-223191[Ƒ] for 3 days.
MTT was added and cell growth determined as descibed in Figure 3.29 legend. Each point represents the average of mean ±
S.D for triplicate samples from one experiment. Curves were fitted using the sigmoidal response equation (GraphPad Prism
5.0 Software). Ordinate: absorbance at 590 nm. Abscissa: logarithms of molar concentrations of the compounds tested.
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metabolizing proteins, which could also explain the minor observed increase in cell growth. 
Mixtures of 50 nM 5F 203 and a range of TCDD concentrations, had similar growth inhibition
compared to 5F 203 alone and there was no significant change in cell number (p>0.05, t-test,
n=3). High concentrations of TCDD did not inhibit 5F 203 inhibitory activity. If the 5F 203 is
inhibiting the cell growth by antagonizing AhR, then high concentrations of TCDD would re-
store the cell growth to control levels. These results further confirm that the cytostatic effect of
5F 203 is not due to AhR antagonism in MCF-7 cells, and is consistent with the lack of antag-
onism of induction of CYP1A1 by TCDD in these cells.
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Chapter 4  Discussion
Recently, it was reported that the phenylbenzothiazole analogues induce CYP1A1 mRNA in
several cells that are sensitive to their antitumourigenic activity, e.g, human breast cancer MCF-
7 [182] [253]. However, there is no published data on binding of these compounds to AhR. 
Quantitative comparison of ligand binding and induction potency requires data from the same
species to be meaningful, and so rat was used as a model species. Such quantitative comparisons
between ligand affinity for receptor and the resulting pharmacological effect, allow the applica-
tion of various concepts from pharmacology. 
Section 4.1 The [3H]-TCDD radioactive binding assay
Section 4.1.1  Validation of the [3H]-TCDD radioactive binding assay
AhR competitive binding assays have been established in vitro and have been central to inves-
tigations of direct AhR-ligand interaction, which is the initial step in AhR-mediated responses.
Several techniques have been used to characterize the AhR, such as velocity sedimentation on-
sucrose density gradient analysis [193], hyroxyapatite [170] and charcoal adsorption using tri-
tiated TCDD [6] [164] or 7-(125I)iodo-2,3-dibromodibenzo-p-dioxin [156] as high-affinity
ligands. In the present study, the use of charcoal adsorption followed by centrifugation to sep-
arate bound and free radioligand mixture was found to be a simple, quick, practical and repro-
ducible method. These attributes enable multiple replicates and samples, and hence robust
characterization of binding parameters such as KD or Bmax. This is in contrast to e.g, density
gradient centrifugation methods.
As the aim is to develop a binding assay and therefore determine the binding kinetics of TCDD
to AhR, it is essential to optimise several aspects of the assay. Several factors were found to af-
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fect [3H]-TCDD specific binding and thus affect KD value of TCDD, such as the time of incu-
bation, the high level of non specific binding, the concentration of protein and [3H]-TCDD,
ligand depletion and finally the poor solubility of [3H]-TCDD in aqueous solutions. 
In attempts to control these factors, cytosolic protein preparations were incubated for sufficient
time (16 h) at 4°C to allow equilibrium between AhR and ligands. The [3H]-TCDD specific
binding was not significantly changed from 2 h up to 16 h at 4°C (Figure 3.1), thus the (AhR-
[3H]-TCDD) complex appeared stable up to 16 h at 4°C. 
The use of charcoal efficiently reduced background radioactivity. An amount of 2 mg of char-
coal / mg of cytosol protein selectively stripped off nonspecifically bound [3H]-TCDD without
affecting the concentration of [3H]-TCDD specifically bound in the rat cytosol (Figure 3.2),
which reflects the high affinity of the rat hepatic AhR for TCDD [193]. 
Characterization of AhR ligand binding using a radioligand with a low specific radioactivity,
such as [3H]-TCDD (29.77 Ci/mmole), necessitates a sufficient amount of [3H]- TCDD and cy-
tosolic protein and (hence, AhR), (Figure 3.4) and (Table 3.2) to give a reliable measure of spe-
cifically bound radioactivity. However, increasing protein concentration yield increased
nonspecific to specific binding ratio (Figure 3.2 & Figure 3.3), and this finding was previously
reported by Bradfield and Poland (1988) [156]. In their work, Bradfield and Poland worked with
7-(125I)iodo-2,3-dibromodibenzo-p-dioxin as a radioligand with much higher specific activity
(2176 Ci/mmole) as opposed to the lower specific activity of [3H]-TCDD (29.77-50 Ci/mmole),
thus they worked at much lower protein concentrations, thereby mitigating the complications of
misclassifying the free radioligand [156]. Misclassification of non-specifically bound AhR as
free ligand is proposed to be the reason why the apparent KD of TCDD from the present study
along with those reported in literature is significantly greater than the theoretical KD value of 6
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pM reported by Bradfield et al. [156] by extrapolating to an infinite dilution of protein (Table
3.2). The nonspecific binding represents the noise background of the assay that ideally should
remain constant at all test competitor concentrations and across experiments. The nonspecific
binding of [3H]-TCDD in the presence of test competitor was determined by co-incubating ex-
cess TCAOB with varied concentrations of test competitor. [3H]-TCDD non specific binding
was consistent at all test competitor concentrations within the same experiment and varied
slightly across experiments (data not shown). This also provided evidence that the test compet-
itor does not compete with [3H]-TCDD for non specific sites, as it is not uncommon that drugs
would compete for non specific sites at high concentrations [166]. 
The hydrophobic nature of TCDD is the reason for its high non specific binding. Another chal-
lenging aspect that emerges from the hydrophobic nature of TCDD is its poor solubility in aque-
ous solutions (Figure 3.5), which is consistent with previous findings [38]. This is particularly
why binding assays using TCDD as a ligand would suffer from misclassification of free TCDD
if not controlled properly. The use of centrifugation after charcoal treatment enabled the meas-
urement of the free [3H]-TCDD. The binding assay was optimised as to retain TCDD in solu-
tion, so that around 20% only is coming out of solution, which was considered acceptable. That
was controlled by optimizing both protein concentrations (Figure 3.5) and [3H]-TCDD concen-
tration (Figure 3.6). More [3H]-TCDD at 1 nM concentration is retained in solution in the pres-
ence of a concentration of 5 mg/ml cytosolic protein. [3H]-TCDD starts to come out of solution
at  2 nM; but numerous reports in the literature use [3H]-TCDD in solution at  5 nM [169]
[67] [170].The aqueous solubility of TCDD could be increased by the addition of ampholytes,
non-ionic detergents, or macromolecules, but it seems that each of these additions affects the
measurement of the specific binding of TCDD [6].
Another potentially important parameter in binding assays is ligand depletion by binding to re-
Rana Bazzi   Section 4.1.1
Page 165
ceptors. Since the binding of a ligand to a receptor must obey to the law of mass action, it is
essential that only a small amount of ligand binds the receptors, i.e, the concentration of “free”
ligand approximates the concentration of “added” ligand, so that the law of mass action holds
true. This parameter was controlled in the current binding assay, such that only 20% of TCDD
is depleted by binding (Figure 3.4). Under these conditions, there is no need to correct for ligand
depletion by binding.
The [3H]-TCDD binding assay described in this study showed specific and saturable binding of
TCDD to AhR. The binding kinetics, KD and Bmax, of [
3H]-TCDD to AhR determined from the
standard binding assay were reproducible over three experiments (Table 3.1). Moreover, the KD
for TCDD determined from the direct binding assay was essentially similar to that determined
from the competition assay using unlabelled TCDD as competitor, which validates the compet-
itive binding assay. The binding kinetics derived from the current binding assay are consistent
with previously reported values (Table 3.2). The KD values from literature reported in Table 3.2
were determined from Scatchard plot analysis. The KD for [
3H]-TCDD determined by Farrel
and Safe (1987) using the hydroxyapatite assay followed by centrifugation [170], was within
two-fold of the KD derived in this study. The use of the charcoal alone without hydroxyapatite
assay in the current binding assay gave KD for TCDD similar to that reported by Farrel and Safe
(1987) [170], which shows that the charcoal technique, without further separation steps, is
equally sensitive. The KD value determined in this study is similar to that reported by Poland et
al., (1976) using cytosol from C57BL/6J mice [6]. From the data reported from literature, it
seems that Wistar and Sprague-Dawley rat and C57BL/6 mice hepatic cytosol binds TCDD
with high-affinity given the low KD values. The C57BL/6 mouse seems to have slightly higher
affinity [6]. The range of KD values (0.37-1.45 nM) for Wistar rats summarised in Table 3.2
have been found to be influenced by several experimental variables, such as temperature and
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duration of incubation, variable protein (AhR) concentration and high concentrations of [3H]-
TCDD. All these factors have significant impact on the amount of functional AhR in the prep-
arations, the accurate classification of “free” [3H]-TCDD in solution and the high non specific
binding of [3H]-TCDD. 
Section 4.1.2  Characterization of the binding of phenylbenzothiazoles to 
AhR 
Once the [3H]-TCDD binding assay was validated, the binding affinities of the phenylbenzothi-
azoles were determined from competitive binding assays (Table 3.3), thereby showing that they
are high-affinity ligands, with Ki values in the nanomolar range for the AhR. Of the 24 com-
pounds tested for their binding avidity to the AhR, only two compounds bearing a hydroxyl
group, the 2-(4-amino-3-methylphenyl)-6-hydroxybenzothiazole, (IH 130) and the 2-(3-hy-
droxy-methoxyphenyl)-5-fluorobenzothiazole (JP-2) were low-affinity ligands, with Ki value >
1 PM. The 2-(4-aminocarboxymethoxy-3-methylphenyl)-5-fluorobenzothiazole (JMB 81) had
intermediate affinity for AhR.
The mechanism of action of phenylbenzothiazole analogues is still unknown. These agents in-
duced CYP1A1 in sensitive cancer cells [141] [253], suggesting AhR as a possible target for
these chemicals. Although the CYP1A1 induction is a well characterized biomarker for expo-
sure to AhR ligands [94], it is also possible that induction of CYP1A1 could result from activa-
tion of the AhR through a non-ligand binding mechanism. This has been shown with a
benzimidazole compound, omeprazole (OME) that was able to activate the AhR via a ligand-
independent mechanism [194] [101], likely through a signaling transduction pathway that in-
volved protein tyrosine kinase (PTK) [101]. Given the structural similarity between benzimida-
zoles and phenylbenzothiazoles (PBT), it is possible that the PBT activate the AhR without
necessarily binding to the receptor. The competition assays provide evidence of direct binding
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between phenylbenzothiazole analogues and AhR and so ligand-independent activation of the
AhR by PBT is therefore a less likely possibility.
Historically, PBTs have been shown to induce CYP1A1. For example, a related compound, the
2-(4'-chlorophenyl)-benzothiazole (CPBT), was previously shown to bind AhR by displacing
TCDD from binding sites [195]. However, the PBTs currently studied are considerably more
potent than these other PBTs [195]. 
Section 4.1.3  Structure-Activity Relationships (SARs)
Section 4.1.3.1 Structure-activity relationships for binding AhR
Because of the lack of crystal structure for AhR, ligand structure-based methods provide an al-
ternative way for our understanding the mode of AhR binding with dioxin and other ligands
such as the benzothiazole drugs. 
The results of Table 3.3 summarise the Ki values for the competitive binding affinities of the
phenylbenzothiazole analogues for the rat cytosolic AhR. The magnitude of the Ki values for
the phenylbenzothiazoles was dependent on the structure of substituents and varied over ~6000-
fold (>3 log) from the IH 445 to the JP-2 which displayed the lowest and highest Ki values re-
spectively. 
Generally, it was observed that the presence of two hydrophobic groups or more, specifically
two halogenated atoms or a halogen atom and an alkylated group, favours high-affinity binding.
Three possibilities may explain this observation. First, it could be that the introduction of such
groups at the 3' position in the phenyl and the 5' position in the benzothiazole moieties forces
the whole molecule to become planar. However, it seems that absolute planarity is not a require-
ment for AhR binding as shown in this study by another compound not related to the phenyl-
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benzothiazole analogues, tetarchlorophenothiazine (TCPT) [196].
The second explanation is increased hydrophobicity of the molecule caused by the introduction
of hydrophobic groups. Previous QSAR studies with a series of 7-substituted 2,3-dichlorod-
ibenzo-p-dioxins showed that the binding affinity was linearly dependent on the lipophilicity
(ʌ) of the 7-X-group [197].
The third explanation is the steric effect of these groups. The introduction of bulky groups in
the lateral positions increases the size of the molecule so it can fit the size required for binding.
This seems to be in agreement with the tolerance of steric effect in the lateral positions proposed
by Waller and Mckinney (1995) [40]. Finally, a combination of these scenarios is also possible.
Phenylbenzothiazole analogues and TCDD have two aromatic rings but are structurally differ-
ent. Comparing their SARs enables more understanding of the mode of binding to the AhR. The
comparison of their SARs revealed some similar structural requirements for binding to the Ah
receptor. Generally, for PCDDs, any pattern that includes chlorination at positions 2,3,7 and 8
is known to be associated with the compound's strong binding to the AhR. This is true only if
one ring position is unoccupied [198]. Structure-activity relationships for binding of a series of
2-substituted 3,7,8-trichlorodibenzo-dioxins to AhR revealed that binding was dependent on
substituent lipophilicity, steric effects and hydrogen bonding and that correlation between bind-
ing and CYP1A1 induction for these compounds was dependent  the steric factor of substituent
[199]. A major difference between the SAR of dioxins and PBTs is observed when an amino
group is introduced at the 7-position of the 2,3-dichlorodibenzo-p-dioxin. The EC50 of the 7-
amino- 2,3-dichlorodibenzo-p-dioxin was greatly reduced in the rat hepatoma cell [197]. The
binding affinities of phenylbenzothiazole analogues were considerably higher although these
have an amino-group in the phenyl ring of all the analogues in series (1). But it does not seem
Rana Bazzi   Section 4.2
Page 169
that the amino group is critical for binding given that replacement of an amino by a methoxy
group did not affect the binding significantly (JP-1). Generally, the phenylbenzothiazole ana-
logues tolerate structural modifications more than TCDD. For example, a cyanide group or a
hydrogen atom in position 7 in the 2,3-dichlorodibenzo-p-dioxin, has a marked inhibitory effect
on TCDD binding [197], whereas the introduction of the same groups in one of the lateral po-
sitions of the phenylbenzothiazole analogues, does not inhibit their binding to the Ah receptor.
These data suggest that these compounds compete with dioxin at the same sites on the AhR, but
they interact with different residues in this site.
Section 4.2 CYP1A1 induction assay using TaqMan real-time RT-PCR
Section 4.2.1  The choice of the cell cultures
The CYP1A1 induction assay was initially conducted cultured cells to minimise metabolism.
The cell line chosen to generate the log concentration-response curves for the test compounds
was the rat hepatoma H4-II-E cell line. This cell line represents a useful model system because
of low basal CYP1A1 activity and high inducibility of the enzyme activity in response to dioxin-
like inducers [179] [173] [58] [175] [174]. 
Section 4.2.2  qRT-PCR analysis
The initial choice of quantitative reverse transcriptase real time PCR (qRT-PCR) and TaqMan
technology for measuring messenger RNA (mRNA) levels allows measurement of AhR gene
expression before any post translational/functional modifications [200] or enzymatic inhibition
(EROD) [201] [202]. Furthermore, qRT-PCR is more sensitive over EROD activity in detecting
CYP1A1 induction [258] [203] and northern or slot blotting for measuring RNA [258] and has
the advantage of speed and throughput compared with conventional quantification methods,
such as northern blot analysis, ribonuclease protection assay or competitive PCR. Finally, as op-
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posed to semi-quantitative PCR, real-time PCR analysis yield more accurate results as the reac-
tion is occurring and measurements are taken during exponential phase of PCR amplification as
opposed to end point PCR, where the reaction is complete (www.stratagene.com). 
In the present study, the quantitative PCR chosen consists of relative quantification since the
issue is to compare the mRNA induced levels to vehicle or TCDD controls and not to determine
the number of templates in the original sample as for the absolute quantification method. The
relative quantification method consists of normalizing the mRNA levels to those of a house-
keeping gene, whose expression must remain unchanged in response to experimental conditions
and increasing drug exposure.
Section 4.2.3  Normalisation to housekeeping genes 
The validation of the reference genes was performed systematically at every single experiment.
E-actin and AhR gene expression was routinely found within ~ two-fold of control levels, in
both rat and human cells, at all treatments and all experimental conditions performed, which
provides evidence that the perturbation in CYP1A1 RNA levels represents genuine gene-specif-
ic expression and is not a result of sample differences (RNA quantity and quality) or variation
of the reference gene expression. 
Housekeeping gene expression is not necessarily stable with all treatments [205] [206]. The use
of one single reference gene for normalization is not optimal practice because it can give errors
in normalization [207]. Therefore, to gain more accurate and reliable results, two reference
genes were selected in the present study, the E-actin and the AhR genes. The rationale of the use
of two reference genes is that the AhR/E-actin ratios should be close to 1 which reflects a high
expression stability [207]. The coefficients of variation (cv) for E-actin mRNA and AhR/E-actin
mRNA ratios were between 20-30%, which reflects on the low variation among the data. E-ac-
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tin and AhR genes were chosen based on previous findings, that E-actin and AhR gene expres-
sion was relatively constant in response to TCDD in rats [153]. 
Section 4.2.4  Factors affecting CYP1A1 RNA induction in H4-II-E cells
The induction levels achieved by TCDD in the H4-II-E cells varied significantly between ex-
periments according to the controls used (Figure 3.13 B and Figure 3.14 A). The CYP1A1/E-
actin mRNA ratio induced levels in Figure 3.13 B were relative to 4 h DMSO-treated cultures
in fresh medium, whereas in Figure 3.14 A, the levels induced were derived relative to untreated
cells (not subjected to medium change), and treatment levels were significantly higher. Basal
CYP1A1/E-actin mRNA ratio for DMSO incubations set up as the background of CYP1A1
mRNA expression was consistently detectable (Figure 3.13 C and Figure 3.14 B). The fresh me-
dium was hypothesised to have an induction capacity. This hypothesis was investigated in Sec-
tion 3.2.5.3. The results showed that the CYP1A1/E-actin mRNA ratio in DMSO-treated cells
was 8-fold higher in fresh medium than in pre-incubated medium. Since the values for TCDD-
induced CYP1A1/E-actin mRNA ratios are derived relative to DMSO-treated incubations, that
resulted in an apparent lower induction observed by TCDD. 
This is with good agreement with previous work reported by Kocarek et al (1993), where they
found CYP1A1 mRNA induction when primary cultures of rat hepatocytes were exposed to
fresh medium [172]. Work on rainbow trout gonadal cells (TRG-2) showed that the addition of
fresh medium to cells resulted in a 20-fold induction of P4501A mRNA over untreated cells
[178]. It was suggested that the induction observed when changing medium is due to a compo-
nent in the fresh medium, and Kocarek et al (1993) isolated the inducing factor as a photoacti-
vated tryptophan derivative [172]. The oxidized product of tryptophan induces 1A1 and the
results suggest that the transient nature of the 1A1 induction is due to elimination of activated
tryptophan molecule at 24 h. That was also reported by Helferich and Denison (1991) [208],
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where they found that ultraviolet-irradiated tryptophan bound specifically to the Ah receptor
and caused DRE binding and gene transcription. 
The results in Section 3.2.5.3 proved that DMSO had no effect on CYP1A1 mRNA induction
(Figure 3.15 A), which is consistent with [178]. 
Overall, these results provide evidence for the importance of controlling the background control
levels in induction assays as, according to the results provided in this study, that can seriously
affect the magnitude of the response and hence reduce the signal-to-noise ratio. The results have
proved that fresh medium induced CYP1A1 mRNA and that DMSO (0.1%) has no effect on in-
duction.
Section 4.2.5  Validation of the induction assay in H4-II-E cells using 
TCDD
The use of TCDD as a positive control in induction analysis was based on two reasons: first,
TCDD is very potent inducer of CYP1A1 mRNA and second, it resists oxidation by xenobiotic
metabolizing enzymes and thus produces a sustained induction (reviewed in [3]). With regard
to CYP1A1 mRNA induction, H4-II-E showed high inducibility and high sensitivity in response
to TCDD, under the conditions optimised (4 h and pre-conditioned medium). 
The fold-induction of CYP1A1/E-actin mRNA ratios by 1-10 nM TCDD was 300-fold above
vehicle controls. Significantly- induced levels of CYP1A1 mRNA by TCDD were detected at
concentrations <100 pM (Figure 3.24 A). The EC50 values of TCDD for CYP1A1 mRNA induc-
tion varied from 30 pM to 60 pM, on four different occasions, which is within two-fold variation
(Table 3.6). This showed reproducibility of the induction assay. The EC50 values for TCDD are
comparable with literature values (Table 3.12). However, the values from the literature raise
several issues: (a) low-fold induction coupled to high levels in controls, which could result in
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an apparent underestimated EC50 value [175] [183], (b) improper definition of the top and bot-
tom levels (plateau) for the dose-response curves, which might yield erroneous results [184], (c)
the dose-response curves are not shown [186] [13] [185], or (d) most of the work has been con-
ducted at late time points, i.e, at saturation levels of the response, which could significantly af-
fect the EC50 of TCDD as previously shown by [180]. Finally, most of these reports are lacking
the statistical characterization of the measurements (S.D or 95% confidence intervals). Litera-
ture values for the EC50 for TCDD were collected from enzymatic assay rather than mRNA,
given that CYP1A1 induction was mainly characterized via these assays. The induction of
CYP1A1 mRNA by TCDD in H4-II-E cells has been characterized but using few concentrations
of TCDD [175] [209]. As a result, there is a need for a dose-response curve with an accurate
measurement of EC50.
Having established the feasibility of the CYP1A1 mRNA induction assay, the method was used
to generate the log concentration-curves and thus determine the EC50 of the benzothiazole an-
alogues for the CYP1A1 mRNA induction. 
When TCDD and chemicals were tested on several occasions, EC50 values did not change sig-
nificantly between experiments (p>0.05, n=3, t-test, n=3). The slope also did not change signif-
icantly between compounds and across all experiments. The maximal level of induction varied
less than 3-fold. 
3-Methylcholanthrene (MC) is another potent AhR ligand, but in contrast to TCDD, MC is
prone to metabolism [180]. Using the conditions of the current induction assay, the induction of
CYP1A1 mRNA by 3-methylcholanthrene (MC) was characterized and compared with that of
TCDD. 
TCDD and MC have similar maximal levels of CYP1A1 mRNA induction in H4-II-E cells (Fig-
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ure 3.17 A), as previously reported [180] [177] and was only ~200-fold less potent than TCDD
for inducing CYP1A1 mRNA in H4-II-E cells (Section 3.2.7; Figure 3.17 A). This difference in
potency within 200-fold might be due to some of the metabolism previously shown at 4 h [180].
MC had similar affinity to TCDD (~1 nM) as a ligand for AhR in Sprague-Dawley rats [67] but
is 30,000 times less potent in vivo rat [181] than TCDD as an inducer of AHH activity. Such
discrepancy between binding to AhR and CYP1A1 induction was attributed to the metabolic in-
activation of the MC in vitro by the enzymatic activity of the CYP1A1 at 24 h [6]. One study
estimated the difference in CYP1A1 mRNA induction potency between TCDD and MC to be
(10-fold) when assessed at 2 h in mouse cultured Hepa-1 cells, however, the EC50 values were
not adequately derived given the incomplete log concentration response curves of both com-
pounds [180]. The present study proved MC to be a potent agonist for CYP1A1 with a greater
potency than previously reported [181].
Section 4.2.6  5F 203, DF 203, GW 610 and AW 892 but not IH 445: low 
potent agonists for inducing CYP1A1 mRNA in H4-II-E cells
The phenylbenzothiazole compounds tested, 5F 203, IH 445, DF 203, GW 610 and AW 892 in-
duced CYP1A1 mRNA to TCDD maximal levels and can be classified as full agonists according
to the definition by Jenkinson et al (1995) [210]. However, these compounds, except IH 445,
had low potency in H4-I-E cells (Figure 3.19 A and Table 3.9). 
The binding assay proved direct interactions between the phenylbenzothiazole compounds test-
ed and the AhR, and suggests that the induction of the CYP1A1 mRNA was a subsequent result
from binding to the AhR. In order to show that AhR is required for induction of CYP1A1, it
would be necessary to knock out the AhR and then study the induction by these agents under
the same conditions of the assay. Finally, in order to confirm that the induction of CYP1A1
mRNA by the test compounds is not a specific effect on CYP1A1 but rather a result of a general
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activation of AhR, it would be possible to screen the transcription of other AhR-dependent
genes expression by real-time RT-PCR and follow this with protein expression analysis. Trans-
location of the AhR to the nucleus subsequent to binding could be confirmed by performing
western blotting analysis. 
Section 4.2.7  Interpretation of difference in potency between binding 
affinity and CYP1A1 induction: partial agonism 
IH 445, 5F 203, DF 203, GW 610 and AW 892 were high-affinity ligands for AhR in rat cytosol
with Ki values in the nanomolar range (Table 3.3). These compounds were expected to be potent
inducers of CYP1A1, as generally, AhR binding affinity correlates with induction of CYP1A1
mRNA [202] [199] [197] [159]. The induction potential of the low-affinity ligands (Ki >1 µM)
could not be assessed in H4-II-E cells, because the limited solubility of these compounds (>30
µM) prevented from generating their log concentration-response curves for CYP1A1 mRNA in-
duction. 
The most potent AhR ligand, IH 445 was only 5-fold less potent in inducing CYP1A1 mRNA
than in its binding affinity for AhR (Table 3.9). For the rest of the phenylbenzothiazole com-
pounds tested (5F 203, DF 203, GW 610 and AW 892), there was a poor correlation between
Ah receptor binding affinities and induction potencies in H4-II-E cells. The most striking dif-
ference was observed with 5F 203 and GW 610, with 1000-fold lower induction potency than
binding affinity for AhR. The binding affinity values of AW 892 and DF 203 were 200- and
300-fold lower than the corresponding EC50 values respectively (Table 3.9). Similar disparities
between binding and potency for induction were obtained by others with other compounds, such
as, the 6-substituted 3,4-benzocoumarins [211], PCBs [212] and di-ortho PCBs [213], DNF and
methyltricholodibenzofuran [95] [214] [215] [97], 6-methyl-1,3,8-triCDFs [216]. There was no
quantitative measure of their intrinsic efficacy for activating AhR signaling. Moreover, even
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though direct measurements of some of these compounds to agonize and antagonize AhR sign-
aling has been made, these measurements were performed by endpoint analyses, such as EROD
and at late time points [217] [211], where the response versus time of induction is not linear and
may be subject to posttranslational inhibition of enzymatic activity or metabolism. Other reports
focused on investigating metabolic inactivation of the lower potency agonists as the most likely
possibility without testing the antagonistic activity of these compounds, thereby assuming by
that high intrinsic efficacy for these compounds [181] [180]. 
Given the poor correlation between binding of PBTs to AhR and CYP1A1 mRNA induction in
H4-II-E cells, this cell line provides a suitable system to further investigate the difference in po-
tency between binding to and activation of AhR. So, it was necessary to elucidate what deter-
mines the potency of the benzothiazole analogues, by estimating the intrinsic efficacy of 5F 203
and IH 445 on TCDD for inducing CYP1A1 mRNA in H4-II-E cells. 
5F 203 bound with high affinity to AhR (Ki 2.8 nM), versus a KD for TCDD of 0.37 nM. How-
ever, when tested for its capacity to induce CYP1A1 mRNA in the rat cell line, it was found
much less potent (50,000-fold less than TCDD). The 8-fold difference in binding affinities can
not account for the large quantitative difference, 50,000-fold in CYP1A1 mRNA induction po-
tency between 5F 203 and TCDD. However, other possibilities exist, such as, (a) lower intrac-
ellular concentrations of 5F 203 caused by inefficient cellular uptake or metabolism, (b) 5F 203
and TCDD do not share the same mechanism of action and (c) low intrinsic efficacy of the com-
pound that fails to fully activate the AhR, i.e, that 5F 203 is a partial agonist. These three pos-
sibilities are discussed below. 
(a) Measurements of the induction potency was conducted in cell cultures where the concentra-
tion of the drug can be affected by many factors such as sequestration of the chemical by serum
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proteins and/or the inability to readily traverse the cellular membrane and clearance by metab-
olizing enzymes. These factors would tend to reduce the apparent potency of the chemicals.
However, in the binding assay, these factors are not present and the drug in the medium can im-
mediately gain access to the receptors. Alhough efforts have been made to work under condi-
tions where drug metabolism is not the major determinant factor (by working at an early time
point, 4 h), the possibility that some of the drug may still undergo some metabolic inactivation,
cannot be ruled out. However, as shown for 5F 203, lower concentrations is very unlikely to be
the main factor behind its low potency for two main reasons. First, as shown in Figure 3.14 A,
the induction of CYP1A1 against time was still increasing linearly till 6 h treatment suggesting
that 5F 203 is not subjected to significant metabolism at an early time point (4 h) and second,
co-incubation of TCDD and 5F 203 (Figure 3.20 A) revealed a significant inhibitory effect of
5F 203 (100-fold) on TCDD-induced CYP1A1 mRNA. The strength of the effect of 5F 203 on
TCDD-induced in H4-II-E cells excludes the possibility that the lower potency of 5F 203 in
these cells is a result of low intracellular concentration of 5F 203. Finally, when MC, a com-
pound known to be metabolized [180], was tested in rat cells, it was found only 200-fold less
potent than TCDD for inducing CYP1A1 mRNA as opposed to the 50,000-fold reduced potency
of 5F 203. 
(b) The log concentration-response curves for 5F 203 and TCDD are parallel (Figure 3.18 A)
which provides indirect evidence for a common mechanism of action for the CYP1A1 induction
by Ah receptor. In Section 3.1.8, 5F 203 competitively displaced [3H]-TCDD specifically
bound to the AhR, which proved direct interactions with the AhR (Figure 3.9). That proves that
the induction of CYP1A1 by 5F 203 is, like TCDD, AhR- mediated.
(c) 5F 203 was estimated to have a low intrinsic efficacy with a fraction occupancy around
100% for 50% maximal response. Mixtures of increasing concentrations of TCDD with 1 µM
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5F 203 increased TCDD's EC50 by 100-fold. These results demonstrate that 5F 203 antagonized
TCDD-induced CYP1A1 mRNA in H4-II-E cell line. Thus, 5F 203 is classified as a partial an-
tagonist in H4-II-E cells which provides explanation for its much lower potency than TCDD.
5F 203 binds AhR but fails to activate it at its binding concentrations. 
In H4-II-E cells, 5F 203 behaves like many flavonoids in that it functions as an AhR antagonist
at lower concentrations, while at higher concentrations it behaves as an AhR agonist [218]. This
effect would be apparently exacerbated with a less sensitive assay methodology. Antagonistic
effects between less potent PCBs and highly potent TCDD have been documented in vivo and
in vitro (reviewed in [219]). Many ligands were reported to have dual function as AhR agonists/
antagonists [98] [216] [211] but the molecular factors that determine either activity are still un-
known. One study reported that AhR agonists, but not antagonists, induce conformational
change in the in vitro-translated mouse AhR [220]. Alternatively, it could be that, like steroid
receptors (androgen, oestrogen, progesterone and glucocorticoid), some hormone antagonists
induce conformational changes that are different from those induced by agonists. It is possible
that AhR agonists and antagonists bind to different residues in the binding pocket of the AhR,
resulting in different conformational changes [221]. Assuming that cellular uptake and accessi-
bility of 5F 203 and TCDD to the AhR is similar, the antagonism may be due to events involving
ligand binding/AhR transformation/nuclear translocation/DRE binding that contribute to the ul-
timate difference in CYP1A1 induction potency. There is the example of DNF that competes
with TCDD for binding AhR [95] [215] [222], exhibits weak AhR agonist activity, inhibits the
formation of nuclear TCDD-AhR complexes, and partially antagonizes TCDD-induced
CYP1A1 gene expression in several mammalian cells [96]. Alternatively, the 3'-methoxy-4'-ni-
troflavone binds AhR with high-affinity in mouse Hepa cells but cannot initiate transformation
and nuclear translocation, as result, the 3'-methoxy-4'-nitroflavone bound to AhR remains in the
Rana Bazzi   Section 4.2.7
Page 179
cytosol associated with hsp90 [222].
Overall, little is known about the mechanism of antagonism of AhR, and it would be useful to
investigate the mechanism of antagonism of TCDD-induced CYP1A1 mRNA induction by 5F
203 in H4-II-E cells. The antagonism of 5F 203 to TCDD could be for a specific response,
which is the CYP1A1 gene induction, however, to prove that the antagonism is at the AhR level,
the general response would be antagonized, for example, to determine if translocation to the nu-
cleus of TCDD-AhR complex is blocked by 5F 203 in a dose-dependent manner. So, it would
be important to examine with the mean of a quantitative western blotting whether the 5F 203
alone or in mixtures with TCDD induces AhR translocation to the nucleus, and in case it does,
whether the translocation correlates with its induction potency.
DF203, GW 610 and AW 892, are estimated to be low-intrinsic efficacy agonists, like 5F 203,
with similar receptor occupancy levels. They all display similar binding affinity and induction
potency profiles. These results give reasons to believe that these compounds are likely to be par-
tial antagonists in the H4-II-E cells. In contrast, IH 445 was found to be potent in both binding
to AhR and inducing CYP1A1 mRNA in H4-II-E cells. This compound was estimated to occupy
82% of receptors to achieve 50% maximal response. In order to investigate whether this com-
pound has an antagonistic activity in H4-II-E cells, TCDD was incubated with and without 3
nM IH 445, and this potent agonist did not antagonise TCDD. The 5-fold difference could be
attributed to some loss of activity of the compound by metabolizing enzymes present in the in
vitro induction assay but not in cytosol. Having found a derivative in the series (1) with high
potency for inducing CYP1A1 indicate that the partial agonism observed with 5F 203 is not a
generic intrinsic characteristic of all the phenylbenzothiazoles, but is rather compound-specific.
The difference in agonism/antagonism profile between 5F 203 and IH 445, suggests a different
mode of binding to AhR by these compounds and/or different mode of activation of the recep-
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tor. Perhaps, the most pronounced structural difference between the IH 445 and the other com-
pounds tested, is the bulkier group at the 3’ position (ethynyl group) of IH 445 compared with
the methyl group at the same position for the other compounds. 
Having determined the binding affinity (Ki) of these compounds and their EC50 for inducing
CYP1A1 mRNA in rat, interactive effects of mixtures of these compounds and TCDD could be
roughly predicted by calculating the EC50 concentration of TCDD in the presence of the test
compound [A’] from the equations [6] and [7] (appendix). The prediction that 1 PM 5F 203
would antagonize TCDD by 360-fold was tested and experimentally, revealed 100-fold antag-
onism. This is a useful approach to predict whether a low efficacy compound, could be a partial
agonist in a particular cell line. The choice of concentration of the test chemical in mixtures with
TCDD is very important. This choice has to be based on the affinity and the induction response,
so that the antagonism could be measured accurately. 
Schild regression is a powerful method for drug classification. Not only does it allow an inde-
pendent estimation of KB value and determination of the slope, but it also gives an indication
whether the system has reached equilibrium [264]. The Schild regressions on TCDD concentra-
tions in combination with three different concentrations of 5F 203 proved linearity, with a
Schild slope not significantly different from unity (Figure 3.21 and Figure 3.22). This result pro-
vides information that the analysis was performed under equilibrium. Another useful applica-
tion of the Schild analysis, is that it allows analysis of the nature of the antagonism, i.e, whether
it is reversible competitive or non-competitive, as demonstrated for the reversible competitive
antagonism of 5F 203 on TCDD (Figure 3.21) which validates the results of the competitive ra-
dioactive binding assays (Figure 3.9). Furthermore, Schild analysis allows the determination of
the fraction of receptor occupancy for TCDD in mixtures with another compound. Based on KB
experimental value, from equation [5] (appendix), the fractional receptor occupancy at 50% re-
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sponse of TCDD in the presence of 1 PM 5F 203 was calculated to be 0.2% compared to the
14% in the absence of the antagonist 5F 203. Schild regressions on 5F203 revealed an 8-fold
higher KB in the induction assay compared to the KD determined in the binding assay. This close
agreement provides evidence that 5F 203 has reached receptor sites and that the intracellular
concentrations in cells in cultures are not significantly lower than when compared to extracel-
lular conditions, if sequestration by serum protein and some metabolism are taken into account. 
In this study, it has been demonstrated that 5F 203 is a partial antagonist in H4-II-E cells which
could provide explanation for the difference in potency between binding to and activation of
AhR. The antagonistic effect of 5F 203 on the EC50 for induction of CYP1A1 mRNA by TCDD
was quantified. Quantifying the relative agonistic and antagonistic activities of anticancer phe-
nylbenzothiazoles is important for drug assessment.  
Section 4.2.8 TCDD and 5F 203: potent agonists in human MCF-7 cells
The phenylbenzothiazole analogues tested, except IH 445, had low potency for inducing
CYP1A1 in H4-II-E cells, but were previously shown to induce CYP1A1 in MCF-7 cells [140]
[141] [253], thus was used as a standard of comparison. Therefore, it was interesting the test the
potency of one of these compounds, 5F 203, under the conditions of the current induction assay
and compare with literature.
The fold-induction of CYP1A1/E-actin mRNA ratios by 1-10 nM TCDD was 1300 above vehi-
cle-controls MCF-7 cells. Induced levels were detected from 100 pM (Figure 3.24 A). Low con-
stitutive levels of CYP1A1/E-actin mRNA ratios were detected in MCF-7 cells. Although it was
reported that neither activity nor expression of the P450 CYP1A1 is constitutive in MCF-7 cells
[141], this difference may be attributed to the lower sensitivity of Western blotting and EROD
assay, where low levels could not be easily measured, as compared to the sensitive measurement
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by qRT-PCR. When run in two separate experiments, the EC50 values of TCDD for CYP1A1
mRNA induction were within two-fold (Table 3.11). These results further confirm the repro-
ducibility of the induction assay previously shown in rat cells (Table 3.6). The EC50 values for
TCDD in MCF-7 are comparable with literature values (Table 3.12). However, the values from
the literature are suffering from several caveats that were covered in Section 4.2.5.
5F 203 induced CYP1A1/E-actin mRNA ratios to levels seen with TCDD. The EC50 values of
5F 203 for CYP1A1 mRNA induction was 2 nM (95% CI, 0.9-5) (Figure 3.25 A). 5F 203 in mix-
tures with TCDD, did not exhibit any antagonistic activity on TCDD-induced CYP1A1 mRNA
(Figure 3.27 A). These results identify 5F 203 as a full AhR agonist for inducing CYP1A1
mRNA in MCF-7 cells, with no antagonistic activity relative to TCDD. Thus, 5F 203 is a potent
agonist for inducing CYP1A1 mRNA in MCF-7 cells.
The finding that 5F 203 is a potent agonist in MCF-7 cells confirms previous findings [263].
Given the low potency of the phenylbenzothiazoles tested in rat cells the next step would be to
investigate the compounds for CYP1A1 mRNA inducibility as well as for binding the AhR in
the human cells (MCF-7 cells) and subsequently generate a QSAR model out of these data. 
Section 4.2.9  Agonism/antagonism species-specific differences
The potency (EC50s) for CYP1A1 mRNA and the maximal levels of induction for TCDD were
characterized in both H4-II-E and MCF-7 cells. The relative potency (EC50s) and the maximal
levels of induction for 5F 203, DF 203, IH 445, AW 892, GW 610 and IH 318 were character-
ized in both H4-II-E and MCF-7 cells.
Under the conditions of the current induction assay, TCDD showed similar potency in human
and rat cells but lower magnitude of induction in rat compared with human as assessed by qRT-
PCR at 4 h (Figure 3.24 A). This lower magnitude of induced levels in H4-II-E cells was also
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manifested with 5F 203 (Figure 3.26). CYP1A1 mRNA induction assays were consistently per-
formed in both cell lines exactly under the same conditions, i.e, cell number and confluence (90-
95%), duration of treatment (4 h), same stock of each chemical and same reagents. Species-spe-
cific differences have been reported for CYP1A1 mRNA induction for TCDD. Silkwork et al
(2005) reported species-specific differences for induction of CYP1A1 mRNA by TCDD in rat
fresh hepatocytes and human HepG2 cell line (RT-PCR), however, significant variations were
observed for cell lines within the same species [203]. It is noteworthy that cell-specific differ-
ential expression of CYP1A1 was reported. In humans, CYP1A1 is mainly expressed extrahe-
patically, whereas in rodent, it is mainly hepatic [125]. Human hepatocytes have a lower
maximal induction level and EC50 value for CYP1A1 induction by TCDD than Sprague-Daw-
ley rat hepatocytes [203], whereas induction of CYP1A1 in human lymphocytes was higher
than the level of induction in rodent lymphocytes [223]. A correlation between the levels of nu-
clear Ah receptor with the magnitude of the induction (CYP1A1) was reported [7] [224] [211],
but this finding is controversial [225] [226] [211]. AhR might be differentially regulated in dif-
ferent cells at different steps of its signaling pathway [53], and the molecular basis for differ-
ences in levels of induced CYP1A1 across species is unknown. 
These results identified 5F 203 as a potent agonist in human cells but a partial antagonist in rat
cells. However, both cell lines are CYP1A1 inducible. This difference in agonism profile could
be attributed to species-specific differences. Species-specific antagonism of AhR was previous-
ly reported. Aarts et al (1995) found that 2,2’,5,5’-Tetrachlorobiphenyl (PCB52) antagonized
the expression of a luciferase reporter gene under transcriptional control of AhR in mouse
H1L1.1c7 hepatoma cells exposed to TCDD but little to no inhibition was observed in guinea
pig G16L1.1c8 intestine and human HG2L1.1c3 hepatoma cells [227]. Moreover, this com-
pound did not show any agonistic activity in all three cells. Since PCB52 bound AhR in mouse
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but not in human nor in guinea pig [227], this could explain the inability of PCB52 to antagonize
TCDD in human and guinea pig. 3'-methoxy-4'-nitroflavone (MNF), was found to be a pure an-
tagonist in mouse hepatoma Hepa cells but a partial agonist in Guinea pig adenocarcinoma cells
using luciferase reporter gene. This compound can compete with TCDD to bind AhR in both
cells and inhibits its nuclear uptake and transformation only in mouse cells [99] [222]. The Arg
355 residue in mouse AhR which is equivalent to Ile in guinea pig AhR and Thr in the human
AhR, was identified to distinguish the agonistic versus antagonistic activity (MNF) [228]. Spe-
cies-specific agonism of AhR has been reported, with the example of the benzimidazole drug
omeprazole (OME). It activated AhR in human cells but not mouse cells in culture [229], but
OME does not bind the human or mouse AhR [194]. None of the studies have identified a com-
pound that is an agonist in one species but an antagonist in another. 
A compound’s potency depends on both affinity and efficacy [210]. The binding affinities of
phenylbenzothiazoles were determined in the rat but not the human cells. Species-and tissue-
specific differences have been reported in the binding properties, specificity, and physiochem-
ical properties of the Ah receptor [230] [231] [232]. Moreover, it was reported that species-spe-
cific activity for induction of CYP1A1 correlates with species-specific binding to AhR [233]
[35] [234]. In the present study, TCDD has a KD of 0.37 nM for rat AhR (Figure 3.7). Literature
values for TCDD KD for human AhR varied from 1.6 nM [35], 10 nM [235] to 18.6 nM [236].
From these results, TCDD binds human AhR with lower affinity than the rat AhR. TCDD in-
duced CYP1A1 mRNA in MCF-7 cell line with only 10-fold higher potency than 5F 203 (Figure
3.25). In comparison with OME that does not bind the human, rat nor mouse AhR [194] but in-
duced CYP1A1 in a ligand-independent pathway [101], 5F 203 binds the rat AhR (Figure 3.9
and Table 3.3). It does not seem from these preliminary data that the difference in 5F 203 po-
tency across the rat and human cells is due to the species- specific binding. However, the com-
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pounds in this study were not tested for their binding to the AhR in MCF-7 cells and it will be
necessary to gain this information in the future and investigate the correlation between the bind-
ing and the activity across the rat and human cell lines. 
As a conclusion, care has to be taken when classifying compounds based on their ability to in-
duce CYP1A1. The classification depends on the tissue/species in which the measurement is
made. As the present study revealed, a low-efficacy drug, namely 5F 203, can be a potent ago-
nist or a partial antagonist depending on the species from which the cell line is derived. The ex-
pression of CYP1A1 was not consistent between rat and human cells. This difference in gene
expression needs to be taken into consideration when using cell models to assess drug efficacy
and when extrapolating results from rat to humans.
Section 4.3 AhR, a target for anticancer phenylbenzothiazole ana-
logues: mechanistic investigations
The general hypothesis of the mode of action of the anticancer phenylbenzothiazole series (1)
consists of activation of AhR and subsequent metabolism by induced CYP1A1. However, how
the receptor mediates their function remains to be elucidated. This hypothesis was based on sev-
eral pieces of data from literature: 1) these planar compounds induced CYP1A1 in sensitive
(MCF-7) but not in inherently resistant (MDA-MB-435) human breast cancer cells, where the
AhR seems to be present constitutively in the nucleus [141] which raised the possibility of a role
of the AhR in mediating the anticancer activity of these compounds, 2) the observation that
cotreatment of MCF-7 cells with DF 203 and the AhR antagonist, D-naphthoflavone at 10 PM
abrogated the inhibitory effect of DF 203 [141], 3) comparative analysis on 5F 203 growth in-
hibition in wild-type MCF-7 with AhR-deficient AHR100 [144], derived from MCF-7 human
breast epithelial cancer cells by continuous exposure to increasing concentrations of the poly-
cyclic hydrocarbons benzo[a]pyrene [237], yield reduced anticancer efficacy of 5F 203 in the
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AHR100 compared to full efficacy in the sensitive wild-type cell line. However, it was not clear
from the work reported by Trapani et al (2003) [144] whether the AhR-mediated signaling could
account for all the cytotoxic effect of the compound. The use of the AhR antagonist D-naphtho-
flavone was shown to inactivate cytochrome P450 enzymatic activity by competitively interact-
ing with the substrate binding site when used at high concentrations (10 PM) [238].
Consequently, the use of D-naphthoflavone at 10 PM furnished evidence on the importance of
the catalytic activity of CYP1A1 on the growth inhibition by DF 203 and does not necessarily
prove the involvement of the AhR. Thus, the loss of cytotoxicity of DF 203 in mixtures with 10
PM D-naphthoflavone could be due to the lack of metabolism by CYP1A1, previously suspect-
ed to be important for its anticancer activity [140].
Section 4.3.1  Correlation between SARs for binding and anticancer activ-
ity
The choice of rat over human species for developing the binding assay was based on two main
reasons: first, it is not easy to get human liver for cytosol preparation and second, characteriza-
tion of a binding assay in human cells is very demanding [168] [235] given the lability of the
human AhR. The anticancer activity of PBT, except for 5F 203, was not assessed in MCF-7
cells, therefore the analysis for anticancer activity of PBT in MCF-7 cells was based on litera-
ture. 
Although binding affinities of phenylbenzothiazoles (series 1 and 2) was conducted in rat but
not in human cytosol, structure-activity relationships for the anticancer potency of these series
in human MCF-7 cells seem to generally correlate with their structure-binding relationships for
rat AhR. Concerning the compounds of series (1), the 5F 203 with its non-fluorinated analogue,
DF 203, retained nanomolar affinity values in rat, with DF 203 being ~4-fold less potent than
5F 203 (Table 3.3). This correlated well with the anticancer activity of these compounds in
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MCF-7 cells (Figure 3.31) [144] [253], where the presence of the fluorine atom at this position
was not found to be essential for anticancer activity, but prevents the drug from hydroxylation
by endogenous cytochrome P450 [126]. Shifting the fluorine atom from position 5 to either po-
sition 4 or 6 retained the nanomolar binding Ki values (with 5- and 10-fold decrease for the 6-
fluoro and 4-fluoro regioisomers respectively) (Table 3.3). Similarly, both regioisomers re-
tained nanomolar concentrations of GI50 values in MCF-7 cells [126]. In conclusion, for series
(1), the fluoro-group was not essential for anticancer activity neither for binding. 
The C-6 hydroxylated metabolite of DF203, 6-OH 203 (IH 130) had a Ki of ~1.5 PM (Table
3.3). It was reported that this compound antagonises DF 203 anticancer activity, most probably
by CYP1A1, and maybe not through the AhR signaling pathway. IH 130 is devoid of anti-tu-
mour activity in sensitive human cells [141]. When the binding of IH 130 to AhR was charac-
terized with a competitive binding assay, it showed low affinity. This suggests that the
antagonistic activity of the 6-OH 203 on DF 203 is not AhR-mediated.
In contrast to series 1, it seems that the fluoro group was required for the anticancer activity of
compounds from series 2 in MCF-7 cells [151], but not for binding to the AhR (Table 3.3). For
example, the non-fluorinated analogue (AW 892), was a high-affinity ligand for the AhR (Table
3.3), but devoid of activity in MCF-7 cells [151]. This is in contrast with series 1, where the
fluoro group was not essential for anticancer activity nor for binding. The fluorinated analogue
2-(3-methyl-4-methoxyphenyl)-5- fluorobenzothiazole (JP-1) has a GI50 value of 48 nM in
MCF-7 cells [151] and a Ki value of 26 nM in rat (Table 3.3). However, replacement of one
methoxy group by a hydroxyl (JP-2) or a methylenedioxy (JMB 81) yields inactive compounds
and low-affinity ligands. The 4- (4F 610) and 6-fluoro regioisomer both have inhibitory activity
on cell growth [151] and binding affinity (Table 3.3) in the nanomolar range. The 6-fluoro re-
gioisomer is 27-fold less potent than GW 610 for binding AhR. This series (2) of phenylbenzo-
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thiazoles tolerates structural modification poorly. So far, it seems that the mechanism of action
of GW 610 is different from that of DF 203, in that it is independent of CYP1A1 induction
[151]. A comparative analysis on the SARs of series (1) with series (2), revealed different SARs
for binding and anticancer activity, which further supports mechanistic differences.
Importantly, the KD for binding AhR and GI50 for cell growth inhibition in H4-II-E cells were
markedly different for most of the compounds tested (5F 203, DF 203, GW 610, IH 318) but
closer for AW 892 (20-fold) and IH 445 (100-fold). As a conclusion, binding AhR by itself does
not account for anticancer activity of these compounds in H4-II-E cells. 
Section 4.3.2  Correlation between SARs for inducing CYP1A1 RNA and 
anticancer activity
It was reported that cell sensitivity to the anticancer activity of 5F 203 correlates with CYP1A1
inducibility in human cancer cells [126] [140] [141]. However, in the present study, 5F 203, DF
203 and GW 610 increased CYP1A1/E-actin mRNA ratios with relatively low potency in H4-
II-E cells (Figure 3.19 A), and these cells were resistant to the anticancer activity of 5F 203 and
DF 203 and poorly responsive to the anticancer activity of GW 610 (Table 3.13). So, there was
a correlation between poor potency for CYP1A1 induction and loss of anticancer activity for DF
203 or 5F 203 in rat cells and therefore, it was suspected that the low potency could account for
the low anticancer efficacy of these compounds in the rat cells. The hypothesis was that induc-
ing CYP1A1 in H4-II-E cells would sensitize them to the anticancer activity of 5F 203. There-
fore, cells were pre-treated with 10 nM TCDD for 24 h, before treating with 5F 203. The results
showed that activation of the AhR failed to enhance the anticancer activity of 5F 203 (Figure
3.30). However, the possibility that the 5F 203 could be cleared by the CYP1A1 and other me-
tabolizing proteins induced by TCDD, cannot be ruled out. These results show that the sensitiv-
ity of H4-II-E cells to the anticancer activity of 5F 203, is not simply related to CYP1A1
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induction. A correlation between inducing CYP1A1 mRNA and anticancer activity was found
for IH 445 and GW 610, though not linear (Table 3.13). It is noteworthy that AW 892 induced
CYP1A1 mRNA at micromolar concentrations (2 PM) and inhibited H4-II-E cell growth at sub
micromolar concentrations (GI50 223 nM) (Table 3.13) but was found inactive in MCF-7 cells
(GI50 53 PM) [151]. In contrast, a correlation was observed for CYP1A1 mRNA induction po-
tency (EC50, 2nM) and cytostatic effect (GI50, 18  nM) of 5F 203 in MCF-7 cells (Figure 3.31
and Table 3.13). 
These results reveal species/cell-specific differences in sensitivity to 5F 203, moreover, a cor-
relation was observed between the potency of cytostatic effect of 5F 203 and CYP1A1 induction.
Section 4.3.3  Investigating the effect of AhR agonism on cell growth
Given the relationship between induction of CYP1A1 and anticancer potency of phenylbenzo-
thiazoles series 1 [126] [140] [141], it was of interest to investigate the effects of AhR agonism
by testing the effects of TCDD on the growth of MCF-7 as well as H4-II-E cells. The present
study confirmed that TCDD has no inhibitory activity of growth of both H4-II-E and MCF-7
cells as determined by MTT assay (Figure 3.29) and (Figure 3.31). These results provide direct
evidence that AhR agonism is not sufficient to inhibit the growth of both cell lines. The effect
of TCDD on cell growth is controversial in the literature. Wiebel et al, (1991) showed that
TCDD did not inhibit the growth of H4-II-E cells as determined by assaying the increase in the
amount of protein [239]. Knutson and Poland (1980) investigated the toxicity of TCDD on
twenty-three cells in culture, among them are the H4-II-E cells. In all these cells, TCDD did not
alter the morphology nor affected the cell growth or viability [192]. Likewise TCDD did not
significantly affect the proteins or enzymes of the cell cycle [191]. This is contrast with an in-
hibitory effect of TCDD in MCF-7 cells reported [11]. In this latter report, cells were treated
with 10 nM TCDD for 7 days and cell growth was measured fluorometrically by Hoechst. How-
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ever, 10 nM TCDD inhibited cell growth by 40%, and 50 nM TCDD inhibited 60% of cell
growth.  
Other researchers have claimed that TCDD inhibits the growth of the cells, with the observation
that in mixtures of TCDD and estradiol (E2), TCDD inhibits estrogen-induced proliferation
through an inhibitory AhR-ERDcross-talk, suggesting an anti-estrogenic-like effect of TCDD
in MCF-7 cells [240]. However, these conclusions seem to be controversial, since the presence
of E2 seems to be the limiting factor for the estrogenic/anti-estrogenic like effect of TCDD as
suggested by another recent study reported by Ohtake et al (2003) [190].
Section 4.3.4  Investigating the effect of AhR antagonism on cell growth
One of the aims of this project is to investigate the involvement of AhR in mediating the anti-
cancer activity of 5F 203. That can be done by co-incubating cells with 5F 203 and a range of
concentrations of the AhR antagonist CH-223191. The choice of CH-223191 as AhR antagonist
over other AhR antagonists was based on several issues. First, the CH-223191 was identified as
an AhR antagonist in human hepatic HepG2 cells with no agonistic activity up to a concentra-
tion of 10 PM. The lack of agonistic activity of CH-223191 on AhR signaling was further con-
firmed in the present study, where CH-223191 did not increase the CYP1A1/E-actin RNA levels
up to a concentration of 30 PM by qRT-PCR in MCF-7 cells (Figure 3.28). CH-223191 was
shown to inhibit TCDD-induced CYP1A1 expression and CYP1A1 enzymatic activity in a
dose-dependent manner by RT-PCR and Western blot assay and EROD activity [188]. Second,
contrary to known AhR antagonists, flavone, resveratrol, and D-naphthoflavone, a high concen-
tration of 10 PM of CH-223191 did not have any agonistic activity on AhR in the absence of
TCDD as assessed by luciferase activity [188]. In addition, CH-223191 was shown to have
more inhibitory potency on TCDD-induced luciferase activity than flavone, resveratrol, and D-
naphthoflavone [188]. Third, it showed no effect on oestrogen receptor-mediated gene activa-
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tion [188], whereas flavone and resveratrol have high affinity for the oestrogen receptor [259]
[241] and resveratrol stimulates the proliferation of human breast cancer cells [242]. Unexpect-
edly, the GI50 of CH-223191 was 420 nM in MCF-7 cells, so CH-223191 alone elicited a
growth inhibitory activity (Figure 3.31), a finding that hampered the experiment mentioned
above. Having found that the CH-223191 elicits a cytostatic effect, it was hypothesized that the
AhR antagonism of CH-223191 was responsible for cell growth inhibition. This hypothesis was
addressed pharmacologically by co-incubating cells with CH-223191 with a range of concen-
trations of TCDD. At low TCDD concentrations, 500 nM CH-223191 inhibited cell growth to
levels similar to 500 nM CH-223191 alone but higher TCDD concentrations (100 pM) restored
some of the cell growth but not to DMSO control levels (Figure 3.32). The results of the present
study indicate that the cytostatic effect of CH-223191 is not mediated by the AhR (Figure 3.32)
and that another mechanism is likely to be involved. 
As mentioned above, TCDD does not inhibit the growth of MCF-7 cells. This information en-
ables the use of TCDD as an AhR agonist in mixtures with 5F 203 to exclude the possibility that
the cytostatic effect of 5F 203 could be due to AhR antagonism. MCF-7 cultures were incubated
with increasing concentrations of TCDD and 50 nM 5F 203. As expected, high concentrations
of TCDD did not abrogate 5F 203 cell growth inhibitory activity (Figure 3.32), excluding AhR
antagonism as a mechanism for 5F 203 cell growth inhibition. Mixtures of 50 nM 5F 203 with
TCDD did not enhance the cytostatic effect of 5F 203. As 5F 203 is only within 10-fold with
lower potency than TCDD for inducing CYP1A1 in MCF-7 cells (Figure 3.25 A), TCDD is un-
likely to change the levels of CYP1A1 and would not further change metabolism of 5F 203.
However, although 5F 203 and TCDD bind AhR, it is possible that 5F 203 and TCDD might
have different targets or trigger different effects on the same target. Thus both TCDD [209] and
5F 203 [150] induce AhR-regulated genes, such as xenobiotic metabolizing genes, CYP1A1 and
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CYP1B1, in MCF-7 cells. However, TCDD is not genotoxic and does not induce DNA damage
genes [209], whereas 5F 203 induced genes associated with DNA damage in MCF-7 cells (CD-
KN/A (p21/Cip1), p53-induced gene-3, the apoptosis-initiating receptor TNFRSF6 (CD95/
FAS) and DNA binding protein 2 [150]. Moreover, TCDD, unlike 5F 203, is resistant to metab-
olism [61]. Furthermore, the observation that TCDD, which is resistant to metabolism [61] did
not inhibit MCF-7 cell growth, compared to 5F 203, which is known to be metabolised [146]
suggests that AhR activation is not sufficient for this effect without additional factors down-
stream of binding AhR, presumably, metabolism.
Section 4.3.5  Mechanism of action of 5F 203: relevance of the mecha-
nism of Genotoxicity?
Quantitative analysis from the present study on the CYP1A1 induction and the anti-proliferative
activity of the 5F 203 in MCF-7 cells demonstrated that this drug inhibited 50% of the growth
of the MCF-7 cells at 18 nM (Figure 3.31) and was able to induce CYP1A1 mRNA at 2 nM (Fig-
ure 3.25). Thus the concentration at which 5F 203 induces CYP1A1 falls in at the same range
of concentration at which this drug is manifesting its physiological effect on cell growth inhibi-
tion. This coincidence encourages consideration of the alternative hypothesis that genotoxicity
of 5F 203 is a cause for its cytostatic effect. In this hypothesis, 5F 203 is inhibiting the cell
growth by damaging DNA active metabolite/DNA adduct formation. However, DNA adducts
of 5F 203 were only detectable at concentrations that exceed 0.1 µM [146]. However, the con-
centration of 5F 203 at which it elicits its cytostatic effect (18 nM) is much lower than the con-
centration at which the DNA adducts are formed (>0.1µM) [146]. While the levels of exposure
required for the anticancer activity of 5F 203 are in the nanomolar range (nM), the finding that
a concentration 100-1000-fold higher results in DNA adducts does not provide convincing ev-
idence that genotoxicity is responsible for the cytostatic effect seen at ~ 18 nM 5F 203.
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Section 4.3.6  Relevance of partial agonism in risk assessment
The importance of the quantitative analysis of the partial agonism of AhR ligands lies in the fact
that mixtures of ligands for AhR, naturally occurring dietary as well as environmental or syn-
thetic xenobiotics, that have different intrinsic efficacy will not necessarily show additive ef-
fects in producing a stimulus (e.g, CYP1A1 induction or toxicity). Thus this concept potentially
has significant implications for the toxic equivalency factor (TEQ) risk assessment scheme,
since it relies on the concept of additivity [1] [243]. The default assumption of additivity i.e, that
most of AhR ligands are high-intrinsic efficacy agonists can be tested quantitatively using the
methodology described herein for 5F 203.
Section 4.3.7  Concluding remarks
Pharmacological and toxicological studies are critical before the optimal concentration of a drug
that yields the physiologically desirable effect can be determined. From the toxicological stand-
point, at high concentrations, the drug could exhibit adverse effects. From the pharmacological
standpoint, if a drug is a partial AhR agonist with a moderate induction of the CYP1A1 at low
concentrations, at high concentrations, it can act as an agonist. In this regard, quantitative data
are very important and should be taken into account for preclinical drug assessment.
The results showed that the cytostatic effect of 5F 203 is not mediated by AhR antagonism. On
the other hand, AhR agonism does not account for the growth inhibitory of 5F 203 either and
additional factors to AhR seem to be required. The potency of the cytostatic effect of 5F 203
parallels the potency for inducing CYP1A1 in H4-II-E and MCF-7 cells, i.e, 5F 203 was found
to be a potent agonist for inducing CYP1A1 as well as for inhibiting cell growth in MCF-7 cells,
whereas this compound was found to be a partial agonist in H4-II-E cells and failed to inhibit
cell growth in these cells. These results indicate that there is a correlation between species-spe-
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cific partial agonism of AhR and species-specific anticancer activity. But whether agonism/an-
tagonism for the induction of CYP1A1 mRNA is related to the anticancer effect of 5F 203
remains to be elucidated.
5F 203 was assessed for inducing CYP1A1 mRNA in cell lines from two different species, hu-
man and rat. The results indicate species-specific differences in potency and antagonistic activ-
ity. The use of the rat cell line allowed the classification of 5F 203 as a low-intrinsic efficacy
compound, a finding that would have been masked if tested only in humans where 5F 203 ex-
hibits an apparent high potency. This study stresses the importance of assessing drug effects in
several species in order to gain an accurate classification. Among the phenylbenzothiazoles test-
ed, IH 445,was found to be a potent agonist, with no detectable antagonistic activity on TCDD-
inducible CYP1A1 mRNA in rat cells. This important finding indicates that the partial agonism
observed with 5F 203 is a compound-specific and thus not an experimental artifact. 
It was demonstrated in this study by means of competitive displacement analysis using [3H]-
TCDD and Schild analysis that the PBTs tested induced CYP1A1 mRNA via a ligand-dependent
activation pathway which excludes the possibility of a ligand-independent pathway. These re-
sults elucidate the mechanism of action of these compounds on AhR signaling activation.
In order to understand the mechanism of action of drugs, they should be screened in different
cell lines and different species. PBTs have been previously tested and showed different patterns
of activity in the NCI panel of 60 human cell lines derived from nine organ sites; the breast can-
cer cell line MCF-7 was highly responsive to these compounds. In this study, the PBTs were
tested in rat cells and revealed species/cell-specific differences for antiproliferative activity, a
finding that raises doubts about the strategy of assessing drug activity in animal model cells than
extrapolating to humans. Actually, the lysylamide prodrug of 5F 203, Phortress, is in Phase I
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Clinical Trial. Unravelling the target for the PBTs would be of great importance for drug devel-
opment in cancer therapy. 
Finally, this study extended the number of AhR agonists/antagonits in a species/cell-specific
context and gives insight into the mode of interactions between PBTs and AhR. Further study
of a significant number of ligands/agonists for AhR would contribute significantly to a better
understanding of the AhR biology.  
Prospective work
5F 203 showed species-specific differences in agonism/antagonism of the AhR. It would be in-
teresting to investigate whether species-specific differences in AhR are responsible for these
differences. Transgenesis experiments may address this issue. In such experiments, human or
rat AhR genes could be translated into cells lacking AhR. Such a model is available, e.g., AhR
knock out mouse Hepa cells.
PBTs were found to be low potent agonists in rat cells which did not allow the development of
a QSAR model. However, given the high potency of 5F 203 in MCF-7 human cells, more com-
pounds need to be quantitatively assessed for inducing CYP1A1 mRNA in the same cell line be-
fore QSAR can be established. The binding affinity of PBTs to rat AhR was determined but not
to human AhR, therefore, it will be essential to determine the binding affinity of the PBTs to
human AhR using a human recombinant AhR expressed in Spodoptera frugiperda (Sf9) cells.
Then it would be good to compare QSARs for PBTs binding data (human AhR) and CYP1A1
mRNA induction data in MCF-7 cells and classify the PBTs into agonists/antagonists in human
cells. Finally, it would be useful to generate a full picture for the PBT’s binding data for rat and
human AhR as well CYP1A1 mRNA induction in rat and human cells and classify PBTs as ag-
onists/antagonists in each species, i.e., rat and human cells. 
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In order to confirm that the induction of CYP1A1 mRNA in MCF-7 cells is not a specific re-
sponse of CYP1A1 alone but rather a result of AhR activation, it would be possible to screen
other AhR-dependent gene expression by real-time PCR and follow that analysis with protein
expression and function (western blotting analysis and EROD activity). Subsequent to binding
AhR, translocation of AhR to the nucleus and binding to the XRE could be confirmed by west-
ern blotting and EMSA analyses respectively.
Finally, AhR is suspected target for mediating the anticancer activity of Phortress. MCF-7 cells
have proven to be a good model to study the involvement of AhR in the anticancer activity of
5F 203. Generating knockout AhR MCF-7 cells by means of small interfering RNA (siRNA)
and examining the cell growth inhibition when these cells challenged with the compounds,
would be a useful tool. 
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Appendix - Pharmacological background
Pharmacological definitions
A receptor is any substance that recognizes chemicals and responds to that recognition.
KD: is the equilibrium dissociation constant of the drug. It reflects the affinity of the drug to the
receptor. The smaller the KD value is, the higher is the affinity. The affinity constant Ka is the
reciprocal of the KD.
IC50: is the concentration of the competing ligand that inhibits 50% binding of the radioligand.
Ki: is the inhibition constant of the drug. This value can be related to KD and IC50 by the Cheng-
Prusoff equation.
Ke: is the intrinsic efficacy constant, and represents the concentration of ligand-receptor com-
plex that gives half-maximal response.
Drug properties
Affinity: is the chemical property that causes the drug to associate with the receptor. 
Efficacy: is the chemical property that produces a change in the receptor to produce a stimulus.
Biochemical binding studies
In principle, a fixed concentration of radiolabelled ligand [L*] is added to the receptor prepara-
tion for a certain time sufficient for the receptor and the ligand to reach the binding equilibrium
quantity of [L*.R] complex. 
The binding of labelled ligand L* to a homogenous population of receptor follows the law of
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mass action. It is a simple bimolecular association reaction:
Equilibrium is reached when the rate of formation of ligand-receptor complexes equals the rate
at which existing RL* dissociate. 
At equilibrium, [Ligand].[Receptor].kon=[Ligand.Receptor].koff.
The equilibrium dissociation constant KD is given by equation (1):
 [1] 
Where KD is the concentration of ligand that binds half of the receptors at equilibrium.
In other terms, the complex [Ligand.Receptor] is referred as to the bound ligand "B" to
 the receptor and the free fraction is "F". In equation (1):
[2] 




It is the factor relating receptor occupancy and stimulus. This proportionality factor is given the
name intrinsic efficacy. It represents the stimulus per molecule receptor produced by an agonist.
It also represents the concentration of agonist-receptor complex that produces 50% of response.
It is a drug-related property. It can be estimated given the receptor occupancy and the KA (or
KD) for each agonist are known. 
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[4] 
An agonist would have a factor of 1 and an antagonist would have a factor of 0, whereas a partial
agonist would have a factor between 0 and 1 [244].
Competitive reversible antagonism
A competitive reversible antagonism is a condition when the agonist and antagonist bind com-
petitively and reversibly to the same sites on the receptor. This effect can be observed on agonist
dose-response curves and can be quantitated using the equation derived by Gaddum [245]:
[5] 
Where [A] and [B] are the agonist and antagonist respectively. [A.R] represents the agonist-re-
ceptor complex, Rt represents the total receptor population and KB is the equilibrium dissocia-
tion constant for the antagonist-receptor complex.
Equation [5] gives the fractional occupancy by an agonist [A.R]/[Rt]) for any given concentra-
tion of agonist and antagonist [246].
Schild regression
This gives a measurement of antagonist potency. It was introduced by Arunlakshana and Schild
[247]. The model describes a simple competitive antagonism and the antagonist potency is
measured by the equilibrium dissociation constant for the antagonist-receptor complex.
From equation [5], in the absence of antagonist ([B]=0), the receptor occupancy by [A] is given
by:
[6] 
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The concentration of agonist [A’] in the presence of antagonist produces an equal response, and
presumably, an equal receptor occupancy, therefore, equation [5] becomes:
[7] 
At the same response, equation [6] equals equation [7], and the ratio of equiactive concentra-
tions of agonist in the presence and absence of antagonist (concentration ratio, cr) is given by
[A’]/[A]:
[8] 
From this equation, the magnitude of the concentration ratios depends on [B] and KB. Whereas,
[B] is known, cr is determined experimentally, thus KB can be calculated. A practical represen-
tation for equation [8] uses logarithmic conversion, so it yields a straight-line regression also
known as a Schild regression:
[9] 
The regression supports a mechanism of competitive antagonism if the slope =1, and in this case
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